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Summary 
 
The human immunodeficiency virus type 1 (HIV-1) interacts with multiple host 
components and usurps cellular regulatory mechanisms, such as phosphorylation to help 
direct different events of its replication cycle. Protein phosphorylation is a posttranslational 
modification widely used by the cell to convey specific messages in response to specific 
stimuli and allows the coordination of a myriad of cellular processes in a timely and specific 
manner. The C-terminal p6 domain of the HIV-1 Gag protein, besides carrying the PTAP L-
domain required to mediate virus release, is subject to phosphorylation. Although p6 has 
been identified to exist as the major phosphoprotein in HIV-1 particles, an in-depth study of 
the functional role of p6 phosphorylation has not been conducted to date. Thus, these 
observations prompted us to perform a comprehensive analysis of the consequences of 
potential p6 phosphorylation in the HIV-1 replication cycle.  
Information derived from phosphorylation prediction programs and from HIV-1 
subtype sequence alignments allowed us to select the p6 residues: T8, S14, T23 and S25 for 
mutational analysis. None of these residues, except for T8, had an effect in virus maturation, 
production, or replication capacity. We observed a partial enhancement in virus release by a 
T8D mutant—designed to mimick a phosphorylated state—that is likely due to a slightly 
greater affinity for the cellular interaction partner, Tsg101. We coupled our mutational 
analysis with the power of mass spectrometry to identify phosphorylated residues in p6. 
Multiple phosphoresidues were detected: T21, T22/23, S40, S43, and S51 and some appear 
to occur at specific processing stages of the Gag precursor protein.  
Surprisingly, a p6 T8N mutant behaved similar to the wildtype virus both in release 
and in single-round infection. Biochemical and structural studies revealed that this mutant is 
engages the ESCRT machinery, most likely through Tsg101. This interaction putatively occurs 
with a 5-fold lower affinity that is sufficient to mediate the recruitment of the ESCRT 
machinery to sites of virus assembly and budding. This finding elicits further characterization 
of the complex which would be especially relevant in the design of p6-Tsg101 peptide 
inhibitors. In addition, we speculate that the PNAP motif, present in a few other viruses and 
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eukaryotic proteins might have preferentially evolved into a motif of higher affinity, namely 
the PT/SAP motif.  
This study has advanced our knowledge of the phosphorylation state of HIV-1 p6 and 
suggests potential functional consequences of this modification. In addition, it reveals an 
unprecedented interaction between a PNAP late domain and Tsg101, highlighting the 
structural flexibility that might exist to accommodate other residues at the T8 position, 
which would be an important consideration in the design of peptide inhibitors. Finally, it 
provides a potential instance of viral late domain motif evolution. 
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Zusammenfassung 
 
Das humane Immundefizienz-Virus Typ 1 (HIV-1) kann mit vielen Proteinen und anderen 
Komponenten seiner Wirtszelle interagieren und so zelluläre Regulationsmechanismen wie 
die Phosphorylierung für seinen Replikationszyklus ausnutzen. Die Phosphorylierung  von 
Proteinen ist eine translationale Modifikation, die von der Zelle genutzt wird, um spezifische 
Reiz-Signale weiterzuleiten und die zeitliche und spezifische Koordination unzähliger 
zellulärer Prozesse zu gewährleisten.  
Das p6 Protein am C-Terminus von HIV-1 Gag besitzt nicht nur eine PTAP late domain 
sondern ist auch Ziel vieler Phosphorylierungen in der Wirtszelle. Obwohl p6 schon als das 
am häufigsten phosphorylierte Protein in HIV-1 Partikel identifiziert wurde, sind bis heute 
keine vertiefenden Analysen über die Funktion dieser p6 Modifikationen durchgeführt 
worden. Deshalb widmet sich die vorliegende Arbeit der ausführlichen Untersuchung der 
Auswirkung von möglichen Phosphorylierungs-Stellen in p6 auf den HIV-1 Replikationszyklus. 
Mit Hilfe von Bioinformatik-Programmen zur Identifikation von möglichen 
Phosphorylierungsstellen und zusätzlichen HIV-1 Subtypen Sequenz Analysen  konnten vier 
konservierte und möglicherweise phosphorylierte Aminosäuren in p6 identifiziert werden: 
T8, S14, T23 und S25, die dann detailliert durch Mutationsanalysen untersucht wurden.  
Bis auf die Aminosäure Threonin an Position 8 hatte keine der anderen drei zuvor 
identifizierten Aminosäuren einen Effekt auf die Replikation, Virusreifung oder 
Virusproduktion. Wir konnten eine leichte Erhöhung der Virusfreisetzung im Vergleich zu 
anderen Mutationen bei der T8D Mutante beobachten, die extra konstruiert wurde, um die 
Phosphorylierung an dieser Position nachzuahmen. Dieser Effekt kam vermutlich durch eine 
höhere Bindungsaffinität dieser Mutante zum zellulären Interaktionspartner Tsg101 
zustande. Zusätzlich zur Mutationsanalyse haben wir mittels Massenspektrometrie die 
Phosphorylierungsstellen in p6 genau bestimmt. Dabei wurden mehrere 
Phosphorylierungspositionen ermittelt: T21, T22/23, S40, S43 und S51 von denen einige 
vermutlich nur zu bestimmten Zeiten der Prozessierung des Gag Vorläuferproteins in 
Erscheinung treten.  
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Überraschenderweise verhielt sich die p6 T8N Mutante in der Virusfreisetzung und 
Infektion genau wie Wildtyp. Biochemische Untersuchungen und Strukturanalysen zeigten, 
dass das mutierte Virus mit dem ESCRT Komplex interagieren können, sehr wahrscheinlich 
über Tsg101. Diese Interaktion geschieht sehr wahrscheinlich mit einer 5-fach geringeren 
Affinität als mit Wildtyp Virus, diese reicht aber aus für die Rekrutierung des ESCRT 
Komplexes zum Ort des Viruszusammenbaus und dem Virusaustritt. Diese Beobachtung ist 
ein erster Schritt für die weitere Charakterisierung dieser Interaktion, die besonders wichtig 
für die Entwicklung von p6-Tsg101 Peptid-Inhibitoren ist. 
 Zusätzlich dazu könnte man spekulieren, dass sich das PNAP Motiv, das in einigen 
wenigen anderen Viren und auch zellulären Proteinen vorhanden ist, evolutionär zum 
PT/SAP Motiv mit höherer Bindungsaffinität entwickelt hat. 
Die vorliegende Arbeit könnte den aktuellen Wissensstand bezüglich der 
Phosphorylierung des HIV-1 p6 Proteins erweitern  und zeigt darüberhinaus die möglichen 
funktionalen Folgen dieser Modifikationen auf. Zusätzlich dazu konnte eine neue Interaktion 
zwischen einer PNAP late domain und Tsg101 identifiziert werden,  was die strukturelle 
Flexibilität und Anpassungsfähigkeit der Aminosäure an der Position T8 betont. Diese neuen 
Erkenntnisse sind sehr wichtig für die Entwicklung von Peptid-Inhibitoren. Darüberhinaus 
wurde hier in dieser Arbeit eine Möglichkeit für die evolutionäre Veränderung und 
Entwicklung einer viralen late domain aufgedeckt. 
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1 Introduction 
 
Composed of only a genome and protein, viruses cannot subsist by themselves and 
therefore rely on a host to replicate. Thus, parasitizing a susceptible host cell and overtaking 
its intracellular components is an absolute requirement for their survival and propagation. 
These tiny infectious agents, which range in size from 20 nm to about 400 nm, have evolved 
multiple ways to recognize, bind to and enter their hosts, providing some with the ability to 
infect a wide range of hosts. Moreover, once they have gained access into the host cell’s 
interior, they can efficiently usurp the cell’s cytoskeletal components and use them as 
trafficking roads on which they can reach specific regions and organelles within the cell. 
Viruses may even use the cell’s replication machinery to copy their own genetic information 
while they entirely rely on the host’s translation machinery to give rise to the components 
necessary to build and assemble new progeny virions. Newly formed virions are then ready 
to exit the cell—either through lysis of the host cell or by budding through cellular 
membranes—and continue their further propagation. 
Overall, viruses have evolved elegant ways to take advantage of the subtlety with 
which cellular networks function. For instance, posttranslational modification of cellular 
proteins conveys specific messages to the cell and makes it possible to orchestrate a myriad 
of cellular processes. Likewise, some viral proteins have adopted the capability to undergo 
modification, granting the virus access to cellular pathways that facilitate its travel through 
and out of the cell. 
This study mainly addresses the cellular biology of the Human Immunodeficiency 
Virus type 1 (HIV-1)-host cell interactions and focuses on the potential role of 
phosphorylation during different stages of its replication cycle.  
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1.1 The Human Immunodeficiency Virus type 1 (HIV-1) 
 
In the early 1980s, a rare epidemic characterized by a pronounced impairment in 
immune function was reported in countries all over the world. This deficiency was termed 
Acquired Immunodeficiency Syndrome (AIDS) and was observed to be often accompanied by 
a series of opportunistic infections, such as Pneumocystis carinii infection and Kaposi’s 
sarcoma (52). It was in 1983 when the Human Immunodeficiency Virus type 1 (HIV-1) was 
identified as the retrovirus causing AIDS (7, 46). HIV-1 has caused the death of an estimated 
1.8 million people worldwide in 2009 alone. According to the most recent UNAIDS report, 
there are 33.3 million people living with HIV-1, of whom 22.5 million are living in sub-
Saharan Africa(141). 
A member of the Retroviridae, HIV-1 is an enveloped lentivirus that carries two 
copies of a single-stranded RNA genome of about 9700 nucleotides in length of positive 
polarity. The overall genome organization is depicted in Figure 1.1. The viral genome of all 
simple retroviruses gives rise to 3 main genes: group specific antigen (gag), polymerase (pol) 
and envelope (env). In addition to these three main genes, the HIV-1 genome encodes for 
the accessory proteins nef (negative factor), vif (virion infectivity factor), vpr (viral protein R), 
vpu (viral protein U), tat (transactivator) and rev (regulator of virion) which play important 
roles during HIV-1 pathogenesis. The gag gene encodes the main structural component of 
the virion, Gag. During virus maturation, Gag is proteolytically processed into the proteins 
matrix (MA), capsid (CA), nucleocapsid (NC), spacer peptides 1 and 2 (SP1 and SP2) and the 
p6 protein. The pol gene gives rise to 3 enzymes: protease (PR), reverse transcriptase (RT), 
and integrase (IN), while the env gene encodes for the surface (SU) and transmembrane 
(TM) glycoproteins that coat the surface of the viral lipid envelope (30, 63). The illustration in 
Figure 1.1 shows both the arrangement of the major and regulatory viral components 
encoded by the viral genome, as well as a model for virus structure in both the immature 
and cleaved, mature form. 
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Figure 1.1. HIV-1 genome organization and virion structural features. 
Above, the HIV-1 genome encodes 3 main genes: gag, pol, and env, as well as the accessory proteins vif, vpu, 
vpr, tat, rev, and nef. The RNA transcripts that give rise to these proteins are generated as unspliced (gag and 
pol), singly spliced (env, vif, vpr, vpu) or multiply spliced (tat, rev, nef). For tat and rev, the 5‘ and 3‘ exon splice 
junction sites are marked by a bold line. Sequences found at both the 5‘ and 3‘ ends of the genome contain the 
long-terminal repeats (LTRs), regions that dictate viral RNA synthesis and integration, while genome packaging 
into new progeny virions is directed by the packaging signal psi at the 5‘ terminus of the transcript. The HIV-1 
genome in this illustration is based on the HXB2 isolate. Below, a schematic of the structural features of the 
two virus forms: immature (left) and mature (right). The immature virus is characterized by a thick layer of 
uncleaved gag polyproteins underlying the virion membrane, whereas proteolytic processing of the gag 
polyproteins during maturation gives rise to a cone-shaped core that encloses the viral RNA and additional viral 
proteins. This processing step renders the virus infectious. Adapted from (47, 86). 
1.2 The HIV-1 replication cycle 
 
The HIV-1 replication cycle occurs as a series of steps depicted in Figure 1.2. The first 
step involved in granting the virus access into the host cell cytoplasm is mediated by the 
binding of the envelope surface (SU) glycoprotein gp120 to the cellular receptor CD4 and the 
coreceptor CXCR4 or CCR5, depending on viral tropism. Engagement of both receptor and 
coreceptor leads to conformational changes in gp120 that expose the transmembrane (TM) 
glycoprotein, gp41. In turn, gp41 undergoes a structural rearrangement that creates a 6-
bundled helix, bringing together the lipid bilayer of the virion and the host cell plasma 
membrane leading to fusion of the two membranes, thus allowing the viral core to be 
released into the cytoplasm (41, 51, 91). Nevertheless, recent evidence suggests that HIV-1 
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primarily relies on endocytic uptake to reach the cytoplasm (98). Once in the cytoplasm, HIV 
cores disassemble rapidly in a process known as uncoating. During this process, a reverse 
transcription complex (RTC) comprised of NC (nucleocapsid), RT (reverse transcriptase), IN 
(integrase), Vpr and viral RNA forms and reverse transcription of the viral RNA takes place. 
The product of the reverse transcription reaction is a full-length, double-stranded linear DNA 
version of the genome, flanked at each end by two long-terminal repeats (LTRs) that are 
important for integration of the proviral DNA into the host genome and for viral RNA 
expression (41, 63, 85). The viral protein-DNA complex, now referred to as the 
preintegration complex (PIC) is transported across the nuclear membrane in a process that 
might be facilitated by the Vpr and/or IN proteins. Once inside the nucleus, the viral IN 
protein acts to insert the linear DNA into the host cell chromosome (63). The integrated viral 
DNA, known as the provirus, serves as the template for the synthesis of the viral RNAs. HIV 
transcripts can be unspliced, singly spliced or multiply spliced. The unspliced and singly 
spliced transcripts are transported by the viral Rev protein from the nucleus to the 
cytoplasm (91). The unspliced RNA is used to make Gag and Gag-Pol proteins and also serves 
as the genome. The singly spliced RNA is used to make the Env glycoproteins which are 
synthesized in the ER followed by their transport to the plasma membrane via the secretory 
pathway (41, 63). The Gag and Gag-Pol polyprotein precursors are synthesized on 
cytoplasmic ribosomes and the newly synthesized polyproteins recruit two copies of the 
single-stranded viral genome (87) before travelling to the plasma membrane. At the plasma 
membrane, the assembly of the Gag proteins generates curvature that leads to formation of 
a bud. During budding, the viral Env glycoproteins are incorporated into the nascent 
particles. The budding step is completed as the particle pinches off from the plasma 
membrane (41). Concomitant with or shortly after budding, the viral protease mediates virus 
particle maturation through cleavage of the Gag and Gag-Pol polyproteins, leading to 
formation of an electron-dense MA layer beneath the envelope and a conical capsid core at 
the center of the particle (91). 
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Figure 1.2. Schematic of the HIV-1 replication cycle.  
Virus entry into the host cell cytoplasm is mediated by the initial binding of the viral gp120 envelope protein 
with the host’s cellular receptor and coreceptor CD4 and CXCR4, respectively. This interaction results in a series 
of rearrangements that permit the envelope transmembrane protein, gp41 to mediate fusion of the viral 
membrane with the host cell membrane. Once it has gained access into the cytoplasm, the viral core is 
uncoated and reverse transcription of the viral RNA takes place within a reverse transcription complex (RTC). 
This reaction generates a full-length double-stranded DNA copy of the viral genome that remains associated 
with viral proteins (shown as the black dots) in the form of a pre-integration complex (PIC). This complex is 
then transported into the nucleus where the viral protein IN catalyzes the insertion of the proviral DNA into the 
host genome. Viral transcripts are exported into the cytoplasm where Gag and Gag-Pol precursor proteins are 
made. In contrast, the Env proteins are made in the rough endoplasmic reticulum (rER) (where the brown dots 
represent ribosomes) and travel via the secretory pathway to reach the plasma membrane. The Gag and Gag-
Pol precursors associate with viral RNA transcripts in the cytoplasm before they reach the plasma membrane, 
where they assemble and induce bud formation. Nascent viral particles are ultimately released from the cell by 
the action of ESCRT proteins, which severe the membrane stalk connecting the virion to the host membrane. 
During the budding process, the immature virion undergoes proteolytic processing by the viral protease 
resulting in the formation of a conical capsid shell that surrounds the viral genome. 
 
1.3 The mechanism of HIV-1 exit 
1.3.1 Virus assembly at the plasma membrane and bud formation 
 
In natural target cells of HIV-1, such as T cells and macrophages, the major site of 
virus particle assembly and budding is the plasma membrane (106, 149). The viral Gag 
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protein directs both of these processes, in fact, assembly of Gag alone at the plasma 
membrane results in the production of immature, non-infectious virions (50), indicating that 
Gag itself contains sufficient information to mediate the entire budding process. Ivanchenko 
et al (73), recently investigated the kinetics with which the assembly and budding reaction 
take place. By making use of GFP-tagged HIV-1 virions, they found that the fluorescence 
intensities of individual gag clusters changes in 3 phases—phase I was characterized by an 
increase in fluorescence intensity during the first minutes after nucleation of an assembly 
site was detected; in phase II, the fluoresence signal intensity remained stationary or 
constant, while during phase III a decay in the fluoresence intensity was observed. Overall, 
these phases can be translated into an assembly reaction of the Gag shell at the plasma 
membrane that requires around 8-9 minutes and culminates in the release of the nascent 
virus particles 16 minutes later(73)  
Synthesis of the Gag polyproteins takes place in the cytoplasm of the infected cell 
and they must therefore find a way to reach the plasma membrane to initiate assembly. It is 
still a matter of debate how Gag precursor proteins are transported to the plasma 
membrane.Some evidence suggests that active transport of Gag might not be required for 
assembly since disrupting cytoskeletal components has no major effect on the appearance 
of HIV-1 Gag at the plasma membrane or virus yield (79). Alternatively, it has been suggested 
that host transport proteins such as GGA (golgi-localized, gamma ear-containing, ADP 
ribosylation factor-binding) or Arf (ADP ribosylation factor) mediate Gag movement to the 
plasma membrane (77). It is also still undefined whether Gag is transported as monomers or 
oligomers to the plasma membrane, but a recent study by Kutluay et al (87) found Gag to be 
present as monomers or low-order multimers during its association with viral RNA in the 
cytoplasm. Moreover, high-order Gag multimerization required membrane binding, 
suggesting this event occurs once Gag reaches the plasma membrane. Despite these 
uncertainties regarding Gag assembly, the process by which Gag associates with the plasma 
membrane has been more extensively characterized. The matrix (MA) domain of HIV-1 Gag 
contains a cluster of basic residues and an N-terminus that is co-translationally myristylated 
(11, 106, 146). Both of these features are critical for its affinity and binding to areas of the 
plasma membrane that contain the negatively charged phospholipid, phosphatidylinositol-
(4,5)-bisphosphate or PI(4,5)P2.  A study conducted by Ono (106) showed that PI(4,5)P2 is 
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essential for both efficient Gag membrane binding and specific localization to the plasma 
membrane. Furthermore, MA binding of PI(4,5)P2 triggers myristate exposure, anchoring Gag 
to the lipid bilayer while sequestering a PI(4,5)P2 unsaturated acyl chain inside the MA 
molecules (126). The Gag-PI(4,5)P2 interaction is thought to help partition Gag to lipid-raft-
like microdomains (126). This notion would be in agreement with the fact that the HIV-1 viral 
envelope is enriched in cholesterol and sphingolipids relative to the host cell plasma 
membrane (16). 
1.3.2  Bud scission 
1.3.2.1.1  The role of viral late domains in virus budding 
 
It is likely that Gag lattice formation at the membrane and lipid interactions provide 
the energy necessary to bend the membrane and enwrap the nascent virion. Early during 
Gag assembly and lattice formation, specific cellular proteins are recruited to the budding 
site to catalyze the release of nascent HIV-1 particles. This task is fulfilled through the p6 
domain of the viral Gag protein. 
The first hint that this region of HIV-1 Gag was involved in the release process came 
from a study by Göttlinger et al 20 years ago (53). Mutation of specific p6 sequences within 
the context of a full-length HIV-1 molecular clone resulted in impaired virus production. 
Visualization of this defect by electron microscopy (EM) showed that budding virus particles 
remained attached to the host membrane through a thin membrane stalk (53) (Figure 1.3). 
 
Figure 1.3 HIV-1 p6 mutants have a 
pronounced defect in release. 
 Electron microscopy image of HIV-1 virions 
that carry mutations in p6 Gag. The 
membrane of both host cell and nascent 
virion remain connected through a thin 
membranous stalk. Adapted from (53). 
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A few years later, Huang et al., pinpointed this phenotype to a P-T-A-P motif at the N-
terminus of p6 where the threonine can also occur as a serine. Residues within this motif are 
critical for efficient virus release, while mutations outside this motif have little or no effect in 
virus particle production (64). Importantly, these studies laid the foundations for the 
discovery of similar and novel motifs in other retroviruses. For instance, the rous sarcoma 
virus (RSV) was found to encode a motif of a P-P-P-Y type that was shown to be required for 
budding (150, 153). This same motif was found to occur in the mason-pfizer monkey virus 
(MPMV) gag as well as in the p12 protein of moloney-murine leukemia virus (MuLV). In all 
instances, this motif was shown to be involved in virus production (154, 155). Interestingly, a 
motif of yet another type was uncovered in the lentivirus equine infectious anemia virus 
(EIAV). This motif corresponded to a Y-P-X-L present in its p9 protein (119). These 3 different 
types of motifs, namely PTAP, PPXY, and YPXL became collectively known as late (L)-domains 
for their role in the late stages of the virus replication cycle. More recently, a new viral L-
domain was identified in a paramyxovirus (131). The core sequence of this motif consists of 
the residues FPIV (131). Notably, besides retroviruses, other enveloped viruses such as 
vesicular stomatitis virus (VSV)—a rhabdovirus—and Ebola virus—a filovirus—contain both 
PPPY and PT/SAP L-domains (31, 58, 76, 96). Years later after the characterization of the first 
L-domain in HIV-1, Strack et al, uncovered the presence of a second L-domain of the YPXL 
type at the C-terminus of the p6 domain (136). Additional L-domains have also been 
identified in MPMV and RSV (37, 54). Figure 1.4 illustrates the position, number and type of 
L-domains present in several enveloped viruses.   
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Figure 1.4. The late domains of different enveloped viruses.  
Divergent enveloped viruses have been found to contain late domains in their structural proteins. The position 
and number of late domains vary from one virus family to another or even within virus species. Adapted from 
(12, 100). 
 
The fact that viral L-domain function is position-independent even in the context of 
different retroviruses suggests that L-domains may function as protein modules (110). Thus, 
it seemed likely that these domains bound to and recruited host factors to the site of virus 
budding (43). Indeed, the first reported interaction between a cellular protein and a 
retroviral L-domain was shown for RSV (48). A series of studies followed in which potential 
interaction partners were identified for the different L-domain-containing enveloped viruses. 
A consensus of such studies determined that PPXY L-domains interact with the WW domains 
of E3 ubiquitin ligases of the Nedd4 (neuronal precursor cell-expressed developmentally 
downregulated 4) family (35, 48, 59, 83). This family of ubiquitin ligases has a common 
modular architecture: they contain an N-terminal C2 domain, a central WW domain and a C-
terminal HECT (homologous to E6-AP carboxyl terminus) domain involved in cellular 
targeting, substrate recognition and ubiquitin conjugation, respectively (72). The YPXL late 
domain of EIAV and HIV-1 interact with the adaptor protein AIP1/Alix (ALG-2 (apoptosis-
linked gene 2)-interacting protein X) protein (136) while PT/SAP L-domains interact with the 
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tumor susceptibility gene 101 (Tsg101) (49, 96, 144). Tsg101 forms part of a protein complex 
termed the endosomal sorting complex required for transport (ESCRT) that is involved in the 
sorting of ubiquitinated membrane proteins targeted for degradation in the lumen of the 
lysosome (80). Alix on the other hand, is an adaptor/scaffolding protein that plays a more 
indirect role in the ESCRT pathway in contrast to its putative yeast homolog Bro1, which is 
required for proper endosomal sorting in yeast (124). These findings sparked an interest to 
further characterize the interactions between viral L-domains and their cellular partner(s), 
especially since these are critical for the efficient release of nascent viral particles. At the 
same time, it led to the development of models by which the final scission step between the 
viral and the host cell membrane is thought to occur. The following section will describe the 
cellular machinery usurped by HIV-1 to mediate the final scission step that leads to its 
separation from the host cell membrane.  
1.3.2.1.2  The Endosomal Sorting Complex Required for Transport (ESCRT) 
machinery  
 
ESCRT complex components were initially identified as part of an effort to study 
organelle biogenesis and assembly by using the yeast vacuole of Saccharomyces cerevisiae as 
a model system (121). In that study, a set of yeast protein mutants, termed class E vps 
mutants, appeared to be defective in the sorting process and displayed a characteristic 
morphology by electron microscopy (EM). Class E vps proteins appeared to be sequestered 
within a multilamellar endosome-like compartment that was distinct from the vacuole (121, 
122). This compartment became known as the “class E compartment“ and the genes 
involved in this morphology as “class E VPS (vacuolar protein sorting) genes“ (121). Further 
characterization of the class E genes revealed that they are highly conserved from yeast to 
humans, and its components were subsequently isolated and structurally and biochemically 
characterized into four subcomplexes termed ESCRT-0, -I, -II, and -III. Together, they 
constitute the ESCRT complex, so named for its role in the protein sorting pathway (68, 80). 
The ESCRT complex has a principal role in the downregulation of receptor-mediated cell 
signaling. It recognizes and sorts endocytosed ubiquitinated plasma membrane signaling 
receptors into multivesicular bodies (MVBs) that eventually fuse with a lysosome, where 
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proteases degrade MVB contents. The ESCRT complex subdivides this task among its four 
subunits—ESCRT-0 recognizes and recruits cargo to early endosomes, ESCRT-I and -II 
sequester cargo into MVBs and ESCRT-III is thought to catalyze the final scission step that 
releases the budding MVB into the lumen of the late endosome. Recycling of the ESCRT 
components is mediated by the ATP-dependent Vps4 as depicted in Figure 1.5 (120, 127). 
 
Figure 1.5 The role of the ESCRT complex in protein sorting and MVB biogenesis. 
 (A) Ubiquitylated cell-signaling receptors that need to be downregulated are sorted into intraluminal vesicles 
(ILVs) within endosomal-derived multivesicular bodies (MVBs). Subsequent fusion of the MVB with the 
lysosome results in the proteasomal degradation of the ILV content. The endosomal sorting complex required 
for transport (ESCRT) plays a major role in the recognition and sorting of ubiquitylated cargo. Ubiquitylated 
transmembrane proteins are recognized by the ubiquitin-recognition motifs present in ESCRT-0, ESCRT-I and 
ESCRT-II components. Assembly of these ESCRT components at the limiting membrane of the endosome results 
in initial deformation of the membrane followed by scission of the membrane bud neck mediated by ESCRT-III 
assembly and Vps4 ATP hydrolyzing activity. ESCRT components are the disassembled and recycled back into 
the cytosol by the action of Vps4. Adapted from (27). 
 
The fact that proteins involved in the ESCRT pathway also seemed to participate in 
retroviral budding (see section 1.3.2.1.1) led to the realization that the ESCRT pathway might 
be hijacked by viral components to mediate their exit from the cell. This observation seemed 
plausible due to the fact that MVB biogenesis and viral budding are topologically equivalent 
processes, where budding is directed away from the cytosol. Moreover, it was also observed 
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that cytokinesis, a process employing the same topology during separation of a mother cell 
to generate a new daughter cell, also requires the participation of ESCRT components (23). 
These observations highlight the role of the ESCRTs in a variety of cellular processes that 
seem to include autophagy (69).  
1.3.2.1.2.1  ESCRT-0: cargo recruitment 
 
This complex consists of the subunits Hrs (hepatocyte growth-factor-regulated 
tyrosine kinase substrate) and STAM (signal-transducing adaptor molecule), Vps27 and Hse1 
in yeast (120, 124). Hrs additionally contains a FYVE zinc-finger domain that is specific for 
binding the endosomal lipid phosphatidyl inositol 3-phosphate (PtdIns(3)P) and a PT/SXAP 
motif through which it binds the ESCRT-I component, Tsg101 (Vps23 in yeast) (81). The 
Hrs/STAM complex is thought to be recruited to the early endosomal membrane by 
PtdIns(3)P binding. Once at the endosomal membrane, Hrs recruits clathrin, resulting in 
restricted localization of Hrs that helps to concentrate cargo within a specific area of the 
endosome (124). The complex binds ubiquitylated cargo through their ubiquitin-interacting 
motifs (UIMs) (124, 127). Membrane-bound Hrs/STAM serves as a docking site for 
recruitment of the ESCRT-I complex via interaction between the ESCRT-I component, Tsg101 
and a PT/SXAP motif in the C-terminus of Hrs. 
1.3.2.1.2.2 ESCRT-I and II: stabilization of the membrane bud 
 
The ESCRT-I was initially characterized in yeast and later in mammalian cells. It 
consists of a constitutively assembled complex of four subunits existing in a 1:1:1:1 ratio: 
Tsg101/Vps23, Vps28, Vps37 and Mvb12 (120). The crystal structure of the yeast ESCRT-I 
revealed that the complex exists as a 13 nm-long stalk connected to a 5 nm-long headpiece 
(84). The Tsg101 subunit contains a catalytically-inactive ubiquitin E2-variant domain (UEV) 
that binds to the PT/SXAP motifs in ESCRT-0, viral L-domains, such as that in HIV-1 p6 and 
ubiquitylated cargo (49, 68, 69, 120), contributing to recruitment of this complex to the 
endosomal membrane. In yeast, contact to the ESCRT-II complex is mediated through the C-
terminal helical region in Vps28. 
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ESCRT-II is composed of one molecule each of EAP30/Vps22, EAP45/Vps36 and two 
molecules of EAP20/Vps25. Like ESCRT-0 and ESCRT-I it has ubiquitin-binding activity 
through EAP45/Vps36. ESCRT-0, -I and –II, all recognize and bind the same isoleucine (Ile) 44 
hydrophobic patch in ubiquitin. The complex has a rigid, Y-shaped core and the overall 
structure has a maximal dimension of about 15 nm (70). Contact to the ESCRT-III complex is 
facilitated by Vps25 in ESCRT-II to the ESCRT-III component Vps20 (human CHMP6). It is not 
clear, however, how human VPS28 (in ESCRT-I) might bind to EAP45/Vps36. Although 
essential for endosomal sorting in yeast, the ESCRT-II complex is dispensable for HIV-1 
budding and probably also for cytokinesis (69, 88). 
1.3.2.1.2.3 ESCRT-III: scission of the bud 
 
Subunits within the ESCRT-III complex are highly charged, with an N-terminal basic 
and a C-terminal acidic region. Unlike ESCRT-I and –II subunits, ESCRT-III proteins exist as 
inactive monomers in the cytosol. Upon activation, these subunits undergo conformational 
changes that allow them to interact with other ESCRT-III subunits to form a large protein 
lattice of unknown stoichiometry on the membrane (120, 127). The yeast ESCRT-III consists 
of four subunits: Vps20 (CHMP (charged multivesicular body proteins) 6 in humans) 
Snf7/Vps32 (CHMP4A, B and C), Vps24 (CHMP3) and Vps2 (CHMP2A, and B). The subunit 
that nucleates assembly on membranes is Vps20, which is N-terminally myristoylated and is 
thought to interact directly with the endosomal membrane. Vps20 binds to the Vps25 
subunit of ESCRT-II, which functions to recruit and possibly activate Vps20. Vps20, interacts 
directly with Snf7/Vps32, the most abundant of the ESCRT-III subunits in yeast. This is 
thought to trigger the assembly of Snf7/Vps32 into filamentous oligomers that seem to be 
capped at the growing end by Vps24. Finally, Vps2 associates with the Vps24 cap to mediate 
the recruitment of the AAA+ ATPase Vps4 that will mediate the disassembly and recycling of 
the ESCRT components (120). A schematic illustrating the molecular components and 
interactions between ESCRT subcomplexes is shown in Figure 1.6. 
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Figure 1.6 Molecular components of the ESCRT complex. 
The subunits that make up the ESCRT-0, -I, -II, and –III are illustrated. Shown are the mammalian protein names 
of the subunits but the figure is a combination of data obtained from both yeast and mammalian ESCRTs. 
ESCRT-0 interacts with deubiquitinating enzymes (DUBs), membrane phospholipids, ubiquitylated cargo that is 
recognized through its UIM (Ubiquitin-Interacting Motif) and binds clathrin through its CB (Clathrin-box) motif. 
ESCRT-0 and the ESCRT-I component Tsg101 connect through the PSAP and UEV (Ubiquitin-E2 variant) 
domains, respectively. The ESCRT-I recognizes ubiquitin and interacts with the accessory protein Alix and DUBs. 
The Vps28 subunit bridges the ESCRT-I and –II together. The ESCRT-II binds ubiquitin and membrane 
phospholipids. Its Vps25 subunit recruits and activates the ESCRT-III subunit, Vps20. ESCRT-III subunits are also 
subject to the activity of DUBs. The ATPase Vps4 interacts with ESCRT-III through its MIT (Microtubule 
Interacting and Transport) domain. Vps4 activity is regulated by a number of proteins—Vta1, Vps60, Ist1, Did2. 
Adapted from (120). 
 
1.3.2.1.2.4 Disassembly of the ESCRT-III complex 
 
The role of Vps4 seems to be conserved in all ESCRT-dependent processes, including 
viral budding, cytokinesis and autophagy. Without Vps4 activity, the entire ESCRT machinery 
accumulates on membranes and cargo processing is blocked (4, 5, 69). Vps4 is an AAA+ 
ATPase with a ring-shaped dodecameric cylinder. Binding of Vps4 to ESCRT-III promotes Vps4 
assembly into a functional ATPase. Vps4 is thought to act by disassembling ESCRT-III 
components after membrane scission is complete. ESCRT-III subunits are thought to be 
pulled into, and through, the ATPase central pore, releasing them from the membrane and 
back into the cytosol as monomers (69). 
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1.3.2.1.3 ESCRT-mediated viral budding 
 
HIV-1 and other retroviruses engage components of the ESCRT machinery (see 
1.3.2.1.2) to mediate scission of the membrane stalk connecting the nascent virion to the 
host cell. Access to the ESCRT complex is mediated by the viral L-domains (see 1.3.2.1.1) that 
either directly or indirectly recruit members of the protein sorting machinery. For instance, 
HIV-1 enters the ESCRT pathway by binding through its PT/SAP L-domain to the ESCRT-I 
component Tsg101. The functional relevance of this interaction was confirmed since 
knockdown of Tsg101 or expression of Vps4 mutants strongly compromised HIV-1 release 
(49, 96, 144), indicating that HIV-1 particle production is highly dependent on a functional 
Vps pathway. In addition to its Tsg101-binding site, HIV-1 p6 also contains the auxiliary L-
domain LYPXnL that binds to the ESCRT-associated protein Alix (ALG-2 linked interacting 
protein X) (136). Release through this L-domain is inefficient; however, Tsg101-binding site 
mutants can be efficiently rescued by increasing the cellular expression levels of Alix (142). 
Importantly, this effect is dependent on an intact Alix binding site in p6. Alix binds to Tsg101 
through its C-terminus but although this interaction is dispensable for HIV-1 release, its 
interaction with the ESCRT-III component CHMP4 is essential. Alix interacts with CHMP4 via 
its N-terminal Bro1 domain (142). Recently, Alix was shown to associate with the HIV-1 
nucleocapsid (NC) through the same domain. This interaction seems to be required for 
efficient rescue of HIV-1 PTAP mutants (115). In another recent study, the NC-p1 region in 
HIV-1 Gag was shown to play an inhibitory role in virus release that can be counteracted by 
the L-domain function of p6 (116). This suggests that—at least in the context of the HIV-1 
Gag protein—the primordial purpose of having viral L-domains is precisely to counteract 
such inhibitory or regulatory sequences present within viral structural proteins, Gag in this 
case, in order to engage the cellular machinery that will mediate virus release.  
Interestingly, although HIV-1 does not possess an L-domain of the PPXY type, it has 
been shown that overexpression of a specific isoform of the Nedd4 E3 ubiquitin-ligase can 
enhance release of an HIV-1 clone lacking both known L-domains (22). The ability to enhance 
release is nevertheless dependent on Tsg101, suggesting that HIV-1 still acts through ESCRT-
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I. Moreover, this rescuing activity was also dependent on the ubiquitinating ability of the 
ligase; however, the target for ubiquitination is so far unknown (22). These examples reflect 
the advantage of carrying more than one L-domain and the ability of a virus to enter the 
ESCRT pathway in more than one way. 
The functional relevance of the HIV-1 PTAP-ESCRT interaction in the context of HIV-1 
assembly and release was recently addressed in a study by Carlson et al. Their findings 
suggest a revised model for HIV-1 morphogenesis in which Gag assembly at the plasma 
membrane takes place concomitant –and in kinetic competition—to ESCRT recruitment. In 
this model, Gag assembly mediates early budding and recruits ESCRT-I and ESCRT-III. ESCRT-
III in conjunction with Vps4 would serve to constrict the wide membrane neck of the nascent 
particle. This early recruitment of the ESCRT would lead to the formation of productive, 
incomplete gag shells with an average Gag content of 2400 molecules per virion that upon 
maturation form the cone-shaped capsid shells. In contrast, budding-arrested, unproductive 
nascent particles have almost complete gag shells and are characterized by a thin membrane 
stalk connecting them to the infected cell (21).  
Equine infectious anemia virus (EIAV) contains a YPDL type of L-domain within its C-
terminal p9 domain and it enters the ESCRT pathway through its interaction with Alix (136). 
This interaction is critical for efficient release of EIAV since Alix knockdown or dominant 
negative forms of this protein severely compromise particle release. In contrast, EIAV release 
is resistant to dominant negative forms of Tsg101 or to its depletion (95), indicating that 
unlike HIV-1, EAIV strongly depends on its L-domain-Alix interaction for efficient budding. 
PPXY L-domain-containing viruses depend on the endosomal sorting pathway for 
efficient release (95). However, unlike the PTAP and YPXL L-domains that directly bind to 
ESCRT pathway components, PPXY L-domains are not known to directly bind any ESCRT or 
ESCRT-associated component. Instead, a wealth of studies indicates that they interact with 
the Nedd4-like family of HECT ubiquitin ligases (93). These ligases are characterized by an 
amino-terminal C2 domain that provides membrane targeting activity, contain central WW 
domains, which mediate the interaction with PPXY motifs and a carboxy-terminal HECT 
domain that contains ubiquitin ligase activity (72). The structural proteins of many PPXY L-
domain-containing viruses such as VSV, Ebola, RSV, HTLV-1, and MPMV have been shown to 
bind to various HECT ubiquitin ligases, including Nedd4, WWP1, WWP2 and ITCH (12, 35, 
  Introduction 
 
27 
 
94). The precise means by which HECT ligases establish a connection to the ESCRT pathway is 
currently unknown. The ability of this interaction to promote virus release seems to be 
dependent on a catalytically active HECT domain, suggesting that ubiquitination of a viral or 
cellular protein could be required for this process. However, the substrate of ubiquitination 
during viral budding remains undefined (20, 157). Upon VPS4 overexpression, HECT domains 
have been shown to localize to class E compartments, suggesting that the HECT domains 
must be recruited to these compartments by ESCRT components or by an as yet unidentified 
bridging factor. Recent studies indicate that PPXY motif-induced recruitment of HECT 
ubiquitin ligases results in a ubiquitination reaction that occurs at or near the site of viral 
budding. Interestingly, the substrate of this ubiquitin modification does not seem to be 
relevant for the subsequent recruitment of the ubiquitin-binding ESCRT components. Thus, it 
seems that the mere presence of ubiquitin at the site of budding is sufficient to engage the 
ESCRT pathway and promote virus budding (157). Figure 1.7 shows a schematic 
representation of the different entry points into the ESCRT pathway for each type of late 
domain. 
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Figure 1.7 The different ESCRT entry pathways used by the three viral late domains. 
The late domains encoded by the three retroviruses HIV-1, EIAV and MLV access the ESCRT machinery 
differently. The HIV-1 PTAP late domain mediates the direct recruitment of the ESCRT-I component, Tsg101. In 
contrast, the YPXnL late domain in both HIV-1 and EIAV interacts with the ESCRT-associated protein Alix which 
in turn can directly interact with the ESCRT-III protein, CHMP4. In the case of PpxY late domains, entry into the 
ESCRT pathway is thought to be mediated by interaction with E3 ubiquitin ligases of the Nedd4 family. 
However, the bridging factor between the ligase and the ESCRT machinery has not been clearly defined. 
Moreover, It is thought that the catalytic activity of the ligase and hence, ubiquitination is necessary for its 
function in virus release. Although different entry points are used by the different late domains, all pathways 
seem to depend on an intact ESCRT-III to mediate the final scission step between the nascent virion and the 
host cell. Subsequent to membrane bud scission, ESCRT-III components are disassembled and recycled back 
into the cytoplasm by the action of the ATPase Vps4. Modified from (93). 
 
1.4 The Tsg101 UEV-PTAP interaction 
 
Recruitment of the ESCRT machinery is required for the release of nascent HIV-1 
particles from the infected host cell. This task is mediated by the recruitment of the cellular 
ESCRT-I component, Tsg101 (see section 1.3.2.1.2.2) through the HIV-1 PTAP L-domain. 
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Initial studies that identified Tsg101 as the cellular binding partner of the PTAP L-domain, 
also determined that the region of protein interaction in Tsg101 corresponds to the first 145 
amino acid residues, or N-terminus of the protein (49, 96, 144). The N-terminus of Tsg 101 
corresponds to a ubiquitin E2 variant (UEV) domain that shares structural features of 
classical E2 ubiquitin-conjugating enzymes, but unlike E2 enzymes does not possess catalytic 
activity for ubiquitin conjugation. Nevertheless, UEVs can still recognize and bind ubiquitin 
and ubiquitin-modified proteins (42, 118). Indeed, Tsg101 UEV domain contains a separate 
binding site for ubiquitin that is important for its role in the endosomal sorting pathway 
(137). Understanding the structural determinants of the p6-Tsg101 interaction has become 
imperative in the search for novel peptide inhibitors that block virus release (42, 117). Thus, 
a variety of studies have focused on defining the solution and crystal structures of the 
Tsg101 UEV domain alone or complexed either to ubiquitin or the HIV-1 p6 PTAP peptide. 
Early studies by Garrus et al (49) showed that the Tsg101 UEV-p6 interaction fits a 1:1 
binding model with an equilibrium dissociation constant (Kd) value of 27 +/- 5 M under 
physiological conditions as determined by surface plasmon resonance (BIAcore) studies (49). 
Importantly, they could show that Tsg101 UEV bound with similar affinities both full-length 
HIV-1 p6 and truncated versions that spanned different lengths of p6 but which always 
included the PTAP motif (49). A follow-up study by Pornillos et al (118), used nuclear 
magnetic resonance (NMR) spectroscopy to determine the structure of the Tsg101 N-
terminal UEV domain and to map the sites of ubiquitin and PTAP binding. Analysis of the 
Tsg101 UEV domain shows that the UEV fold is in general similar to E2 ubiquitin-conjugating 
enzymes. This ‘E2 fold’ consists of four helices packed against one side of a four-stranded 
anti-parallel -sheet. The structures are most similar around the central active site. 
However, the UEV lacks the two C-terminal helices found in all structurally characterized E2 
proteins. Significantly, this feature allows the UEV to bind the PTAP-containing peptide. 
Moreover, Tsg101 contains two N-terminal helices, whereas canonical E2 proteins contain 
only one. Finally, the first two UEV -strands form an extended -hairpin ‘tongue’ that is 
important for ubiquitin binding. The sequence and secondary structure of Tsg101 UEV is 
illustrated in Figure 1.8 (118, 137). 
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Figure 1.8 Tsg101 UEV sequence and secondary structure. 
 The Tsg101 UEV sequence consists of 145 amino acid residues. The location of beta sheets and alpha helices 
are shown in the sequence and secondary structure. The position of the beta hairpin tongue is indicated. 
Residues in green are important for binding to the p6 PTAP peptide. Modified from (71). 
 
NMR chemical shift perturbation experiments were used to map the binding site of 
the HIV-1 p6 protein on the Tsg101 UEV domain. A nine-residue peptide spanning the p6 
PTAP motif was used since it bound Tsg101 UEV with the same affinity as the full-length p6 
protein, which under slightly acidic conditions displayed a tighter dissociation constant Kd = 
4.3 +/- 1.6 M (118). From this study it could be observed that the Tsg101 UEV-PTAP contact 
surface involves three different structural elements of the UEV: 1) the loop connecting 
strands 2 and 3; 2) the N-terminal third of the vestigial active-site loop; and 3) the C-terminal 
residues of the domain (118). 
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Upon PTAP binding, the binding groove of Tsg101 UEV closes and enwraps the PTAP 
motif (117). The C-terminal residues become well ordered and the biggest change in the 
structure comes from rotation of the phenylalanine (Phe) 142 phenyl side chain allowing it 
to contact the proline (Pro) 10 in PTAP (71). PTAP peptide binding is mediated by extensive 
intermolecular contacts with the four central residues Pro7-Thr8-Ala9-Pro10 as shown in 
Figure 1.9. 
 
Figure 1.9 Binding of the HIV-1 PTAP peptide. 
 Contacts established between Tsg101 UEV residues and the p6 peptide are shown in the crystal structure of 
the complex. See text for details. Image was taken from (71). 
 
The combined solution structure analysis by Pornillos et al (117) and crystal structure 
of the complex from Im et al (71), show that each residue of a p6 nonapeptide 5PEPTAPPEE13 
makes significant contacts to the UEV domain, except for Pro5. Glu6 forms a hydrogen bond 
to the side chain of Asn69 in UEV; however, the energetic contribution of this interaction is 
minimal. The first residue of the PTAP motif, Pro7 is fitted into a tight shallow pocket formed 
by the side chains of Thr58, Pro71, Thr92 and by NMR (nuclear magnetic resonance) analysis 
contact to Met95 is also apparent (71, 117). Pro7 is not as critical for binding as the other 
residues in the PTAP motif. For instance, a Pro7Ala mutant leads to a 3-fold reduction in 
affinity (71, 130). X-ray analysis of the complex revealed that the main-chain amide and the 
side-chain hydroxyl of the PTAP Thr8 residue hydrogen bonds to Asn69 in UEV while the -
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methyl of Thr8 side-chain points towards solvent and does not establish direct contacts (71). 
The Ala9 is strictly required at this position; this can be explained by the tight packing around 
the Ala methyl group formed by the side chains of the UEV residues Ile70, Met95, and 
Val141 (71). Ala9 forms a hydrogen bond to Ser143 in UEV. The Pro10 is buried deep in a 
hydrophobic pocket formed by the side chains of Pro139, Tyr63, Tyr68, and Phe142. Like 
Ala9, Pro10 also forms a hydrogen bond to Ser143 (71, 117). The side chain of Pro11 comes 
into close contact with the side chain of Tyr68. Glu12 and Glu13 are thought to make 
marginal contributions to the overall binding affinity (71).  
The Tsg101 UEV domain binds to ubiquitin (Ub) as part of its function during 
endosomal sorting of target proteins into multivesicular bodies (MVBs) followed by their 
degradation in the lysosome. The UEV domain can bind to ubiquitin at the same time as it 
binds to a PTAP peptide, although the 1:1 interaction between UEV and Ub is much weaker 
(Kd ~ 500 M) (49) and induces only minor conformational changes (109). The site of 
ubiquitin recognition in UEV has been described in detail (118, 137). The crystal structure of 
the UEV-Ub complex shows that Ub forms a five-stranded mixed -sheet packed against a 
helix as in the unbound form (137). UEV recognizes Ub through the -tongue formed by 
strands 1 and 2 and also uses residues from the loop that follows strand 4 as shown in Figure 
1.10. 
 
 
 
 
Figure 1.10 Structure of the complex between the Tsg101 UEV Domain and Ub. 
 The main binding determinants in UEV are the -tongue formed from strands 1 and 2, as well as residues 
within the loop that follows strand 4. Ub binding to UEV includes the Ile44 hydrophobic patch in Ub. Image was 
modified from (137). 
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Mutation of residues within the -tongue reduces Ub binding (118) and can impair 
physiological processes, such as the downregulation of the EGF receptor (137). The 
elongated interface buries Ub Ile44 and surrounding residues, which comprise the Ile44 
hydrophobic patch of Ub that has functional roles in endocytosis, proteasomal degradation 
and HIV release (137). Residues in the loop between strand 4 and strand 5 of Ub also form 
part of the UEV-Ub interface (137). Moreover, x-ray analysis of the complex indicates that 
UEV could in principle bind to polyubiquitin since Lys48 and Lys63 residues, as well as the C 
terminus of Ub are accessible and not buried at the UEV interface (137).  
As mentioned above, UEV can in principle bind to Ub and a PTAP peptide 
simultaneously as depicted in Figure 1.11. 
 
Figure 1.11 Tsg101 UEV can simultaneously bind a PTAP peptide and Ub. 
The Tsg101 UEV domain uses different interfaces to recognize and bind to both Ub and a PTAP peptide. 
Adapted from (137). 
 
This coupled interaction might be relevant in the context of HIV-1 budding since 
fusion of a Ub moiety to the C-terminus of HIV-1 p6 increased the affinity of Tsg101 UEV 
binding about 10-fold, resulting in an average Kd value of 2.3 M. This finding suggests that 
Tsg101 could bind ubiquitinated Gag molecules more tightly in vivo (49). A role for ubiquitin 
in retrovirus budding is not without precedent. It is known that retrovirus particles of avian 
leukosis virus ALV, HIV, SIV and MLV contain free ubiquitin. Moreover, cumulative mutation 
of lysine residues in HIV-1 Gag and proteasome inhibition impede virus budding, presumably 
because it depletes intracellular ubiquitin pools (93). In addition, fusion of a Ub moiety to 
the C-terminus of retroviral Gag proteins can bypass the need for a L-domain or can even 
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have a synergistic effect in the presence of a L-domain (157). The strongest evidence 
supporting a role of ubiquitination in virus egress is provided by the fact that PPXY L-
domains recruit ubiquitin ligases of the Nedd4 family and that virus release is dependent on 
the catalytic activity of the ligase (93, 157). The relevant target for ubiquitination, however, 
is not known. It is possible that ubiquitination of a cellular protein, perhaps related to the 
class E Vps pathway or the endocytic machinery is the functional target of ubiquitination. On 
the other hand, it is plausible that the sole presence of ubiquitin at the site of budding, 
irrespective of the target, might be necessary and sufficient to engage components of the 
ESCRT machinery (157).  
1.5 Phosphorylation as a posttranslational modification usurped by 
HIV-1 
1.5.1 Kinase structure and levels of substrate specificity 
 
Phosphorylation is a versatile posttranslational modification used to orchestrate 
multiple and diverse cell signaling events. For instance, phosphorylation is involved in 
controlling cell division, differentiation, motility, and metabolism. Protein kinases are the 
effectors of phosphorylation and constitute one of the largest families of genes in 
eukaryotes, making up about 2 % of the genome (140). Moreover, it is estimated that 30 % 
of all cellular proteins are phosphorylated on at least one residue. This would mean that a 
typical kinase must recognize between one and a few hundred true phosphorylation site in a 
background of around 700,000 potentially phosphorylatable residues. Even the most 
promiscuous kinases can select their targets from among this big pool of substrates. 
Although the cell can tolerate some off-target phosphorylation, it is of utmost importance to 
identify the proper target. Thus, phosphorylation seems to be an overwhelming task for 
kinases. Hence, multiple mechanisms have evolved that convey accurate specificity to the 
reaction, starting with the kinase itself (140).  
There are more than 500 protein kinases and more than 140 protein phosphatases in 
eukaryotes (66). Most eukaryotic kinases are structurally similar, exhibiting a high degree of 
flexibility and large rotational freedom about their lobes. This allows for the binding of 
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substrates, cofactors, autoinhibitory domains or interacting proteins (15). Typical kinases 
have a conserved catalytic domain of about 250 amino acids in length that consists of an N-
terminal lobe of -sheets and a C-terminal lobe of -helices. ATP-Mg2+ binds in a cleft 
between the two lobes, making many contacts to the N-terminal lobe and burying the 
adenosine in a hydrophobic pocket with the phosphate backbone pointing outwards 
towards the solution as depicted in Figure 1.12 (8). 
 
Figure 1.12 Protein kinase structure with ATP and amino acid phosphorylation reaction. 
A) Crystal structure of the cyclin-dependent kinase-2 (CDK2) illustrates the common structural fold shared by 
many kinases that consists of two lobes: an N-terminal lobe (in yellow) made up of beta-sheets and C-terminal 
lobe (in purple) made up of alpha-helices. ATP is bound in between two lobes. Adapted from (90). B) 
Phosphorylation of hydroxyl groups by serine/threonine and tyrosine kinases (from online lectures by Hartmut 
Luecke, University of California, Irvine http://bass.bio.uci.edu/~hudel. 
 
The protein substrate binds along the cleft and a set of conserved residues within the 
kinase catalytic domain catalyze the transfer of the terminal -phosphate of ATP to the 
hydroxyl of the Ser, Thr or Tyr residue of the substrate. Although all typical kinases share this 
common structure, they differ in terms of the charge and hydrophobicity of surface residues. 
Importantly, these differences contribute to kinase specificity (140).  
As mentioned above, in order to prevent promiscuous activity, phosphorylation is 
subject to different levels of regulation that help achieve target specificity. The first level of 
substrate specificity is achieved by the kinase active site. The structure of the catalytic 
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domain helps discriminate between Ser/Thr and Tyr kinases. The catalytic cleft of Ser/Thr 
kinases is not as deep as that of Tyr kinases, since Ser/Thr residues have smaller side groups 
unlike Tyr residues. This feature also contributes to the specificity of phosphatases. The 
specificity contributed by the catalytic cleft depth is not absolute and there are instances 
when Ser/Thr kinases can phosphorylate Tyr residues; the opposite reaction is not as 
common. A second level of specificity is imparted by consensus sequences: the sequence of 
amino acids N- and C-terminal to the substrate phosphosite (P-site). In the majority of cases, 
the kinase active site will interact with the four amino acids on either side of the P-site. 
Some kinases prefer to phosphorylate a residue having basic neighbors; others prefer to 
have a Pro near to the P-site (103). However, the presence of a consensus phosphorylation 
site in a protein does not guarantee that the protein is a substrate in vivo and authentic 
phosphorylation sites do not always conform to the consensus. The basis for the interaction 
with these consensus sequences involves charge, hydrogen bonding potential or 
hydrophobic interactions (140). In addition, protein folding brings distant residues together, 
thus, the three-dimensional structure can determine whether a protein kinase can recognize 
a residue as a substrate (103). Another level of specificity is conveyed by the presence of 
docking motifs on the substrate that are recognized by interaction domains present in the 
kinase. This greatly increases the affinity of kinases. Some of the best well-known docking 
motifs occur in MAPK substrates. These can occur as D or DEF domains, which conform to a 
specific pattern of residues. The D domains are commonly 50-100 residues away from the P-
site, while the DEF domains are found 10 amino acid residues downstream of the 
phosphorylation site. Docking motifs or interaction domains are also found within kinases 
and consist of SH2 (src-homology-2), SH3 (src-homology-3), and PH (pleckstrin homology) 
domains (to name just a few) in Tyr kinases. In Ser/Thr kinases, the interaction domain is 
usually part of the kinase domain and thus do not offer as much flexibility as Tyr kinases in 
this respect. The cellular localization of a kinase also imparts an important degree of 
specificity to the interaction since it limits the kinase to interact only with those substrates 
present within the same compartment. Scaffolding proteins play a critical role in preventing 
crosstalk between kinases that are involved in multiple pathways, thus making a very 
important contribution to substrate specificity (10). Many substrates require multiple 
phosphorylation events before being activated; this is actually an advantage to off-target 
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phosphorylation, which can occur despite all the described modes to achieve specificity. 
Thus, kinetic proofreading by phosphatases can help ensure that only the correct residues 
are phosphorylated before an effect takes place (140). 
1.5.2 Phosphorylation of HIV-1 proteins 
 
Protein kinase activity has been detected within purified particles of many enveloped 
viruses including retroviruses, herpesviruses, poxviruses and orthomyxoviruses. In many 
cases, these virion-associated protein kinases or VAPKs play important roles in viral 
infectivity, uncoating, transcription and replication (65). It has been shown that kinases are 
incorporated into HIV-1 particles. One is the activated form of the ERK2/MAPK, the other is 
the catalytic subunit of PKA (c-PKA), while the other is an unidentified 53 kDa protein kinase 
(24, 25).  
Capsid  
The capsid (CA) protein of HIV-1 was initially reported to be phosphorylated at Ser 
residues (97, 143) later identified as Ser109, Ser149 and Ser178; however, other additional 
residues in CA seem to be phosphorylated. It was shown that mutation of these three 
residues does not affect virus assembly or budding but instead seems to interfere with the 
virus uncoating process, thus preventing the reverse transcription process. It was further 
hypothesized that CA phosphorylation may generate repulsive forces that lead to core 
destabilization and particle uncoating (26). A follow-up study suggested that the CA is 
phosphorylated by c-PKA (25). More recently, the effect of these mutants designed to 
mimick a constitutive phosphorylated state was studied in the context of in vitro CA 
assembly and was also tested in vivo. The mutations were found to inhibit CA assembly in 
vitro and resulted in aberrant HIV-1 virions in vivo , thus providing support to the idea that 
CA phosphorylation serves to disassemble the CA early after entry promoting the uncoating 
process (17).  
Matrix  
The matrix (MA) protein of HIV-1 has been reported to be primarily phosphorylated 
on Tyr prior to or during virus assembly, while in virions and in isolated pre-integration 
complex (PIC) from infected cells, it seems to be phosphorylated exclusively on Ser residues 
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(39). Further study of Ser mutants within MA revealed that they were important for virus 
infectivity. This observation led to the hypothesis that phosphorylation of MA at these 
multiple Ser residues might disrupt the overall charge balance on MA, disrupting 
electrostatic interactions between MA and the plasma membrane. According to this model, 
cellular kinases specifically incorporated into the virion phosphorylate MA at an early 
postentry step, releasing it from the lipid bilayer and making it available to associate with 
the PIC (18). Previously, MA protein phosphorylation had been implicated in its targeting to 
the plasma membrane; however, it was shown that MA mutations that mimic 
phosphorylation have no effect on its ability to associate with membranes (125).  
Accessory proteins 
In addition, the HIV-1 accessory proteins Vpu, Nef, Rev, Vif, Tat and Vpr have been 
reported to be phosphorylated. The cytoplasmic domain of Vpu is phosphorylated by casein 
kinase II (CKII) and this phosphorylation is necessary for the degradation of CD4 in the 
endoplasmic reticulum. Nef is phosphorylated by the protein kinase C and this 
phosphorylation leads to increased downregulation of CD4 from the cell surface. Rev 
phosphorylation by CKII and MAPK was reported to enhance its binding efficiency to RNA. 
Phosphorylation of Vif seems to be important for HIV-1 replication. Tat phosphorylation by 
CDKII and the dsRNA-dependent serine/threonine protein kinase (PKR) was shown to be 
important for HIV-1 transcription (2, 38). 
  
  Introduction 
 
39 
 
 
1.5.3 HIV-1 p6 as the major phosphoprotein in virus particles 
 
The C-terminus of the structural HIV-1 Gag protein corresponds to the p6 domain. 
Besides containing L-domain activity critical for mediating virus release, it is also subject to 
various posttranslational modifications, such as ubiquitination, sumoylation and 
phosphorylation. In a study conducted by Müller et al (101), p6 was identified as the major 
phosphoprotein in HIV-1 virions; it was estimated that at most 5 % of p6 molecules are 
phosphorylated at multiple Ser, Thr and Tyr residues as determined by phosphoamino acid 
analysis. Moreover, in vitro kinase studies revealed that p6 can be phosphorylated by virion-
associated kinases, most likely ERK2. The functional relevance of p6 phosphorylation was 
subsequently addressed by Hemonnot et al (60); their study suggests that phosphorylation 
of a single residue in p6—Thr23— by the ERK2 kinase is required for efficient virus release. 
Moreover, they found that p6 Thr23 mutant virions display an aberrant morphology and are 
less infectious. However, ERK2 does not seem to be solely responsible for p6 
phosphorylation and they suggest that additional cellular kinases are likely involved in this 
process. 
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Goal of the study 
 
The HIV-1 p6 protein establishes various interactions with cellular and viral proteins 
and plays a critical role in HIV-1 particle release. Moreover, p6 was identified in our group to 
exist as the major phospoprotein within HIV-1 particles. p6 is made up of 52 amino acid 
residues, out of which 13 are potential phosphorylation sites. The phosphorylation state and 
potential function of this modification has not been examined in detail. Thus, the overall aim 
of this study was to analyze the functional consequences of potential phosphorylation site 
mutants in p6 and to identify actual sites of phosphorylation. The first step was to select p6 
residues that were strongly predicted to be phosphorylated and that were highly conserved 
among different HIV-1 subtypes by using phosphorylation prediction programs and p6 
sequence alignments of different HIV-1 subtypes. Mutants of selected residues were 
analyzed for potential effects in virus release, maturation and replication. This analysis was 
combined with mass spectrometry, a powerful analytic tool, to identify actual 
phosphoresidues in p6. Investigating and understanding the relevance of p6 phosphorylation 
might contribute to uncover potential targets for anti-viral therapy and pave the way 
towards effective drugs against cellular activities that support viral replication. 
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2 Materials and Methods 
2.1 Materials and instruments 
 
Material Manufacturer 
Acrylamide Rotiphorese Gel, Roth, Karlsruhe, Germany 
BioCAD Sprint Perfusion 
Chromatography System 
Dialysis tubing 
 
DNA gel extraction kit 
Applied Biosystems Deutschland GmbH, Darmstadt, 
Germany 
Spectra/Por® 3 (MWCO 3.5 kDa/MWCO 0.1-0.5 Kda) 
Sartorius AG, Göttingen, Germany 
Nucleospin® Extraction II, Macherey-Nagel, Düren, 
Germany 
Blotting paper 3MM Chr, Whatman, Dassel, Germany 
Dulbecco's Modified Eagle's 
Medium (DMEM) high glucose 
Gibco/Invitrogen, Karlsruhe, Germany 
ELISA plates Maxisorb, Nunc, Wiesbaden, Germany 
Epon 812 Carl-Roth GmbH, Karlsruhe, Germany 
FCS 
FugeneHD 
Biowest, Nuaillé, France 
Roche, Basel, Switzerland 
Infrared scanner Odyssey, LI-COR Inc., Lincoln, NE, USA  
Interleukin-2 
ITC200 
Kanamycin 
Microfuge® tube 
Biomol, Hamburg, Germany 
MicroCal LLC, Northampton, MA 
Roth, Karlsruhe, Germany 
Beckman Coulter, Krefeld, Germany 
Microtip-sonifier Sonifier 250, Branson, CT, USA 
Mircoplate reader MR5000, Dynatech, Enbrach, Switzerland 
Nitrocellulose membrane 
Ni+2 NTA sepharose 
NuPAGE Bis-Tris 4-12 % gel  
OptiPrepTM 
Phosphatase inhibitor cocktail Set 
V, 50X 
Protran, Schleicher & Schüll/Whatman, Dassel, Germany 
GE Healthcare Europe GmbH, Munich, Germany 
Invitrogen GmbH, Darmstadt, Germany 
Axis Shield, Oslo, Norway 
Calbiochem/Merck, Darmstadt, Germany 
Phytohemaglutinin Sigma-Aldrich, Steinheim, Germany 
Plasmid purification kit NucleoBond MaxiPrep Kit, Macherey-Nagel, Düren, 
Germany 
Prepacked Superdex 200 16/60 
RPMI1640 
Ultracentrifuge 
GE Healthcare Europe GmbH, Munich, Germany 
Gibco/Invitrogen, Karlsruhe, Germany 
Optima XL-70,  Beckman Coulter, Fullerton, CA, USA 
SDS-PAGE electrophoresis 
chamber 
Minigel-Twin, Biometra, Göttingen 
Semi-Dry Blotter Fastblot B44, Biometra, Göttingen 
Spectrophotometer DU 640, Beckman Coulter, Fullerton, CA, USA 
Tabletop ultracentrifuge 
Transmission electron microscope 
EM10 
TL-100, Beckman Coulter, Fullerton, CA, USA 
Zeiss, Germany 
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2.2 Buffers and reagents 
 
Name Concentrations Recipe 
4x separating gel buffer 
 
1.5 M Tris-HCl pH 8.8 
 
90.8 g Tris ad 500 ml H2O 
4x stacking gel buffer 
 
0.5 M Tris-HCl pH 6.8 
 
30.3 g Tris ad 500 ml H2O 
 30% acrylamide (200:1)  1.5 g N,N’-Methylen-bis-
acrylamid,  1000 ml 30% 
Rotiphorese Gel A 
 
30% acrylamide for stacking 
gels 
29% acrylamide  
1% bisacrylamide 
 
 
5x protein sample buffer 200 mM Tris/HCl pH 8.8  
10% Sucrose  
5 mM EDTA 
0.1% Bromphenol Blue 
4% SDS 
2% -MeEtOH 
 
before usage, add 
10 ml 20% SDS 
1 ml -MeEtOH 
to 50 ml sample buffer;  
store at 4°C 
Western blot blocking buffer 5% milkpowder in TBST  
 
Separating gel 
(2 minigels; 10 ml) 
17% acrylamide (200:1) 
375 mM Tris-HCl pH 8.8 
0.1% SDS 
0.1% APS 
0.0014% TEMED 
5.8 ml acrylamide 200:1 
2.5 ml 4x separating gel buffer 
50 µl 20% SDS 
1.8 ml H2O 
for polymerization add  
100 µl 10% APS; 14 µl TEMED 
 
stacking gel  
(2 minigels; 4 ml) 
3% acrylamide 
125 mM Tris-HCl pH 6.0 
0.1% SDS 
0.06% APS 
0.3% TEMED 
400 µl 30% acrylamide 
500 µl 4x stacking gel buffer  
20 µl 20% SDS 
3.0 ml H2O 
for polymerization add  
24 µl 10% APS; 12 µl TEMED 
 
10x TBST  
(1000 ml) 
200 mM 1M Tris 
150 mM NaCl 
0.5% Tween 
200 ml 1 M Tris pH 7.5 
87.66 g NaCl 
5 ml Tween 
 
1x Western blot transfer 
buffer  
(1000 ml) 
48 mM Tris 
39 mM Glycine 
0.375% SDS 
20% methanol 
5.82 g Tris 
2.93 g Glycine 
0.375 g SDS 
200 ml methanol 
50x TAE buffer 
(1000 ml) 
2 M Tris-acetate 
50 mM EDTA 
242 g Tris 
57 ml acetic acid 
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100 ml 0.5 M EDTA pH 8.0 
 
10x SDS-PAGE electrophoresis 
buffer 
(1000 ml) 
250 mM Tris 
1.92 M glycine 
1% SDS 
30.29 g TRIS 
144.13 g Glycine 
10 g SDS 
 
10x PBS 
(1000 ml) 
1.37 M NaCl 
27 mM KCl 
80 mM Na2HPO4 
18 mM KH2PO4 
80 g NaCl 
2 g KCl 
14.4 g Na2HPO4‧2H2O 
2.4 g KH2PO4 
 
 
2x HeBS transfection buffer 
(1000 ml) 
280 mM NaCl 
50 mM HEPES 
1.5 mM Na2HPO4 
pH 7.05-7.12 
 
16.4 g NaCl 
11.9 g HEPES 
0.267 g Na2HPO4‧H2O 
filter sterilize through 0.45 µm 
pore size filters; store at 4°C 
 
2x CaCl2 transfection buffer 
(1000 ml) 
 
250 mM CaCl2 36.8 g CaCl 2‧2H2O; 
filter sterilize through 0.45 µm 
pore size filters; store at -20°C 
 
LB medium 
(1000 ml) 
 
1 % peptone 
0.5 % yeast extract 
171 mM NaCl 
10 g tryptone 
5 g yeast extract 
5 g NaCl 
0.5 ml 10 N NaOH 
pH 7.0 
 
 
LB agar 
 
13 % agar in LB medium 1 l LB medium 
13 g agar 
 
Fixative for thin section-EM 
(6 ml) 
 
 
Silver stain fixative 
2.5 % glutaraldehyde 
0.2 M NaCacodylate 
 
 
50 % methanol 
12 % CH3COOH 
500 l formaldehyde 
 
600 µl glutaraldehyde 
3 ml NaCacodylate 
2.4 ml H2O 
 
500 ml 
120ml 
500 l 
200x NaN3 stock solution 10 % NaN3 in PBS 5 g NaN3 in 50 ml PBS 
 
10x DNA loading buffer 
(10 ml) 
50 % sucrose 
10 mM EDTA 
2 % bromphenol blue 
2 % orange G 
5 g sucrose 
200 µl 0.5 M EDTA 
0.2 g bromphenol blue 
0.2 g orange G 
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2.3 Primers 
Name Sequence (5‘ → 3‘) Used to clone 
alphahuENaCfw GCGCGGATCCATGGAGGGGAACAAGCTGG ENAC α human 
alphahuENaCrv GCGCGAATTCGGGCCCCCCCAGAGGAC ENAC α human 
FL_ANXA1BamHI_rev GCGCGGATCCCCGTTTCCTCCACAAAGAGCC Annexin 1 human 
FL_ANXA1NheI_fw GCGCGCTAGCATGGCAATGGTATCAGAATTC Annexin 1 human 
FL_ANXA1stop_rev GCGCGGATCCTTAGTTTCCTCCACAAAGAGC Annexin 1 human 
FLhuANXA1-BamHI-rev CAAACGGGATCCGTCTTGTG FRB-Annexin 1 
FLhuANXA1-PstI-forw CGACTGCAGAGTGTGAAATC Annexin 1 human 
HAUb-CterAvrII-fw GCGCCCTAGGATGGCTAGCTACCCTTATG HA-Ubiquitin-FRB 
HAUb-CterAvrII-rv GCGCCCTAGGTCAGCGGTTTAAACTTAAGC FRB-HA-Ubiquitin 
HAUb-CterSpeI-rv GCGCACTAGTTCAGCGGTTTAAACTTAAGC FRB-HA-Ubiquitin 
HAUb-NterXbaI-fw GCGCTCTAGAATGGCTAGCTACCCTTATG HA-Ubiquitin-FRB 
huANXA1_1_forw CAATCCATCCTCGGATGTC Annexin 1 human 
huANXA1_1_rev CAGCACGAAGTTCATCAGC Annexin 1 human 
huANXA1_2_forw AGCAGGCCTGGTTTATTG Annexin 1 human 
huANXA1_2_rev CTGGAGTTTTTAGCAGAGC Annexin 1 human 
huANXA1_siRNA1 CACGUUUACGUCUGUCCCCTT Annexin 1 siRNA 
huANXA1_siRNA2 UAAGGGCUUUCUUAAGUGUTT Annexin 1 siRNA 
huANXA1_siRNA3 CAGCGACAUCCAGGAUGGATT Annexin 1 siRNA 
huANXA1CterSpeI-rv GCGCACTAGTGTTTCCTCCACAAAGAGCC FRB-Annexin 1 
huANXA1NterXbaI-fw GCGCTCTAGAATGGCAATGGTATCAGAATTC Annexin 1-FRB 
ITCHBamHI-rv GCGCGGATCCTTACTCTTGTCCAAATCCTTC FRB-Itch 
ITCHCterHECTrev GCGCACTAGTCTCTTGTCCAAATCCTTCTG FRB-Itch HECT 
ITCHCter-SpeI-rv 
MLVGag(Basyuk)-rv 
GCGCACTAGTCTCTTGTCCAAATCCTTC 
GCGCGAATTCGTCATCTAGGGTCAGGAG 
FRB-Itch 
MLV gag 
ITCHHECTNotI-fw GCGCGCGGCCGCATGAGCTTCAGTCCCCAAG Itch HECT domain 
ITCHNotI-fw GCGCGCGGCCGCATGTCTGACAGTGGATCAC Itch Ub ligase 
ITCHNterHECTfw GCGCTCTAGAATGAGCTTCAGTCCCCAAG Itch HECT-FRB 
ITCHNter-NheI-fw GCGCGCTAGCATGTCTGACAGTGGATCA 
CAAC 
Itch-FRB 
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Nedd4LCterHECTrev GCGCACTAGTATCCACCCCTTCAAATCC FRB-Nedd4L HECT 
Nedd4LCter-SpeI-rv GCGCACTAGTATCCACCCCTTCAAATCC FRB-Nedd4L 
Nedd4LDC2CterSpeI-rv GCGCACTAGTATCCACCCCTTCAAATCCTT FRB-Nedd4LdelC2HECT 
Nedd4LDC2NterXbaI-fw GCGCTCTAGAATGGAGCGACCCTATACATT Nedd4LdelC2HECT-FRB 
NEDD4LHECTNotI-fw GCGCGCGGCCGCATGTCCGTGAAAAGACCAG Nedd4L HECT 
NEDD4LMfeI-rv GCGCCAATTGTTAATCCACCCCTTCAAATCC Nedd4L  
NEDD4LNotI-fw GCGCGCGGCCGCATGGCGACCGGGCTCG Nedd4L 
Nedd4LNterHECTfw GCGCTCTAGAATGTCCGTGAAAAGACCAG Nedd4L HECT-FRB 
Nedd4LNter-XbaI-fw GCGCTCTAGAATGGCGACCGGGCTCGGGGAG Nedd4L-FRB 
NterApaI-fw GCGCGGGCCCCTAGGAAAAAGGGCTGTTGG pNL4-3 
pECFP-N1_fw AGTACATGACCTTATGGGAC sequencing 
pNL43-MluI(2)-fw GCGCTTTCTTCAGAGCAGACGCGTGCCAACAGCC pNL4-3 
pNL43-MluI(2)-rv GCGCGGCTGTTGGCACGCGTCTGCTCTGAAGAAA pNL4-3 
pNL43-MluI(3)-fw GCGCCAGAGCAGACGCGTGCCAACAG pNL4-3 
pNL43-MluI(3)-rv GCGCCTGTTGGCACGCGTCTGCTCTG pNL4-3 
pNL43-MluI-fw GCGCCTTCAGAGCAGACGCGTGCC pNL4-3 
pNL43-MluI-rv GCGCGGCTGTTGGCACGCGTCTGC pNL4-3 
pNL43-rv GCGCACTCAGGAATCCAGGTGGC sequencing 
S40N(2)-fw GCGCCCTATCGATAAGGAACTGTATCCTTTAGCTA
ACCTCAGATC 
pNL4-3-uncoupled 
S40N(2)-fw GCGCCCTTTAGCTAATCTCAGATCAC pNL4-3-uncoupled 
S40N(2)-rv GCGCGATCTGAGGTTAGCTAAAGGATACAGTTCCT
TATCGATAGG 
pNL4-3-uncoupled 
S40N(2)-rv GCGCGTGATCTGAGATTAGCTAAAGG pNL4-3-uncoupled 
S51N(2)-fw GCGCGACCCCTCGAATCAAGCCAATTTTTTAGGGT
AGATC 
pNL4-3-uncoupled 
S51N(2)-rv GCGCGATCTACCCTAAAAAATTGGCTTGATTCGAG
GGGTC 
pNL4-3-uncoupled 
S51N-fw GCGCGACCCCTCGAATCAAGCCAAT pNL4-3-uncoupled 
S51N-rv GCGCATTGGCTTGATTCGAGGGGTC pNL4-3-uncoupled 
Ser14Ala-fw GCGCAGAAGAGGCCTTCAGGTTTG pNL4-3 
Ser14Ala-rv GCGCAAACCTGAAGGCCTCTTCTG pNL4-3 
Ser14Asp-fw GCGCAGAAGAGGACTTCAGGTTTG pNL4-3 
Ser14Asp-rv GCGCAAACCTGAAGTCCTCTTCTG pNL4-3 
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Ser25Ala-fw GCGCCAACTCCCGCTCAGAAGCAG pNL4-3 
Ser25Ala-rv GCGCCTGCTTCTGAGCGGGAGTTG pNL4-3 
Ser25Asp-fw GCGCCAACTCCCGATCAGAAGCAG pNL4-3 
Ser25Asp-rv GCGCCTGCTTCTGATCGGGAGTTG pNL4-3 
Thr8Asn-fw GCGCAGAGCCAAATGCCCCACC pNL4-3 
Thr8Asn-rv GCGCGGTGGGGCATTTGGCTCT pNL4-3 
Thr8Gln-fw GCGCAGAGCCACAAGCCCCACC pNL4-3 
Thr8Gln-rv GCGCGGTGGGGCTTGTGGCTCT pNL4-3 
Thr8Glu-fw GCGCAGAGCCAGAAGCCCCACC pNL4-3 
Thr8Glu-rv GCGCGGTGGGGCTTCTGGCTCT pNL4-3 
Tsg101UEV-fw GCGCCTAGTAACGGCCGCCAGTG Tsg101UEV 
Tsg101UEV-rv GCGCCGGCCGCCAGTGTGATGG Tsg101UEV 
Ub-CterSpeI-fv GCGCTCTAGAATGCAGATCTTCGTGAAGAC FRB-Ubiquitin 
Ub-CterSpeI-rv GCGCACTAGTGCGGTTTAAACTTAAGCTTGG FRB-Ubiquitin 
unc-seqBcl-rv GCGCGCTTTATGTCCGCAGATTTCTATGAGTAT sequencing 
unc-seqSP2fw GCGCTTTTGGCTGAAGCAATGAGCCAAG sequencing 
WWP1Cter-AvrII-rv GCGCCCTAGGTTCTTGTCCAAATCCCTC FRB-WWP1 
WWP1CterHECTrev GCGCACTAGTTTCTTGTCCAAATCCCTCTGT FRB-WWP1HECT 
WWP1EcoRI-rv GCGCGAATTCTCATTCTTGTCCAAATCCC WWP1 ligase 
WWP1HECTNotI-fw GCGCGCGGCCGCATGGCATTAAAACCCTATGAC WWP1 HECT 
WWP1NotI-fw GCGCGCGGCCGCATGGCCACTGCTTCACC WWP1 ligase 
WWP1NterHECTfw GCGCTCTAGAATGGCATTAAAACCCTATGAC WWP1HECT-FRB 
WWP1Nter-NheI-fw GCGCGCTAGCATGGCCACTGCTTCACCAAGG WWP1-FRB 
WWP2CterHECTrev GCGCACTAGTCTCCTGTCCAAAGCCCTC FRB-WWP2HECT 
WWP2Cter-SpeI-rv GCGCACTAGTCTCCTGTCCAAAGCCCTC FRB-WWP2  
WWP2EcoRI-rv GCGCGAATTCTTACTCCTGTCCAAAGCCC WWP2 ligase 
WWP2HECTNotI-fw GCGCGCGGCCGCATGAAACCCTATGACCTGC WWP2 HECT 
WWP2NotI-fw GCGCGCGGCCGCATGGCATCTGCCAGCTCTA WWP2 ligase 
WWP2NterHECTfw GCGCTCTAGAATGAAACCCTATGACCTGC WWP2 HECT-FRB 
WWP2Nter-XbaI-fw GCGCTCTAGAATGGCATCTGCCAGCTCTAGC WWP2-FRB 
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2.4 Plasmids 
 
Name Description Reference 
Uncoupled FL pNL4-3 uncoupled backbone, contains point mutants 
of all Ser, Thr and Tyr in p6, except for Thr8  
This work 
Uncoupled Nter pNL4-3 uncoupled backbone, contains point mutants 
of N-terminal Ser and Thr residues in p6  
This work 
Uncoupled Cter pNL4-3 uncoupled backbone, contains point mutants 
of C-terminal Ser and Thr residues in p6 
This work 
pET11c-Tsg101UEV Tsg101UEV domain cloned for protein expression This work 
pHIVGagWT-FKBP 
pHIVGagp6-FKBP 
pcDNA3 backbone, HIV WT Gag tagged with FKBP 
pcDNA3 backbone, HIV Gagp6 tagged with FKBP 
S. Jäger 
S. Jäger 
Tsg101-FRB pC4-RHE backbone, FRB tagged Tsg101 S. Jäger 
FRB-Ub pC4-RHE backbone, FRB tagged Ub Appendix A 
FRB-Itch pC4-RHE backbone, FRB tagged Itch Appendix A 
FRB-WWP1 pC4-RHE backbone, FRB tagged WWP1 Appendix A 
FRB-WWP2 pC4-RHE backbone, FRB tagged WWP2 Appendix A 
Nedd4L-FRB pC4-RHE backbone, FRB tagged Nedd4L Appendix A 
pNL4-3 Subviral plasmid (1) 
pNL4-3-MluI Subviral plasmid; contains MluI silent restriction site This work 
pNL4-3 uncoupled pNL4-3 backbone, uncoupled gag and pol reading 
frames 
This work and 
(89) 
pNL4-3 p6T8D pNL4-3 backbone, contains a single point mutation in 
p6 Thr8 
This work 
pNL4-3 p6S14A pNL4-3 backbone, contains a single point mutation in 
p6 S14 
This work 
 
pNL4-3 p6S14D pNL4-3 backbone, contains a single point mutation in 
p6 S14 
This work 
pNL4-3 p6S25A 
 
pNL4-3 backbone, contains a single point mutation in 
p6 S25 
This work 
 
pNL4-3 p6S25D 
 
pNL4-3 backbone, contains a single point mutation in 
p6 S25 
This work 
 
pNL4-3 p6T8N pNL4-3 backbone, contains a single point mutation in This work 
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 p6 Thr8  
pNL4-3 p6T8E pNL4-3 backbone, contains a single point mutation in 
p6 Thr8 
This work 
pNL4-3 p6T8Q pNL4-3 backbone, contains a single point mutation in 
p6 Thr8 
This work 
2.5 Cell lines 
 
Name Origin/features Reference 
293T 
 
human embryonic kidney fibroblast , transduced with SV40 large  
T antigen  
(134) 
C8166 
 
human umbical blood lymphocytes, infected with defective  
HTLV-I 
(128) 
HeLa human cervix carcinoma (129) 
MT-4 
 
human T-cells isolated from a patient with adult T-cell leukemia, 
HTLV-I transformed 
(99) 
TZM-bl HeLa derived, harboring a Tat-inducible ß-galactosidase and  
luciferase reporter 
(148) 
2.6 Antibodies 
 
Antibody for WB Source Application Dilution 
IRDyeTM800CW anti-mouse-700       Rockland WB 1:20,000 
IRDyeTM800CW anti-mouse-800       Rockland WB 1:20,000 
IRDyeTM800CW anti-rabbit-700       Rockland WB 1:20,000 
IRDyeTM800CW anti-rabbit-800 Rockland WB 1:20,000 
IRDyeTM800CW anti-rat-800       Rockland WB 1:20,000 
Mouse anti-Tsg101 (4A10) GeneTex, Inc WB 1:100 
Mouse anti-Ub (P4D1) Covance WB 1:2000 
Rabbit anti-HIV CA Kräusslich lab WB 1:5000 
Rabbit anti-Nedd4L Wes Sundquist WB 1:300 
Rabbit anti-RSV CA Volker Vogt WB 1:10,000 
Rat anti-HA high affinity Roche WB 1:500 
Sheep anti-HIV CA Kräusslich lab WB 1:5000 
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2.7 Molecular Biological methods 
2.7.1 Transformation and plasmid amplification 
 
Chemically competent bacteria Stbl2, DH5α or BL21 (DE3) were transformed using 
the heat-shock procedure with plasmid DNA (1 µg). Bacteria were thawed on ice; DNA was 
added into the cells and incubated for 15 min on ice, heated for 4 min at 37°C and then 
cooled on ice for 2 min. The transformed bacteria were then incubated for 30min-1 h at 37°C 
in 800 µl antibiotic-free LB medium; they were then streaked out on an LB plate containing 
the appropriate antibiotic. Plates were incubated overnight at 37°C and single colonies were 
used to inoculate LB medium for mini (2.5 ml) or maxi (250 ml) plasmid preparations the 
following day. 
For preparative purification of plasmid DNA the NucleoBond® maxiprep kit 
(Macherey-Nagel) was used. Pellets of purified plasmids were dissolved in 10 mM Tris-HCl 
pH 8.0. Concentration and purity of the plasmid preparations were assessed by measuring 
extinctions at 260 nm and 280 nm in a UV spectrophotometer (Beckman Coulter). 
For analytical mini-preparation of plasmid DNA, the NucleoBond® Buffer Set-I was 
used (Macherey-Nagel). 2.5 ml overnight bacteria culture were pelleted for 5 min at 2000 xg 
(5000 rpm) and resuspended in 250 µl S1 buffer. Bacteria were lysed for 3-5 min through 
addition of 150 µl S2 buffer and the reaction was stopped by neutralization with 250 µl S3 
buffer. Afterwards, cell debris was pelleted for 10 min at 17,000 xg (15.000 rpm) at 4°C and 
discarded. The DNA in the supernatant was precipitated by addition of 600 µl 100% 
isopropanol, pelleted for 10 min at 17,000 xg at 4°C, washed once with 70% ethanol at room 
temperature and finally dissolved in 50 µl water or 10 mM Tris-EDTA pH 7.0 buffer. 
Minipreparations from newly cloned plasmids were tested by restriction digest as well as 
transfection of 293T cells by calcium phosphate transfection (2 µl miniprep-plasmid per well 
of a 12 well-plate). 
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2.7.2 DNA sequencing 
 
Sequencing of plasmids was performed by GATC Biotech (Konstanz, Germany) and 
data were analyzed using BioEdit (Tom Hall, Carlsbad, USA) or Vector NTI® (Invitrogen) 
software. 
2.7.3 Polymerase chain reaction (PCR) 
 
Polymerase chain reaction allows the specific enzymatic amplification of DNA 
fragments located between two oligonucleotide primers complementary to the 5’- and 3’- 
regions of the desired fragment. Primers were designed so that typically 12-18 nucleotides 
at the 3’-end of the primer were complementary to the template. At the 5’-end of the 
primer, restriction sites were introduced when necessary. 
 
For preparative amplification of DNA segments by PCR, the following recipe was used:  
 5.0 µl  10x Pfu-buffer 
 0.3 – 1.0µl * Pfu polymerase 
 2.0 µl fw-Primer (10 pmol/µl = 10 µM) 
 2.0 µl  rev-Primer (10 pmol/µl) 
 3.0 µl  2.5 mM dNTPs 
 0.2 µg DNA template 
 36.8 µl  H2O 
 
* the amount of Pfu polymerase used depends on the length of the expected DNA 
product 
 
Exponential amplification of the template during PCR is achieved by repeated cycles 
of amplification, during which the template is denatured, the primers are annealed to the 
template or PCR product already present, and elongated by the polymerase. The following 
temperature cycling protocol was used for PCR: 
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step temperature duration 
1: denaturation 94°C 5 min 
2: denaturation 94°C 1 min 
3: annealing 55°C 30 sec 
4: elongation 72°C 30 sec – 4 min* 
repeat steps (2-4) 25-30x   
5: elongation 72°C 10 min 
 
* depending on product length (~0.5 kb/min for Pfu polymerase) 
 
5 µl of the reaction was analyzed by DNA gel electrophoresis afterwards. 
2.7.4 Restriction digest and ligation 
 
All enzymes and buffers for DNA cloning were from Fermentas or NEB Biolabs and 
used as instructed. For a control restriction digest, 1 µg plasmid was incubated with 2 U 
restriction enzyme in a volume of 20 µl at the recommended temperature for 1-2 hrs and 10 
µl of the samples were analyzed by DNA gel electrophoresis to check size of the resulting 
DNA fragments. 
For further subcloning of the digested DNA, 2 µl plasmid or 40 µl gel-purified PCR 
product was digested with 20 U restriction enzyme in a volume of 50 µl for 2 hrs. 
Before ligation, vectors were dephosphorylated to avoid religation. For this, 1.5 U calf 
intestine alkaline phosphatase (CIAP) were incubated with the DNA for 30 min at 37°C. 
Ligation was performed using 3 µg vector, an estimated 5 molar excess of insert and 1 U T4 
DNA ligase in 1x ligase buffer in a total volume of 30 µl for 2 hrs at room temperature. The 
samples were subsequently transformed into a 50 µl aliquot of competent bacteria. 
2.7.5 DNA electrophoresis  
 
Depending on the size of the DNA fragment to be purified, 0.5–2 % agarose in TAE 
buffer was dissolved by heating, ethidiumbromide was added 1:20,000 and the gel was 
poured into the gel tray. DNA samples were mixed with DNA loading buffer, loaded onto the 
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gel and resolved for 20-40 min at 90 V. Bands of DNA were visualized with UV light of 312 
nm and compared to a DNA standard run on the same gel. 
For purification of DNA fragments from an agarose gel, the desired DNA band was excised 
from the gel illuminated with UV light of lower wavelength (366 nm) to avoid UV damage 
and purified using a DNA gel extraction kit (Macherey-Nagel). 
2.7.6 FRB and FKBP expression plasmids 
 
To generate expression plasmids for FRB fusion proteins with an HA-tag at the C-terminus, 
coding sequences of the respective protein were PCR-amplified with primers adding an 5’-
XbaI and an 3’-SpeI restriction site. Using the cloning strategy proposed in the kit’s manual, 
which is based on the compatibility of the cohesive ends of XbaI and SpeI sites, the PCR 
product was cloned either into the XbaI or SpeI site of the pC4-RHE vector so that the FRB 
gene is fused either N-terminally or C-terminally. 
2.7.7 Generation of p6 single point mutants 
 
The p6 Ser residues at positions 14 and 25 were selected and mutated to either an 
alanine or an aspartate (S14A, S14D, S25A, and S25D. The single point mutants were 
generated by oligonucleotide-directed mutagenesis using the appropriate primers and 
confirmed by sequencing. Fragments carrying the particular p6 point mutation were cloned 
back into the full-length infectious molecular clone, pNL4-3. 
2.7.8 Generation of an infectious pNL4-3 clone containing uncoupled 
gag-pol frames and p6 mutant derivates 
 
We generated an NL4-3 provirus with uncoupled gag and pol frames based on the 
strategy used by Leiherer et al (89). In brief, we introduced an MluI silent restriction site in 
the NL4-3 proviral clone at nucleotide position 1356 with respect to Gag ATG. The ApaI-MluI 
fragment (nucleotide position 1217-1356 with respect to Gag ATG) was replaced with a 
synthetically produced fragment (GENEART AG, Regensburg, Germany) thereby destroying 
the original slippery site UUUUUUA at position 1296 and the 3’ stem-loop structure by point 
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mutations to abrogate frameshifting. In its place, the complete functional frameshift signal, 
including the slippery site and stem-loop was introduced 5’ to the Gag stop codon. In the 
resulting provirus, the gag and pol genes were extended by 15 and 210 nucleotides, 
respectively, compared to those of the parent NL4-3 provirus clone. We introduced a ClaI 
silent restriction site into this new uncoupled gag-pol construct and derivates of this 
construct were generated by synthetically produced fragments (GENEART AG, Regensburg, 
Germany), which carried mutations in predicted phosphorylated residues of p6 at either of 3 
different regions: N-terminus, C-terminus, or the entire p6. These fragments were then 
cloned back into the uncoupled gag-pol construct by making use of 3 restriction sites: XmaI, 
ClaI and MluI. Predicted Ser and Thr residues in p6 were mutated into Asn, while the single 
Tyr in the p6 amino acid sequence was changed into a Phe. The change to these two amino 
acids was selected since these are thought to better maintain the proper folding of the 
protein (104). 
2.8 Biochemical Methods 
2.8.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western 
Blot 
 
Protein samples for SDS-PAGE were boiled in 1x sample buffer and stored at -20°C. 
For analysis by SDS-PAGE samples were applied on a freshly prepared 12.5 % cross-linking 
polyacrylamide gel and the electrophoresis was performed at 200 V for 1 h or longer. The gel 
was then semi-dry blotted onto a nitrocellulose membrane between three sheets of 
whatman-paper on top and bottom, everything soaked in Western blot transfer buffer for 1 
h (400 V, 240 mA, 10 W for two 6 x 9 cm blots). The membrane was subsequently blocked 
for 1 h at RT in 5 % skim milk/TBST and after 3 x 5 min washing incubated with the first 
antibody 1 h at RT or overnight at 4°C. All primary antibodies used for Western blotting were 
diluted in 1 % BSA/TBST/0.05 % NaN3, stored at 4°C. The blot was then washed 3 x 5 min 
with TBST and incubated with the secondary antibody for 30 min at RT. 
For quantitative detection of immunoreactive bands, membranes were incubated 
with fluorescence-dye-coupled secondary antibodies (Rockland, diluted 1:20 000 in PBST/1 
% BSA) for 30 min at RT, then washed 3 x 5 min followed by 1x PBS 10 min. After washing, 
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the blot was scanned on a digital infrared scanner (LI-COR Inc.). Signals were evaluated with 
Odyssey application software 2.1 (LI-COR Inc.). 
2.8.2 Silver staining 
 
The integrity and purity of OptiPrep-purified virus preparations was confirmed by 
silver staining of virus proteins. 2.5 l samples from sucrose pellet and OptiPrep virus pellets 
were analyzed and virus proteins separated by SDS-PAGE. All silver stain solutions must be 
prepared fresh. Subsequently, the gel was incubated while shaking for 1h RT with 100 ml per 
gel silver stain fixation buffer. The gel washed 3 x 10 min with 100 ml 50 % EtOH/ 50 % 
(solution I) Millipore H2O, followed by 3 x 20 min washes with Millipore H2O. The gel was 
then transferred into solution II (100ml H2O+150 ml solution A: 430 mg sodium thiosulfate in 
5 ml H2O) and incubated for 1 min while shaking. The gel is subsequently washed 3 x 20 sec 
with Millipore H2O and solution III is added (0.2 g AgNO3+75 ml formaldehyde in 100 ml H2O) 
and the gel is incubated for 20 min at RT. Finally, the gel is developed in solution IV (6 g 
sodium carbonate+5 l solution A+50 l formaldehyde in 100 ml H2O). The gel is developed 
for 5-10 min. For storage at 4°C, wash once with water and change into fixation buffer. 
2.8.3 Enzyme-Linked Immunosorbent Assay (p24-ELISA) 
 
The in-house p24-ELISA for detection of HIV-1 CA-protein in samples was used to 
determine virus concentration of p24 equivalents. 
Maxisorb 96-well plates (Nunc, Wiesbaden, Germany) were coated with monoclonal 
mouse-antibody raised against p24 (CA) (183-H12-5C) o/n at RT in a moist chamber and then 
blocked with 10 % FCS/PBST for 2 h in a moist chamber. Virus dilutions in PBST were added 
to the single wells and a titration of purified CA-protein was applied as a standard. Samples 
were incubated o/n at RT in a moist chamber. After washing with PBST, the plate was 
incubated 1h at 37 °C with a rabbit-antiserum raised against CA protein, followed by another 
washing step. Finally, the samples were incubation with horseradish peroxidase-coupled 
secondary antibody raised in goat against rabbit IgG for 1 h at 37 °C. After washing with PBST 
and H2O, the amount of bound antibody was visualized by addition of the chromogenic 
substrate tetramethyl benzidine (TMB) for 5 min. The labeling reaction was stopped by the 
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addition of 0.5 M sulfuric acid and the absorbance of the reaction product quantified in a 
spectrofluorimetric plate-reader at 405 nm wavelength.   
2.8.4 Tsg101 UEV domain purification 
 
A his-tagged version of the 145aa Tsg101 UEV domain (GI: 21465898) was custom 
synthesized into the pCR2.1 vector (MWG Eurofins) via NdeI and BamHI; gene was subcloned 
into the pET-11c vector and expressed in Escherichia coli BL21 codon plus cells. Briefly, 250 
ml LB medium with ampicillin was inoculated with a colony of cells and incubated overnight 
at 37°C. 50 ml of overnight culture were added to each of 4 flasks containing 1 l LB medium 
and grown at 37°C in an orbital shaker (160 rpm). Once the optical density of the culture 
reached a value of 0.8 at 600 nm, protein expression was induced with 100 M IPTG. After 3 
h of growth, cells were harvested by centrifugation and the pellet was resuspended in 1x PBS 
pH 8.0. The cells were broken by sonication (Branson microtip sonifier 250) for 3 x 2 min at 
50 % intensity while cooling on ice and ultracentrifuged for 20 min at 15,000 rpm (rotor JA-
20, Beckman Coulter). The cleared supernatant was loaded onto a Ni+2 NTA sepharose (GE 
Healthcare) column, eluted and dialyzed against either 50 mM Tris pH 8.0, 150mM NaCl for 
crystallization or against 1x PBS pH 8.0, 150 mM NaCl for isothermal titration calorimetry 
experiments. The protein was concentrated and the his-tag was then removed by overnight 
incubation with TEV protease. The untagged protein was then purified by gel filtration using 
a Superdex 200 16/60 (GE Healthcare) column. All chromatographic purifications were 
performed using a BioCAD Sprint Perfusion chromatography system (Applera Dtld. GmbH). 
Protein was concentrated to 43mg/ml using Vivaspin concentrators (3 or 10 kDa cut-off, 
Vivascience) and dialysis was performed in SpectraPor dialysis tubing (Spectra/Por® 3 
(MWCO 3.5 kDa/MWCO 0.1-0.5 Kda) Roth, Karlsruhe, Germany). Protein concentration was 
determined spectroscopically by absorbance measurements at 280nm, using an extinction 
coefficient of 25 900 M-1 cm-1 and a molecular weight of 16.61 kDa. The protein sample was 
either used for isothermal titration calorimetry or sent for crystallization trials to the group 
of Dr. Winfried Weissenhorn at the EMBL in Grénoble.  
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2.8.5 Peptides 
 
Peptides, PEPNAPPEE, PEPTAPPEE, PEPAAPPEE, PEPSAPPEE, were obtained as 
lyophilized salts of trifluoroacetic acid (Peptide Specialty Laboratories, Heidelberg, Germany) 
and resupended in 1x PBS pH 8.0, 150 mM NaCl for isothermal titration calorimetry. 
Additionally, part of PEPNAPPEE peptide was resuspended in 50 mM Tris pH 8.0, 150 mM 
NaCl) for crystallization. Peptides were shock-frozen in liquid nitrogen and stored at -80°C. 
The peptide concentration was estimated by infrared spectroscopy by Prof. Matthias Mayer 
(ZMBH, Heidelberg University). 
2.8.6 Phosphopeptide mass spectrometry analysis 
 
The samples that were delivered for MS analysis consisted of Optiprep gradient-
purified HIV-1 particles derived from 293T cells 48 h after transfection. Virions collected 
from the supernatant were immediately treated with a phosphatase inhibitor cocktail 
(Calbiochem), adding fresh inhibitors after each successive purification step. The virus pellet 
was resuspended in 50 l 1x PBS and the quality of the samples was assayed by silver gel 
staining and the virus concentration was determined by p24 ELISA. A virus capsid amount 
equivalent to 1 g of p6 protein, were loaded onto a NuPAGE Bis-Tris 4-12 % gel (Invitrogen) 
(initially provided by Xabier Contreras, BZH). The gel was run at 150 V. p6-containing bands 
were identified by simultaneously running a small virus sample, which was analyzed by 
Western blotting. Four different bands were cut and excised corresponding to p6 as part of 
the Gag precursor protein, as a cleavage intermediate or in its free, cleaved form. The 
protein-containing bands were sent for analysis and successively digested with trypsin, 
peptides extracted and further analyzed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) on an LTQ Orbitrap velos mass analyzer. Remaining samples from 
each band were pooled and phosphopeptides enriched by metal oxide affinity 
chromatography using titanium dioxide (TiO2-MOAC). The eluate of each sample was again 
analyzed via LC-MS/MS. Data was analyzed using the MASCOT search algorithm and 
identified phospho-peptide MS/MS spectra were manually validated. 
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2.8.7 Isothermal Titration Calorimetry (ITC) 
 
To determine binding affinity of peptides (PEPNAPPEE, PEPTAPPEE, PEPAAPPEE, 
PEPSAPPEE) to Tsg101 UEV isothermal titration calorimetry was used. Purified TSG101 UEV 
domain was dialyzed against 1x PBS pH 8.0, 150 mM NaCl buffer overnight at 4°C. Peptides 
were dissolved in the same buffer. The day of the experiment, protein and peptide aliquots 
were quick-thawed at 37°C. Protein concentration was determined spectroscopically by 
absorbance measurements at 280nm, using an extinction coefficient of 25 900 M-1 cm-1 and 
a molecular weight of 16.61 kDa. Protein and peptides were diluted to the appropriate 
concentration. The samples were then degassed by applying vacuum for about 5 min. All ITC 
experiments were carried out at 25°C on an ITC200 instrument (MicroCal LLC, Northampton, 
MA). The sample cell contained 0.2 ml of 25 μM Tsg101 UEV protein and the peptides (500 
μm-2 mM) were added in 18 injections of 1.5 μl each. The data were processed using Origin 
software (MicroCal). The binding constant (Kd) was fitted as a one-site model. 
2.9 Cell Biological Methods 
2.9.1 Cell culture 
 
Adherent cell lines 293T and HeLa were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM) high glucose, supplemented  with 10 % FCS, 100 U/ml penicillin, 100 μg 
streptomycin and 20 mM HEPES buffer at 37°C, 5 % CO2. Suspension cells MT-4 and C8166 
were cultured in RPMI 1640, supplemented with 10 % FCS, 100 U/ml penicillin, 100 μg 
streptomycin and 20 mM HEPES buffer at 37°C, 5 % CO2. Freshly isolated primary blood 
mononuclear cells (PBMCs) were cultured in RPMI 1640. 
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2.9.2 Transfection of cells 
 
 Cells were seeded app. 24 h before transfection with one of the following methods: 
 
Polyethylenimine (PEI)-method 
 
Polyethylenimine is a cationic polymer that forms positively charged complexes with 
DNA that can then enter the cell.  For this method, DNA was diluted in DMEM without any 
supplements and 3 times the amount (μg) of DNA was added in volume of 
polyethyleneimine (1 mg/ml in H2O), mixed well and incubated for at least 30 min at RT. The 
mixture was subsequently added dropwise to the cells. 
 
Calcium phosphate precipitation method 
 
DNA was added and mixed into 0.25 M CaCl2. The mixture was then slowly pipetted 
into the same volume of 2x HeBS buffer while vortexing, incubated for 30 min at RT and then 
slowly added to the cells. The medium was exchanged 6 h post transfection. 
 
FuGene method 
 
Two times the amount of DNA to be transfected of FuGene6 reagent was added in 
volume to DMEM without any supplement and incubated for 5 min at RT. Then, DNA was 
added and incubated for further 15 min before adding the mixture to the cells.  
2.9.3 RNA interference 
 
siRNAs were purchased from MWG Biotech (Eberseberg, Germany) as standard 
desalted 21mer duplexes and stored as 100 M solution. The target sequence used for a 
Tsg101 specific siRNA molecule is published in (49). For RNAi-mediated silencing of a target 
protein, 293T cells grown at low confluency (app. 30 %) were transfected with the siRNA 
applying the calcium phosphate transfection protocol. For one well of a 6 well plate, 100 
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pmol siRNA was transfected in 500 l total transfection mixture. Approximately 24 h later, 
expression plasmids were cotransfected with a second dose of either 40 pmol or 80 pmol 
siRNA. About 24 h later, cell lysates and supernatants were collected and knockdown 
efficiency was evaluated by quantitative Western blotting. 
2.9.4 Analysis of heterodimerizer-mediated Gag-FKBP release 
 
For the small molecule-induced interaction of retroviral Gag proteins with cellular 
factors the ARGENT™ Regulated Heterodimerization Kit was used. This kit is based on the 
natural macrolide rapamycin that can bind both to the FKBP (FK506 binding protein) and the 
FRAP (FKBP-rapamycin associated protein) protein at the same time. The ARIAD kit provides 
a cell permeable and chemically optimized derivative of rapamycin called AP21967 
(“heterodimerizer”): two proteins of interest can be joined together through AP21967 when 
one is fused to FKBP and the other to FRB. The heterodimerizer AP21967 was stored as a 1 
mM stock solution in 100 % ethanol at -20°C and added 1:20,000 to the cell culture medium. 
To analyze release of Gag-FKBP induced by recruitment of a cotransfected FRB-fusion 
protein, 293T cells seeded in 12 well plates were transfected with 30 µl CaCl2, 30 µl 2x HeBS, 
0.6 µg pGag-FKBP plasmid and variable amounts of FRB-tagged plasmid. 6 hrs after 
transfection, the medium was changed with 1 ml medium containing 50 µM AP21967. 30-32 
h post transfection, cells were dissolved in 150 µl protein sample buffer, while the 
supernatant was collected, cleared by low speed centrifugation and pelleted through a 
sucrose cushion to concentrate Gag particles. After centrifugation the supernatant was 
carefully sucked off and the pellet was dissolved in 30 µl sample buffer. 5 µl of the pelleted 
supernatant and the cell lysate were analyzed by quantitative Western blotting. Gels of cell 
lysates and particles were blotted on the same membrane to minimize deviations from 
different blotting efficiencies. The efficiency of Gag release was calculated as a ratio of Gag 
in the supernatant to total Gag and expressed relative to a positive control (mostly pTSG101-
FRB), which was set to 1.0. 
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2.9.5 Isolation of human peripheral blood mononuclear cells (PBMCs) 
 
Peripheral blood mononuclear cells (PBMC) were purified from buffy coats of HIV-
negative blood donors, grown in supplemented RPMI 1640 (10 % FCS, Na pyruvate, 
Pen/Strep, MEM non-essential amino acids, all used 1:100)=R10+. About 35 ml of each buffy 
was poured into a T75 cm2 flask and filled up to 70 ml with PBS. The mixture was poured 
over a 15 ml Ficoll gradient at RT and centrifuged 40 min at 2000 rpm, RT without 
acceleration/deceleration. White blood cells from each donor were subsequently isolated, 
pooled and centrifuged 10 min 2500 rpm. 3 ml ACK lysis buffer was added to each pellet to 
lyse erythrocytes, pellet was gently resuspended and incubated for 10-15 min RT, then filled 
up to 50 ml with PBS. This was followed by centrifugation at 2500 rpm for 10 min. The 
pellets were finally resuspended in 150 ml fresh RPMI (R10+) and immediately stimulated by 
the addition of 10 ng/ml IL-2 and 2 μg/ml PHA. PBMC pooled from three donors each were 
used for infection. 
2.9.6 Thin-section electron microscopy of cell samples 
 
HeLa cells were fixed at 48 hrs post transfection with 2.5 % Glutaraldehyde in 0.1 M 
Cacodylate buffer, pH 7.2. After 1 h at RT the cells were washed with 0.1 M Cacodylate 
buffer, pH 7.2 and post-fixed with 2 % OsO4 in 0.1 M Cacodylate buffer, pH 7.2 for 30 min at 
4°C. OsO4 was washed away with excess of water and cells were dehydrated with ethanol (a 
graded series of 40, 50, 60 and 70 % ethanol at RT). Afterwards the cells were incubated with 
6 % uranyl acetate in 70 % ethanol for 2 h in dark at 4°C and further dehydrated with a 
graded series of 80, 90 and 100 % ethanol. To release the cells from the plastic dish 
propylene oxide was used and collected cells were embedded in epoxy resin EPON 812. 
EPON was polymerized at 60°C for one day and sectioned to 50 nm slices using 
ultramicrotome (Ultracut, UCT (Leica), diamond knife (Diatome)). Sections containing cells 
were picked up on electron microscopic grids (100 mesh) covered with film of formvar and 
carbon. Grids with sections were stained for 2 min with 2 % lead citrate and examined in a 
transmission electron microscope EM10 (Zeiss).  
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Viral particles were counted using systematic uniform random sampling and classified 
into three groups: mature, immature and budding particles.  
2.10  Virological methods 
2.10.1 Virus propagation and purification by OptiPrep gradient 
 
293T cells were seeded at 3 x 106 in 10 cm-dishes 24 h prior to transfection with the 
calcium phosphate transfection method. 10 μg pNL4-3 were transfected per dish. 
Supernatants were harvested app. 40-48 h post transfection and cleared by brief 
centrifugation at 1500 rpm for 5 min at 4°C and subsequently filtered through 0.45 μm filter. 
Approximately 33 ml of supernatant were layered onto a 6 ml sucrose cushion (20 % sucrose 
(w/v) in PBS) and pelleted in the ultracentrifuge using an SW32 rotor at 24,000 rpm for 2 h at 
4°C. The pellet was resuspended in 50 μl of buffer (PBS, 20 mM HEPES, 10 % FCS) and added 
to a layered OptiPrep gradient from 35 % (bottom layer) to 6 % (top layer) in an SW60 rotor 
and centrifuged at 32,000 rpm for 1h 30 min. The virus band was collected and resuspended 
in approximately 4 ml PBS and centrifuged at 44,000 rpm for 45 min using an SW60 rotor. 
Pellets were incubated for 30 min on ice and subsequently resuspended in 50 l PBS. 
Aliquots of the virus were stored at -80°C.  
2.10.2 Analysis of HIV-1 particle release 
 
293T cells or HeLa cells were seeded at 3.5-5 x 105 and transfected by calcium 
phosphate precipitation or FuGene 6 with the appropriate pNL4-3-derived plasmid. 30-48 h 
after transfection, cell lysates and supernatants were collected. For quantitative analysis of 
infectious HIV-1 particles in the cell culture supernatant by Western blotting or ELISA, 2.5 ml 
culture supernatant were centrifuged for 5 min at 100 xg (1500 rpm) or filtered through a 
0.45 M pore-sized filter. 1.4 ml of the cleared supernatant was layered on 100 µl 20 % 
sucrose/PBS in a 1.5 ml-Microfuge® tube (Beckman) and centrifuged for 1h at 124,000 xg 
(45,000 rpm, TLA-45 rotor). Pellets were subsequently resuspended in 50-140 l SDS sample 
buffer or PBS. Cell lysates were collected in 500 l SDS sample buffer. All samples were 
stored at -80°C. 
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2.10.3 Infectivity assay 
 
TZM-b1 cells were seeded in 96-well plates at 5 x 103 cells/well in 100 μl. After 24 h 
they were infected with 100 μl of supernatant harvested from transfected 293T cells (HIV-1 
was produced by transfection with the plasmid pNL4-3) and serial 3 fold dilutions were 
performed in DMEM. Cells were incubated for 48 h at 37°C. Supernatant was removed and 
cells were lysed with 50 μl of Steady-Glo® reagent in 50 μl DMEM (Steady-Glo® Luciferase 
Assay System, Promega, Mannheim, Germany) for 30 min at RT. 80 μl of cell lysate was 
transferred to a white 96-well plate and luminescence was measured in a plate 
luminometer. 
2.10.4 Replication kinetics of HIV-1 and p6 mutant derivatives  
 
HIV-1 was produced by transfection of 293T cells with the plasmid pNL4-3, pNL4-3-
uncoupled or corresponding mutant variant of either parental plasmid. The amount of p24 in 
the supernatant was determined by ELISA and 5 ng of virus p24 was used to infect 1 x 105 
C8166 cells or PBMCs in 200 μl fresh RPMI (supplemented R10+ for PBMCs) per well (96-well 
plate, V-bottom). 95 μl of supernatant were collected every 2 days and inactivated with 5 μl 
of 5 % Triton X-100, leading to a final concentration of 0.25 % of Triton X-100. 
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3 Results 
3.1 Identification and selection of predicted and conserved 
phosphorylated residues in the p6Gag domain of HIV-1 
 
In higher eukaryotes, protein phosphorylation involves serine, threonine and tyrosine 
residues. The p6Gag domain of HIV-1 consists of 52 amino acid residues, of which 13 could in 
principle be phosphorylated. However, protein phosphorylation results from the recognition 
of specific amino acid sequences or motifs by a particular kinase. This is the principle behind 
phosphorylation prediction programs that are widely available on the internet, such as 
NetPhos/NetPhosK, GPS (group-based prediction system) and DISPHOS (disorder enhanced 
phosphorylation sites predictor). Such programs mainly rely on sequence-based prediction 
algorithms, designed to identify common prevalent features of amino acid sequences 
surrounding Ser, Thr and Tyr residues. These short sequences or motifs are then compared 
to existing databases of phosphorylated proteins. Some of these programs have the 
additional feature of assigning a kinase to a predicted residue. Thus, to assess the number of 
predicted phosphorylation sites in p6Gag I made use of the 3 prediction programs mentioned 
above and used high threshold values for identification of phospho sites and kinases, in 
order to reduce the number of false positives. Table 3.1 compares results obtained with the 
3 different prediction programs, showing only those residues that obtained the highest 
prediction scores.  
 
Predicted residue DISPHOS NetPhos(K) GPS Pedicted kinase 
 
Serine 
3 3 N.P. PKC 
14 14 14 CKI, ILK 
25 25 25 DNAPK, ATM 
40 40 N.P. PKC 
43 43 N.P. CKI 
47 47 N.P. GSK3 
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50 N.P. N.P. U.D. 
51 51 N.P. CKII, DNAPK, ATM 
 
Threonine 
8 8 N.P. GSK3 
N.P. 21 N.P. GSK3, GRK, PLK 
22 N.P. N.P. GRK 
23 23 23 p38MAPK, CDK, MTOR 
Tyrosine N.P. 36 36 BTK 
 
Table 3.1 Predicted phosphorylated residues in the p6
Gag 
domain of HIV-1. 
Shown above the table is the 52 amino acid sequence of HIV-1 p6. Potential phosphorylation sites are 
highlighted in green. This marking does not reflect the residues that were highly predicted to be 
phosphorylated by the programs. Three different prediction programs were used to obtain putative 
phosphorylated residues in the p6
Gag
 domain of HIV-1. The table compares the residues obtained as a result of 
the analysis of the p6 sequence with the respective program: NetPhos combined with NetPhosK, DISPHOS or 
GPS. The predicted kinase(s) responsible for phosphorylation of the particular residue is indicated when 
available. NP indicates a residue that was either not predicted to be phosphorylated or had a prediction value 
under the threshold and was therefore not included. NP= not predicted, UD= undetermined. 
 
p6Gag consensus sequences derived from different HIV-1 subtypes were aligned in 
order to identify residues that are highly conserved among these strains as shown in Table 
3.2. Results from this analysis, as well as data obtained from the phosphorylation prediction 
programs was combined to select p6 residues that displayed both a high degree of 
conservation among HIV-1 subtypes and a high prediction score for phosphorylation.  
 
 
Table 3.2 Sequence alignment of p6 consensus sequences derived from different HIV-1 subtypes. 
 Dots indicate conserved residues among the sequences. If a residue is not conserved it is indicated as it occurs 
within a particular sequence. Ser, Thr and Tyr residues are highlighted in red. The consensus sequences for 
subtypes A, B, C, D, F, G, H, and K were compared to the reference sequence derived from the HIV-1 clone NL4-
3. Sequences were obtained and aligned using the Los Alamos HIV sequence compendium and HIV sequence 
alignment feature (86). 
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To assess the functional role of the potentially phosphorylated residues in the HIV-1 
replication cycle, we introduced specific point mutations into the p6 sequence. The p6 
residues, Ser14 and Ser25 were chosen for further study and were thus mutated either to an 
alanine or an aspartate (S14A, S14D, S25A, and S25D). Importantly, aspartate was chosen 
based on the premise that such a residue contains the negative charge and bulkiness that 
would resemble a phosphorylated residue. In addition, an initial set of p6 mutants of the Thr 
residue within the highly conserved PT8AP motif (T8A, T8I, T8D) and of the Thr residue at 
position 23 (T23A, T23D, T23I) that had been previously generated by B. Müller were also 
included in this study. The Thr23 mutants had been previously tested by B. Müller and no 
detrimental effect was observed on virus particle release or infectivity. However, a later 
study by Hemmonot et al indicated that a p6 Thr23 mutant was strongly impaired in release 
(60). Therefore, we decided to include and retest the effects of this mutant. The p6 mutants 
were generated by oligonucleotide-directed mutagenesis and confirmed by sequencing. 
Fragments carrying the particular p6 point mutation were cloned back into the full-length 
infectious molecular clone, pNL4-3. Of note is that due to the fact that the virus gag- and 
pol-reading frames overlap, introducing changes into the gag sequence may result in amino 
acid changes in the Gag-Pol polyprotein precursor. Indeed, in most instances (T8A, T8D, 
S14A, S14D, S25A, S25D, T23A, and T23D) it was not possible to mutate the p6 residue 
without affecting the pol frame sequence. However, it has been reported that mutation of 
the central region of the pol frame, corresponding to residues 21threonine-glutamine61 and 
to residues 5proline-aspartate32 in the p6
Gag domain, has no deleterious effect on virus 
protein expression and stability, assembly, release or productive infection of T cell lines (13, 
111).  
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3.2 Effect of p6 mutants in HIV-1 release and viral protein 
processing 
 
The effect of the proviral p6 mutants T8, S14, S25, and T23 in virus production and 
viral protein processing was tested by transient transfection of 293T cells and compared to 
wt NL4-3. Shown in Figure 3.1 are the western blots of cell associated viral products and 
released virus particles. 
 
 
Figure 3.1 Effect of p6 mutants in virus production and Gag protein processing. 
 Western blot analysis of 293T cells transfected with the proviral HIV-1 clones harboring a point mutation 
within the p6
Gag
 sequence. (A) Virus supernatants and cell lysates were collected 48 h posttransfection (pt) and 
virus supernatants were layered and pelleted over a 20 % sucrose cushion. The amount of released virus can be 
visualized as the 24 kDa capsid (CA) band (indicated by an arrow), representing mature virions. Gag processing 
products are shown in the cell lysate samples and Gag processing intermediates are indicated by arrows. The 
PTAP- construct was used as a negative control for release. (B) The levels of virus p24 (CA) were determined for 
each viral construct by quantitative Western blotting using a preset CA standard. Membranes were probed 
against CA-specific antibody. Positions of molecular mass standards are shown with numbers in kDa at the left. 
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It is evident that the amount of virus produced by the Ser14, Ser25 and Thr23 
mutants is not affected and is comparable to that of the wt while it is clear that, as expected, 
the Thr8 mutants are strongly impaired in release. Moreover, the cell associated viral 
products show a Gag processing pattern is identical to the wt in the case of the Ser and 
Thr23 mutants. In contrast, the T8 mutants accumulate intermediate Gag processing 
products as indicated by the arrows in the blot. The PTAP- construct has the PTAP motif in p6 
exchanged for a LIRL sequence; consequently, its budding efficiency is strongly inhibited. 
This construct served as a negative control for these experiments. The efficiency with which 
virions were released was determined by quantitative western blot analysis of virus sucrose 
pellets and compared to a p24 capsid (CA) standard to obtain ng amounts of released virus. 
The graph in Fig 3.1 B shows that similar amounts of p24 CA are obtained for the Ser and T23 
mutants relative to the wt, while the amount of virus released by the T8 mutants and by the 
PTAP- construct is highly impaired as previously shown (36, 64). However, the T8D mutant 
had a less pronounced effect on release as compared to the other T8 mutants as shown in 
Figure 3.2.  
 
Figure 3.2 Comparison of the levels of HIV-1 produced by the T8 mutants. 
 Comparison of virus p24 levels released by the p6 T8 mutant virions show that the p6 T8D mutant (indicated 
by an asterix) has less pronounced effect on release in comparison to the other T8 mutants. Relative values of 
p24 CA are shown. Error bars represent the standard deviation of four independent experiments. 
 
Taken together, these findings imply that neither the T23 nor the S14 and S25 
residues, individually, are required for efficient particle release, suggesting that 
phosphorylation of the single residues is not required for this late viral step. Moreover, the 
T8D mutant shows a slightly enhanced effect on release that might be attributable to 
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putative phosphorylation of this residue. Instead, it is plausible that the aspartate at this 
position partially satisfies structural requirements to mediate interaction with its cellular 
partner, Tsg101. Therefore, this mutant requires further analysis. 
3.3 Infectivity and replication capacity of HIV-1 p6 mutants 
 
To determine whether the p6 mutants are impaired in viral processes other than budding, 
the capacity of these viruses to undergo single-round infection was assayed. 
Supernatants of 293T cell-derived mutant viruses were titrated onto TZM-bl reporter 
cells containing -galactosidase and luciferase reporter genes under the control of a long 
terminal repeat (LTR) promoter. Luciferase activity of the reporter cells was measured 48h 
post infection (pi). Figure 3.3 displays the relative infectivity of all the p6 mutants in 
comparison to the WT. Since it was clear to us--from this study and previous studies--that  
Figure 3.3 Single-round infectivity of HIV-1 p6 mutants. 
 Virus supernatants derived from transfected 293T cells were titrated onto the HeLa reporter cell line, TZMbl. 
Cells were lysed 48h pi and luciferase activity was measured as relative light units. (A) The graph displays 
infectivity values of each mutant relative to the wt levels. (B) The infectivity values were normalized to the ng 
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amount of virus CA (values ranged between 2800 ng p24/ml to 750 ng p24/ml) present per mutant. Error bars 
represent the standard deviation from three independent experiments, each done in triplicate. 
 
the T23 p6 mutant does not play a role in the replication cycle of the virus, we decided to 
discontinue experiments with this mutant. As it can be observed, the infectivity values for  
the Ser mutants are not affected and levels similar to the wt are obtained. In contrast, the T8 
mutants are strongly impaired; however, when the infectivity values are normalized to the 
amount of virus CA (p24) found in the supernatant per mutant, no obvious differences are 
apparent. Because this assay does not allow one to observe more subtle differences in 
replication over an extended period of time, a viral replication kinetics assay was carried out 
in two different cell types: C8166, a CD4+ lymphocytic cell line and on primary lymphocytes 
isolated from 3 different donors. Briefly, sucrose-purified virus particles produced from 
transfected 293T cells were used to infect C8166 cells with a defined concentration (5 ng p24 
per well) and supernatants were monitored for p24 release every second day for a total 
period of 13 days. Primary lymphocytes were infected with 5ng of virus collected from the 
supernatants of transfected 293T cells. Virus supernatants were collected every 2 days for a 
total period of 15 days and assayed for p24 levels by ELISA (enzyme-linked-immunosorbent 
assay). In Figure 3.4, the amount of virus released into the supernatant is plotted over time 
for wt, T8, S14 and S25 p6 mutants. Figure 3.4 A and B shows that the Ser14 and Ser25 
mutants display kinetics almost identical to those of the wt throughout the course of 
infection. In contrast to the p6 T8A and T8I mutants that are replication defective and 
display delayed kinetics relative to the wt, the T8D mutant achieves slightly better 
replication levels at early time points (Figure 3.4 C). 
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Figure 3.4 Replication kinetics of HIV-1 p6 mutants. 
 C8166 cells were infected with 5ng of wt or the corresponding p6 mutant. Virus supernatant was collected 
every 2 days for a period of 13 days and assayed for p24 levels by ELISA. (A) and (B) Both S14 and S25 mutants 
replicate equally efficient relative to the wt virus. (A) All T8 mutants display delayed kinetics in comparison to 
the wt; however, the T8D mutant shows a slightly enhanced replication capacity at early timepoints. Error bars 
show the standard deviation of 3 independent experiments done in triplicates. 
 
Overall, these results indicate that phosphorylation of the p6 Ser14 and Ser25 
mutants is not likely to play a role in virus infectivity in C8166 cells. On the other hand, the 
p6 T8D mutant has a slightly better replication capacity than the T8A and T8I mutants, again 
suggesting that the negative charge and bulkiness of the aspartate at this position provides 
some gain of function capability to this mutant. This could indirectly hint at a role for 
phosphorylation of this residue.  
The replication capacity of the different viruses was also assayed in a more relevant 
cell system. Therefore, I infected primary lymphocytes combined from 3 different donors 
with wt HIV-1 and the T8 p6 mutants. Additionally, the T23 p6 mutant was included in this 
assay to completely exclude a possible role of this residue in the replication efficiency of HIV-
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1 while the S14 and S25 mutants were excluded from this study since all previous 
experiments suggested against these residues being involved in the replication cycle of the 
virus. A PTAP- mutant and an efavirenz (a reverse-transcriptase inhibitor)-treated wt HIV-1 
sample served as negative controls. Results from this analysis are shown in Figure 3.5. 
 
Figure 3.5 Replication kinetics of HIV-1 p6 mutants in primary lymphocytes. 
 Peripheral blood mononuclear cells (PBMCs) were isolated from 3 different donors, combined among each 
other and infected with 5 ng of HIV-1 wt or the corresponding p6 mutant virus. Virus supernatants were 
collected every 2 days for a total period of 15 days and assayed for p24 levels by ELISA. The graphs show the 
replication curves obtained from infected donor 1+3 (A), donor 2+3 (B) or donor 1+2 (C) primary lymphocytes. 
In all cases it is observed that the Thr23 p6 mutant is not affected in its replication capacity, while all Thr8 
mutants display delayed kinetics. 
 
The behavior of the mutants was comparable in all donors and it can be observed that 
in all cases, the T23 mutant replicates in a similar manner to the wt. The T8 mutants display 
delayed replication kinetics, also in the case of the T8D mutant which in only one case peaks 
at the same day and close to level of the wt. Importantly, the T8I mutant never reaches the 
virus production levels that are reached by the wt or the T8D mutant at later days, 
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suggesting still that the T8I mutant has a replicative disadvantage that can be partially 
overcome by the T8D mutant.  
3.4 Analysis of a p6 T8E mutant 
 
Due to its negative charge and increased side chain bulkiness relative to an aspartate, 
a glutamate residue (E), might in principle, better resemble an amino acid modified with a 
phosphate group. Expecting to obtain a stronger phenotype which would corroborate our 
observations with the T8D mutant, two new p6 mutants were prepared, one containing a 
T8E point mutation and as an additional negative control, one containing a T8N point 
mutation. Contrary to our expectations, the T8E mutant did not show an increased effect on 
virus release as depicted in Figure 3.6. 
Figure 3.6 Effect of a p6 T8E mutant on HIV-1 
release and gag processing. 
 Western blot analysis of wt and p6 mutant viruses 
derived from 293T transfected cells. Cell- and 
particle-associated virus products were harvested 
30h pt. Particles released into the cell supernatants 
were pelleted over a 20% sucrose cushion and all 
samples were probed against virus-specific CA 
antibody. The blot shows that the amount of viral 
particles obtained from the p6 T8E mutant is not 
enhanced relative to the T8D mutant. Accumulation 
of Gag processing intermediates are observed at 
about the 40KDa and below the 55KDa bands for 
the T8 mutants. Positions of molecular mass 
markers in KDa are shown at the left and the 
mature virus band is indicated at the right. 
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This observation was confirmed in repeated experiments. On the other hand, the T8N 
p6 mutant, to our surprise, showed wt levels of released virus in repeated experiments, as 
well as a wt-like gag processing pattern as illustrated in Figure 3.7. The western blot shows 
that the highest levels of virus release can be obtained with either the wt construct or the p6 
T8N mutant. Moreover, out of all the p6 mutants, the T8N mutant most closely resembles 
the cell-associated Gag processing pattern of the wt virus Figure 3.7 A. The enhanced effect 
in release by the p6 T8N mutant was corroborated in multiple experiments as depicted in 
Figure 3.7 B, which compares the relative p24 values among some of the p6 mutants to the 
wt virus. 
 
Figure 3.7 Effect of the HIV-1 p6 T8N and T8Q mutants on virus release and Gag processing. 
Western blot analysis of wt and p6 mutant viruses derived from 293T transfected cells. Cell lysates and virus 
supernatants were harvested 30h pt. Virus particles were purified over a sucrose cushion and all samples were 
probed against virus CA antibody. (A) The amount of viral particles obtained from the p6 T8N mutant is 
comparable to that of the wt. Although, both the T8E and T8Q mutants are slightly more efficient in release 
than the PTAP- control, they do not achieve the levels obtained with the T8N mutant. (B) Graph represents the 
quantitative WB analysis of p24 CA bands obtained from each virus relative to the wt. The T8N mutant achieves 
the highest levels of virus release in comparison to all other p6 mutants. Error bars show standard error of the 
mean from nine independent experiments. Positions of molecular mass markers in kDa are shown at the left. 
 
Overall, these results argue against an involvement of PTAP phosphorylation in its 
virus budding activity and open the door to further exploration and characterization of the 
p6 T8N mutant and its role in HIV-1 release. 
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3.5 Comprehensive analysis of predicted phosphorylation sites in 
HIV-1 p6 
 
In order to study the relevance of p6 phosphorylation in HIV-1’s life cycle, it is 
necessary to examine the effect of p6 mutations in each one of its predicted phosphorylated 
residues. It is possible that only a combination of point mutations at different residues is 
needed to observe an effect in virus release and/or replication capacity. However, this type 
of analysis is hindered first of all, by the fact that generating combinations of point mutants 
throughout the whole p6 sequence is rather time-consuming and second and most 
important of all, by the fact that the gag and pol reading frames of the virus overlap. A 
frameshift signal located at the spacer peptide 1 sequence in gag (the amino terminus of the 
p6* transframe sequence in gag-pol) normally causes the ribosome to slip back every 1 out 
of 20 translation events, resulting in the synthesis of the pol products as depicted in Figure 
3.8. Therefore, it is not possible to make extensive mutations in p6 without seriously 
compromising the integrity of the pol sequence and its products. 
 
Figure 3.8. The HIV-1 frameshift determinants. 
 (A) Pol is in a different reading frame than gag, thus a ribosomal frameshifting event ensures the synthesis of 
the pol products at a strict ratio of 20:1 Gag to Gag-Pol molecules. The arrow indicates the position of the 
frameshift signal in gag. (B) The frameshift event is promoted by both a heptanucleotide slippery site sequence 
and a 3‘ stem-loop structure present at the amino terminus of the p6* sequence. MA = matrix, CA = capsid, p2 
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= space peptide 2, NC = nucleocapsid, p1 = spacer peptide 1, p6* = p6 transframe, PR = protease, RT = reverse 
transcriptase, IN = integrase. 
 
3.5.1 Uncoupling the overlapping gag and pol reading frames 
 
Recently, Leiherer et al published a study in which they uncouple the gag and pol 
reading frames of HIV-1 to examine the role of the p6* protein in viral replication (89). p6* is 
located at the amino terminus of the Pol moiety within the Gag-Pol precursor and is thought 
to play a role in the activation of the viral PR. The strategy used by Leiherer et al is based on 
the destruction of the original slippery site and 3’ stem-loop structure by point mutations 
(without altering the p1 sequence) to abrogate the frameshift signal. The complete 
functional frameshift signal, including the slippery site and stem-loop was introduced at the 
5’ end of the Gag stop codon. In the resulting provirus, the gag and pol genes are extended 
by 15 and 210 nucleotides, respectively, compared to those of the parent NL4-3 provirus. A 
schematic of the strategy used by Leiherer et al is depicted in Figure 3.9. 
 
Figure 3.9 Schematic of the strategy used to uncouple the HIV-1 gag- and pol-reading frames. 
 (A) The wt provirus‘s Gag and Gag-Pol products translated in the presence of the original frameshift. In order 
to uncouple the overlapping reading frames, the frameshift signal at the amino terminus of the p6* TF is 
abrogated by point mutations that do not change the p1 sequence. (B) An artificial frameshift site is inserted at 
the 3‘ end of the gag gene, indicated by the arrow, resulting in the synthesis of a Gag-Pol polyprotein with p6* 
TF directly fused to p6
Gag 
highlighted in magenta. Insertion of the frameshift signal also results in a gag reading 
frame extended by 5 residues and terminated by insertion of a stop codon highlighted by the arrow. FS = 
frameshift signal, MA = matrix, CA = capsid, p2 = space peptide 2, NC = nucleocapsid, p1 = spacer peptide 1, p6* 
= p6 transframe, PR = protease, RT = reverse transcriptase, IN = integrase. 
 
We made use of this strategy to address more extensively the role of p6 
phosphorylation in the replication cycle of HIV-1. Therefore, a 363 base pair gene fragment 
harboring an abrogated frameshift signal and designed to contain the new slippery-site and 
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stem-loop at the end of the Gag codon was synthetically produced and cloned into the NL4-3 
proviral clone. 
3.5.2 Effect of frameshift displacement on virus maturation and particle 
production 
 
Because the new ‘uncoupled’ proviral construct was significantly modified in order to 
separate the gag and pol reading frames, it was necessary to determine to what extent viral 
protein synthesis and particle production could have been affected by the corresponding 
mutations. For this purpose, 293T cells were transiently transfected with the WT and 
uncoupled construct and released virus particles and cell-associated viral products were 
collected 30h pt. Cell lysates and purified virus particles were subjected to Western blot 
analysis using a CA-directed antibody. As shown in Figure 3.10, both the parental NL4-3 WT 
virus and the uncoupled viral construct produced comparable amounts of mature virus 
particles as well as Gag-derived products in the cell lysates. The extension of the p6Gag 
carboxyl terminus by five amino acids (0.5 kDa) was nicely reflected by a slight shift of the 
uncoupled-specific 55 kDa Gag precursor. 
 
Figure 3.10 Influence of frameshift displacement on virus maturation and release. 
 293T cells were transiently transfected with the indicated viral plasmids. For analysis of virus composition, 
particles released into cell supernatants were harvested 30h pt and sedimented through a 20% sucrose 
cushion. Left, viral proteins were separated by SDS-PAGE and analyzed by Western blotting using a CA-specific 
antibody. Viruses containing the frameshift displacement (uncoupled) are released to comparable levels as the 
parental WT virus. In addition, cell-associated Gag products exhibit a similar processing pattern that is slightly 
shifted in the uncoupled construct due to the extension of the gag and gag-pol genes. Positions of molecular 
mass markers are shown at the left, and the arrow at the right indicates virus-specific protein bands. Right, the 
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amount of virus particles produced by the WT and uncoupled constructs was determined by quantitative WB of 
the CA band intensities derived from (A) and compared against a standard amount of p24 CA. Results are 
shown for the viruses transfected with 2 g of DNA as depicted in (A). 
 
Together, these observations strongly argue for the functionality of the displaced 
frameshift signal in the uncoupled provirus and suggest that virus production, packaging and 
maturation of the precursor proteins are equally efficient in WT and uncoupled viruses.  
3.5.3 Effect of frameshift displacement on virus infectivity 
 
To evaluate whether the uncoupled virus was capable of infecting cultured cells, WT 
and uncoupled particles released from transfected 293T cells were used to infect TZM-bl 
indicator cells. Luciferase activity was measured 48h pi. As shown in Figure 3.11, the 
infectivity of uncoupled particles was slightly decreased to approximately 80% of the WT 
infectivity. 
 
Figure 3.11 Analysis of frameshift displacement on virus infectivity. 
 To evaluate viral infectivity, WT and uncoupled virus supernatants produced from transfected 293T cells were 
used to infect the CD4+ TZM-bl reporter cell line. (A) At 48h pi, luciferase activity was measured and values 
obtained were related to the WT infection (100%). The uncoupled virus is slightly less infectious than the WT 
virus. (B) Infectivity values were normalized for CA content by quantitative WB using a CA standard. 
 
The reduced infectivity of the uncoupled virus might be due to compromised frameshifting 
or to the rearranged protein domains. In sum, these data are in agreement with the study by 
Leiherer et al (89) and show that the NL4-3 derivative uncoupled is an infectious virus 
mutant representing an excellent tool to perform extensive mutations in p6.  
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3.5.4 Generation of uncoupled viruses carrying extensive mutations in 
HIV-1 p6 
 
The uncoupled provirus offered the possibility to specifically modify predicted 
phosphorylated residues within all of p6. First, I constructed three p6 mutant derivates from 
the uncoupled construct and thus three gene fragments were synthetically produced 
containing the specific mutations and cloned back into the uncoupled construct. In the first 
mutant derivative, termed FL, all of the Ser, Thr and Tyr residues within p6 were mutated to 
either an Asn (in the case of Ser and Thr) or to a Phe (in the case of the Tyr residue). Asn and 
Phe residues were chosen since they are thought to best conserve the folding properties of 
the substituted amino acids. The second mutant, termed Nter (p6 residues Leu1-Glu29), 
contains Asn mutations in every Ser and Thr residue found at the N-terminal region of p6. 
For the third mutant, termed Cter (p6 residues Pro30-Gln52), mutations were made in every 
Ser, Thr or Tyr residue found at the C-terminal region of p6. In addition, I added silent 
restriction sites along the length of p6 in order to facilitate the cloning procedure of the 
three mutant fragments (see Materials and Methods). Importantly, the T8 within the critical 
PT8AP motif was not mutated in any of the fragments. This was done to prevent 
misinterpretation of the results due to the strong detrimental phenotype obtained by 
mutation of this residue. Figure 3.12 illustrates the three main fragments generated to 
create p6 mutant uncoupled constructs. 
 
 
 
 
Figure 3.12 Schematic of the three fragments containing multiple mutations in p6. 
 Illustrated is the amino acid sequence of p6 with mutated residues highlighted in red. Three gene fragments 
containing extensive mutations in p6 were synthetically produced and cloned into the uncoupled virus 
construct. The FL (full-length) fragment carried mutations on each Ser, Thr and Tyr residue, except for the Thr8 
which was not mutated in any of the generated fragments. The Nter (N terminus) fragment contains mutations 
in the p6 sequence covered from Leu1 to Glu29, while the Cter (C terminus) fragment carries mutations in the p6 
C-terminal residues Pro30 to Gln52. The last five amino acid residues depicted in the p6 amino acid sequence 
correspond to the extension generated by insertion of the frameshift signal at the end of the Gag codon as 
described in section 3.5.1. 
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To assess the impact of the extensive p6 mutations on virus production and 
processing of viral precursor proteins, 293T cells were transiently transfected with the 
(parental NL4-3) WT, uncoupled (WT) and uncoupled mutants. Virus particles released were 
harvested 30h pt, and the protein content of both virus particles and cell-associated viral 
products were analyzed by Western blotting. As observed in Figure 3.13, no obvious defect 
in viral protein processing in any of the mutants could be seen. 
 
Figure 3.13. Characterization of virus 
maturation and production by the 
uncoupled p6 mutant viruses. 
 293T cells were transiently transfected with 
the corresponding proviruses. (A) Cell 
lysates and virus supernatants were 
harvested 30 h pt and virus particles were 
isolated through a 20 % sucrose cushion. 
Particle- and cell-associated proteins were 
separated by SDS-PAGE and analyzed by 
Western blotting using a CA-specific 
antibody. The FL and Cter viruses are 
compromised in release with no apparent 
accumulation of processing intermediates. 
Positions of molecular mass markers in kDa 
are shown at the left, and the arrow at the 
right indicates the mature virus CA band. 
Vertical lines on the right indicate the 
position of the Western blots containing 
either the released virion bands or the cell-
associated virus protein bands. (B) To 
determine the amount of virus that was 
released by each virus, the intensity of the 
mature virus CA band shown in (A) was 
quantitated by Western blotting using a 
preset CA standard. The release efficiency of 
each virus relative to the uncoupled virus is 
shown.  
 
 
Interestingly, we observed a pronounced decrease in the amount of virus that was 
released by the FL and Cter mutants, while the Nter mutant was released to a level greater 
than the WT construct. None of the mutant viral particles seemed to display an aberrant 
accumulation of the processing intermediate p25 which would otherwise suggest a defect in 
particle morphology. These results suggest that predicted phosphorylated residues within 
the C-terminal region of p6 may be involved in some aspect of virus budding. The effect 
observed with the Nter mutant could suggest that phosphorylation within this region might 
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serve to negatively regulate virus release. However, further attempts to corroborate this 
data have proven difficult to achieve. The effect, in particular that of the FL and Cter 
mutants, has been rather variable suggesting at times that potential phosphorylation of p6 
does not play a role in virus release (data not shown). Different transfection reagents, 
plasmid DNA amounts and cell systems were tested to assess their effect in the stability of 
the phenotypes observed; however, no conclusive result was so far obtained. The integrity 
of the mutants as well as the presence of the proper point mutations was corroborated 
several times. Thus, future analysis of these mutants should be able to define their role, if 
any, in the HIV-1 replication cycle. 
3.6  p6 phosphopeptide analysis by Mass Spectrometry 
 
Mass spectrometry (MS) has become an invaluable tool in the identification of 
unknown compounds and in the elucidation of the structural and chemical properties of 
molecules. Moreover, it has also been a fundamental technique for virology; for instance, it 
has been used to identify viral capsid proteins, detect viral mutants, measure intact viruses 
and to characterize posttranslational modifications (139). Indeed, advances in MS have 
quickly evolved so that nowadays ample numbers of in vivo phosphorylation sites can be 
detected and quantified in a relatively short period of time (56). Protein phosphorylation 
events are detected by increases in amino acid residue mass of +80 Da, which report the 
addition of metaphosphoric acid (HPO3). Sites of phosphorylation can be identified from 
mass shifts in fragment ions generated by gas-phase (MS/MS) of phosphopeptides (151).  
Because MS provides a strong and reliable basis to identify protein residues that are 
phosphorylated, we decided to analyze the phosphorylation status of HIV-1 p6 using this 
powerful technique. For this purpose, we initially established a collaboration with the core 
facility for MS at the Zentrum für Molekular Biologie Heidelberg (ZMBH) headed by Dr. 
Thomas Ruppert. The samples that were delivered for analysis consisted of Optiprep 
gradient-purified HIV-1 particles derived from 293T cells. Virions collected from the 
supernatant were immediately treated with a phosphatase inhibitor cocktail, adding fresh 
inhibitors after each successive purification step. A virus capsid amount equivalent to 1 g of 
p6 protein was loaded on a 17.5 % Tris-Tricine gel and bands corresponding to p6 and full-
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length precursor Pr55 Gag protein—shown in Figure 3.14—were in-gel digested with trypsin 
for further analysis. 
 
Figure 3.14. Selection of virus protein bands for mass spectrometry analysis. 
NL4-3 derived virus from transfected 293T cells were harvested 48 h pt in the presence of a phosphatase 
inhibitor cocktail and purified by Optiprep-gradient. (A) A virus p6 protein amount of 1 g was loaded from two 
independent virus preparations (OP1 and OP2) onto a 17.5 % Tris-Tricine gel and analyzed by SDS-PAGE. 
Protein bands were visualized by coomassie staining. Two protein bands (bands 1 and 2) that corresponded to 
the full-length Pr55 Gag precursor protein and the free, cleaved form of the p6 protein (bands 3 and 4) were 
cut out from each virus preparation for further analysis. Positions of molecular mass markers in kDa are shown 
at the left. (B) Concomitant analysis of virus proteins by Western blot. A virus p6 amount of 0,5 g was loaded 
and analyzed by SDS-PAGE as in (A). Subsequently, virus proteins were transferred onto a nitrocellulose 
membrane and the membrane was probed against p6-specific anibody. Corresponding band proteins in the 
blot are indicated by an arrow. 
 
The samples were analyzed by liquid chromatography-tandem mass spectrometry 
(LC-MSMS). In tandem MS, a phosphopeptide mixture is separated by capillary liquid 
chromatography. The eluate is introduced into the mass spectrometer via a process that 
generates multiply protonated gas-phase peptide cations. The mass-to-charge ratio (m/z) 
and intensity of the peptide precursors are recorded and then those with a high. m/z value 
(most abundant peptide cations) are selected for sequencing by tandem MS. The 
phosphorylated peptide generates a series of fragment ions that differ in mass by a single 
amino acid, allowing the identification of the peptide primary sequence and position of the 
phosphoryl modification (56). Results from the MS analysis are shown in Figure 3.15. 
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Figure 3.15 List of peptides obtained from the mass spectrometry analysis of HIV-1 proteins. 
 A list of the viral peptide sequences identified from the indicated viral proteins are shown in the tables A, B, C, 
D. Occurrence of posttranslational modifications is indicated when present and are listed next to the particular 
peptide sequence where the modification was observed. In addition to virus-derived peptides, sequences 
corresponding to cellular proteins were also identified and are listed on the rightmost columns of (A) and (B). 
(A) Results derived from analysis of band 1 (see Figure 3.14); (B) results derived from analysis of band 2; (C) 
results derived from analysis of band 3 and (D) results derived from analysis of band 4. 
 
Peptide sequences corresponding to the viral proteins CA, MA, p6, IN and RT could be 
identified from the bands 1 and 2 (Figure 3.14), which correspond to the gel area that 
includes the Gag precursor protein. The RT is made up of two subunits with a molecular 
weight of 66 and 51 kDa each and thus it is no surprise that it comes up in the analysis of this 
band. Less clear is the reason why IN came up on the analysis since it has a molecular weight 
of 32 kDa. Not only were viral proteins identified, but the MS revealed the presence of 
multiple cellular proteins that seem to be incorporated into the virions. The actin-binding 
proteins ezrin, radixin and moesin were found in both virus preparations. Ubiquitin, which 
has been previously reported to occur in retroviral particles, was also detected. Moreover, 
the ESCRT and ESCRT-associated proteins Tsg101 and Vps4 and the membrane-binding 
annexin proteins could be identified in one of the preparations. Finally, the elongation factor 
1 alpha (EF-1 alpha) known to be incorporated into virus particles and the alanyl t-RNA 
synthetase were also identified in the virus particles. Several of these proteins have been 
previously seen in other biochemical analyses by different groups (28, 108). The only 
posttranslational modifications detected in this analysis were oxidation of MA and CA 
protein peptides and oxidation and deamidation of RT peptides; thus, no phosphorylation-
specific modification was observed for p6 or for any other viral protein although there is 
biochemical evidence that indicates that both the MA and CA proteins are phosphorylated 
(18, 26, 39, 75). Nevertheless, results do not seem to be conclusive for two main reasons: 1) 
no p6-derived peptides containing the PTAP motif could be identified in the analysis and so 
far there is no obvious explanation for this; 2) as mentioned above, although there is data 
indicating that both the MA and CA proteins are phosphorylated, none of the identified MA 
or CA peptides were found to be phosphorylated. Nevertheless, it cannot be excluded that 
treatment with the phosphatase inhibitors was inefficient and did not prevent the removal 
of phosphate groups from phosphorylated viral proteins. Another possibility is simply due to 
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the transient nature of phosphorylation events and it is possible that these events were not 
caught fast enough to preserve them for the analysis. Moreover, phosphopeptides exist at 
low stoichiometric amounts, thus although the p6 protein has been identified as the major 
phosphoprotein in HIV-1 virions, only about 5% of the protein is phosphorylated (101) and it 
plausible that the number or amount of signals emitted from phosphorylated p6 protein 
peptides are not enough to be detected. In addition, phosphopeptides might be otherwise 
suppressed during ionization of the sample. Conveniently, this latter limitation may be 
overcome by phosphopeptide enrichment of the sample (56). Phosphopeptide enrichment 
relies on metal-based affinity approaches. Some of the most frequently used methods 
include immobilized metal affinity chromatography (IMAC), metal oxide affinity 
chromatography (MOAC), and strong cation exchange (SCX). In IMAC, positively charged 
metal ions, such as Fe (III) or Ga (III) are chelated onto a solid phase resin and presented for 
interaction with negatively charged phosphoryl groups. MOAC uses titania or zirconia as the 
metal oxide chromatography modifier. Titanium dioxide (TiO2) is commonly used to capture 
phosphopeptides. SCX works essentially on the same principle and differs in the way that 
phosphopeptides are eluted from the column (56).  
We sought to initiate a new collaboration with Dr. Albert Sickmann and Dr. René 
Zahedi at the Institute for Analytical Sciences (ISAS) in Dortmund, Germany. Dr. Sickmann’s 
group specializes in identifying protein posttranslational modifications and thus has ample 
experience in performing this type of analysis. For this purpose, new optiprep gradient-
purified HIV-1 virions were prepared from transfected 293T cells. Virus supernatants were 
treated with a phosphatase inhibitor cocktail immediately after harvesting and during 
subsequent purification steps. A virus CA amount equivalent to about 1 g of p6 was loaded 
from each of two independent preparations onto a 4-12 % NuPAGE Bis-tris gradient gel and 
virus proteins were separated by electrophoresis. At the same time, 0.8 g of CA protein 
from one of the virus preparations was loaded as a control for subsequent Western blot 
analysis of p6-containing viral products as shown in Figure 3.16. Four different bands were 
analyzed for each virus preparation. The bands corresponded to the Pr55 Gag precursor 
protein, cleaved p6 and the other two bands were meant to include intermediate processing 
products or putative phosphorylated p6 products. Phosphorylated proteins can exhibit a 
shift in their electrophoretic mobility. Thus, we thought it plausible that the bands observed 
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above the 6 kDa band of free p6 could derive from hyperphosphorylated p6 forms. The 
boxed areas in the blot indicate the p6-containing bands that were cut out for the MS 
analysis.  
 
Figure 3.16 Western blot analysis of HIV-1-derived p6 products. 
 NL4-3 derived virus from transfected 293T cells was harvested 48 h pt in 
the presence of a phosphatase inhibitor cocktail and purified by Optiprep-
gradient. A virus CA amount equivalent to 1 g of p6 from each virus 
preparation was loaded onto a 4-12% Bis-Tris gradient gel and virus 
proteins were separated by electrophoresis (not shown). A virus CA 
amount equivalent to 0.2 g of p6 was simultaneously run and analyzed 
further by Western blot. The membrane was probed against p6-specific 
antibody. Boxed areas indicate the four virus bands that were selected for 
MS analysis. Virus bands pertaining to the Gag precursor protein and to 
free p6 are indicated by arrows. Positions of molecular mass markers in 
kDa are shown at the left. 
 
 
 
 
Each of the virus bands was cut and in-gel digested with trypsin. Peptides were then 
extracted and analyzed by nano-LC-MS/MS on an LTQ (linear ion trap) Orbitrap velos mass 
analyzer. Nano-LC allows for high-resolution nano-scale flow separation that is coupled to a 
hybrid mass spectrometer, the LTQ Orbitrap. This mass spectrometer combines two ion 
traps that result in a high sensitivity and accuracy for detection and identification of small 
molecules in the sub-femtomole range. The viral peptides that were identified in this 
analysis are shown in Figure 3.17. Importantly, peptides from all of Gag were identified. This 
included peptides derived from the C-terminal p6 domain. 
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Figure 3.17 Mass spectrometry analysis of p6 posttranslational modifications. 
 At the left, schematic of the Gag protein and prescursor protein domains: MA, CA, NC, p6. The two white 
spaces in between the NC denote the two spacer peptides SP2 and SP1 from left to right of the Gag protein. At 
the right are shown the sequences for the respective protein domains and highlighted in orange are peptide 
sequences identified in the MS analysis. Peptides from every domain in Gag were identified. 
 
In total, four virus bands were analyzed for each optiprep virus preparation (OP1 and 
OP2). Phosphopeptide analysis of OP1 identified two phosphorylations: one in the cleaved 
form of the MA protein at the Ser residue in position 6 and one in the cleaved form of p6 at 
the Ser residue in position 40. Phosphopeptide analysis of OP2 detected multiple 
phosphorylation within the Gag precursor protein. The Ser6 phosphorylation in MA (the 
positions of the phosphoresidues is given in the context of each Gag-derived protein) was 
detected as well as three phosphorylations in the p6 domain, namely Ser40, Ser51 and 
Thr22/23. From the analysis it was not possible to distinguish between the closely spaced 
Thr signals, hence both Thr22 and Thr23 are considered as potentially phosphorylated 
residues. In addition, the Ser40 in free p6 was again detected in the second virus preparation 
(OP2), as well as cleaved MA which was observed to harbor two other phosphoresidues at 
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positions Ser9 and Tyr132 in addition to the Ser6. A schematic of the phosphorylations 
identified in the analysis is shown in Figure 3.18. 
 
 
 
Figure 3.18 Schematic of identified phosphoresidues in HIV-1 proteins by MS analysis. 
 MS analysis was carried out by nano-LC tandem MS coupled to a LTQ Orbitrap mass spectrometer. Four 
different p6-posititve bands were analyzed from each of two independent optiprep-gradient virus 
preparations. (A) Phosphorylations identified in the first virus preparation (OP1) were those of the cleaved MA 
protein and the cleaved form of p6. (B) Phosphorylations detected in the second virus preparation (OP2) 
include the gag precursor protein as well as the cleaved forms of MA and p6. The position of the 
phosphorylated residue is given in the context of each Gag-derived protein. 
 
However, since it is plausible that phosphopeptides are suppressed during ionization 
and because phosphopeptides exist at a low stoichiometric abundance, we wanted to 
maximize the efficiency with which phosphopeptides could be detected. Thus, 
phosphopeptides in the virus samples were enriched by MOAC as described above, using 
titanium dioxide (TiO2) as the metal oxide chromatography modifier. Phosphopeptide 
enrichment of each virus preparation was followed by LC-MS/MS analysis. Overall, this 
analysis not only confirmed most of the phosphoresidues that were initially identified, but it 
also detected additional phosphoresidues in p6Gag, either as part of processing intermediates 
or in the free form of p6. Moreover, phosphorylation of the cleaved CA protein was also 
detected. In addition to the previously identified p6Gag phosphoresidues Ser40, Ser51, 
Thr22/23 and Ser6 in the MA precursor, a new phosphoresidue in p6Gag was detected at 
Ser43. NC-SP1-p6 processing intermediates were identified and carried phosphoresidues 
within p6 at two positions: Thr21 and Thr22/23. The cleaved form of the CA protein was 
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found to be phosphorylated at two positions: Ser146 and Thr148/Ser149. Finally, two new 
phosphoresidues were detected in free p6: Ser51 and Thr22/23. Again, the close spacing 
between the Thr residues in the case pf p6 or Thr and Ser residues in the case of CA did not 
allow to discriminate which Thr residue—T22 or T23— or Thr/Ser—T148 or S149—is actually 
phosphorylated. A schematic of the phosphorylations identified in each virus preparation 
after phosphopeptide enrichment is shown in Figure 3.19. 
 
 
Figure 3.19 Phosphopeptide enrichment analysis of p6 phosphorylation. 
 The positions of the phosphorylated residues are given relative to the individual Gag-derived proteins. Newly 
detected phosphoresidues after phosphopeptide enrichment are highlighted in red; in green are residues that 
were also identified after phosphopeptide enrichment but which had been previously observed in the first 
analysis (Figure 3.18). (A) Phosphopeptide enrichment confirmed the presence of phosphoresidues that were 
observed during the first analysis (Figure 3.18). Moreover, it revealed another phosphoresidue in p6
Gag
, namely 
S43. In addition, the free form of p6 was observed to be phosphorylated at two positions while an NC-SP1-p6 
processing intermediate was identified and carried two phosphoresiduesA phosphorylation within the CA was 
found to occur either at T148 or S149. (B) New phosphoresidues were identified in virus prep 2 (OP2): two 
residues within the CA, two within the NC-SP1-p6 processing intermediate and two more within free p6. 
 
Overall, MS analysis and phosphopeptide enrichment were successfully applied 
towards the identification of phosphorylated p6 residues in HIV-1. Importantly, all identified 
phosphoresidues had high scores for phosphorylation and were manually validated. Taken 
together, the analyses suggest that p6 undergoes phosphorylation at multiple residues that 
are possibly acquired prior to proteolytic processing of the Gag precursor. The only 
exception seems to be the phosphorylation of T21, which according to the data probably 
  Results 
90 
 
occurs after the first processing step catalyzed by the viral protease that separates MACASP2 
from NCSP1p6 and is then lost, since free p6 was not found to contain the phosphorylated 
form of this residue. A third analysis was conducted in HIV-1NL4-3 viruses derived from 293T 
cells. This analysis confirmed phosphorylations in p6Gag at T22/23 (positions of 
phosphorylated residues are given relative to the Gag-derived protein in all cases) and in MA 
at S6. A processing intermediate containing MACA was identified and it contained a 
phosphoresidue within CA at T148/S149. This phosphoresidue was also found in free CA.  
These observations led us to question whether the p6 phosphorylation pattern might 
vary in viruses produced from different cell lines. Therefore, MT-4 cells were infected by HIV-
1NL4-3 coculture and 48 h after infection virus was collected and purified by Optiprep 
gradient. Importantly, the virus supernatant was treated with a phosphatase inhibitor 
cocktail immediately after harvesting and in every subsequent step throughout the 
purification procedure. Two independent virus purifications were prepared from MT-4 cells 
and a virus CA amount equivalent to 1.5 g of p6 from each preparation was loaded onto a 
4-12 % Bis-tris gel. Virus proteins were separated and analyzed by electrophoresis. 
Additionally, a virus amount equivalent to 0.5 g p6 was loaded on the same gel for Western 
blot analysis to identify p6-containing protein bands. Four p6-positive protein bands (Figure 
3.20) were cut, in-gel digested with trypsin, phosphopeptides enriched and analyzed by MS. 
 
 
Figure 3.20 Western blot analysis of HIV-1-derived p6 products. 
 NL4-3 derived virus from infected MT-4 cells was harvested 48 h pi 
in the presence of a phosphatase inhibitor cocktail and purified by 
Optiprep-gradient. A virus CA amount equivalent to 1.5 g of p6 from 
each virus preparation was loaded onto a 4-12% Bis-Tris gradient gel 
and virus proteins were separated by electrophoresis (not shown). A 
virus CA amount equivalent to 0.5 g of p6 was simultaneously run 
and analyzed further by Western blot. The membrane was probed 
against p6-specific antibody. Boxed areas indicate the four virus 
bands that were selected for MS analysis. Virus bands pertaining to 
the Gag precursor protein and to free p6 are indicated by arrows. 
Positions of molecular mass markers in kDa are shown at the left. 
 
 
The MS analysis of MT-4 cell-derived HIV-1 virions identified phosphoresidues in p6 as part 
of the Gag precursor protein, as an NCSP1p6 processing intermediate or in its cleaved form. 
p6Gag residues S40 and T22/23 (position of the residues are given relative to the Gag-derived 
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protein) were observed to be phosphorylated in one of the two virus preparations. The 
processing intermediate NCSP1p6 contained the p6 phosphoresidues T22/23 and S51 in both 
virus preparations. Finally, the free form of p6 is phosphorylated at S40 and S50/51. Other 
HIV-1 proteins found to contain phosphoresidues were the MA protein at S6 and S9 and CA 
at T148/S149 or S149 only. Table 3.3 lists the p6 phosphoresidues detected from 293T cell- 
and MT-4 cell-derived HIV-1.  
 
Table 3.3 Comparison of p6 phosphoresidues identified from 293T cell and MT-4 cell virus preparations. 
Shown is a list of p6 phosphoresidues detected in HIV-1 derived either from 293T or MT-4 cells. The position of 
the p6 phosphoresidues is given relative to the p6 protein. 
 
Overall, three independent 293T cell-derived virus preparations were analyzed while 
two independent MT-4 cell-derived HIV-1 preparations were subjected to MS analysis. Thus, 
the analyses indicate that p6 is indeed subject to posttranslational modification and is hence 
phosphorylated at multiple residues. Moreover, the combined data suggests that the p6 
phosphorylation pattern is cell-type dependent. However, to confirm this assumption it 
would first be necessary to analyze one more independent HIV-1 preparations from MT-4 
cells. Concomitantly, the analysis of the MT-4 derived virus bands could be repeated and 
extended to ensure that only those phosphoresidues listed in Table 3.3 occur.  
3.7 Effect of a p6 T8N mutant in the HIV-1 replication cycle 
 
Mutations within the critical PTAP motif are detrimental for HIV-1 release. By EM, 
such budding mutant virions remain connected to the host plasma membrane through a 
membrane stalk (53). The PTAP motif can also exist as PSAP; however, there is no indication 
of any other residue occurring at this position. As shown in section 3.4 we unexpectedly 
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observed that a p6 T8N mutant can efficiently rescue HIV-1 release. Therefore, we became 
interested in characterizing this mutant’s properties. We were especially interested in 
understanding why this mutant does not occur in nature when it seems to function 
efficiently as a late domain. It is plausible that although the Asn at this position enables the 
virus to bud, this residue may be detrimental to the virus at another step during its 
replication cycle. Thus, we tested this mutant’s ability for single-round infection. For this 
purpose, supernatants from transfected 293T cells were used to infect TZM-bl reporter cells. 
48 h pi, the cells were lysed and luciferase activity was recorded as a measure of virus 
activity. Figure 3.21 A shows that the single-round infectivity of the p6 T8N mutant is not 
significantly compromised and is comparable to that of the WT virus. This is also obvious 
when infectivity values are normalized to CA content as shown in Figure 3.21 B. 
 
Figure 3.21 Effect of the p6 T8N mutant in viral infectivity. 
 An Asn residue within the critical p6 PTAP motif does not affect virus single-round infectivity. 293T cells were 
transfected with the indicated proviruses and the virus supernatant was harvested 48 h pt and titrated onto 
the indicator TZM-bl cell line. Cells were lysed 48 h pi and luciferase activity was measured as relative light 
units (RLU). (A) Infectivity levels as RLU are given for each p6 mutant. (B) Infectivity values normalized to virus 
p24 content for each p6 mutant are shown relative to the WT. 
 
These observations indicate that the p6 T8N mutant is infectious and thus, this does 
not explain why this mutant does not occur in nature. In order to assess whether the p6 T8N 
mutant is capable of sustaining a spreading infection, I infected PBMCs from 3 different 
donors with CA-normalized amounts of WT and p6 mutant virus particles, and viral 
replication was monitored by quantification of CA amounts in culture supernatants over a 
period of 15 days. However, this assay awaits analysis. We have so far assumed that the p6 
T8N mutant supports HIV-1 release by the same means that wildtype p6 does: by recruiting 
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Tsg101 to sites of virus budding. Thus, in order to confirm that the p6 T8N mutant behaves 
in a manner similar to wildtype p6, I conducted siRNA experiments involving Tsg101. Briefly, 
293T cells were transfected with 100 pmol of siRNA against Tsg101. About 24 h later, a 
second transfection was done with either 40 pmol or 80 pmol siRNA against Tsg101. At the 
same time, the cells were transiently transfected with wildtype NL4-3 virus or with the p6 
T8N mutant provirus. Released virus particles and cell-associated viral products were 
collected 40 h pt. Cell lysates and purified virus particles were subjected to Western blot 
analysis to detect the efficiency of the Tsg101 knockdown and to detect levels of virus 
released. As shown in Figure 3.22 A, cellular levels of Tsg101 remaining after siRNA 
treatment were almost undetectable and cells treated with a scrambled version of the RNA 
were not affected in Tsg101 expression. Concomitant transfection with proviral DNA 
revealed that as expected, WT release is strongly inhibited in the absence of Tsg101. 
Importantly, the same was true for the p6 T8N mutant virus. The amount of virus p24 
released into the medium was further quantified and is shown in Figure 3.22 B. Taken 
together these observations suggest that the ability of the p6 T8N mutant to support HIV-1 
release depends on the availability of intracellular Tsg101 pools from which Tsg101 might be 
recruited to sites of p6 T8N virus budding. 
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Figure 3.22 Effect of Tsg101 knockdown on the release efficiency of the p6 T8N mutant virus. 
 (A) Upper panel: Anti-Tsg101 western blot showing depletion of Tsg101 protein from 293T cells. Cells were 
transfected on day 1 with 100 pmol of Tsg101 siRNA or with a scrambled (scr) siRNA as indicated. About 24 h 
later, cells were transfected with either 40 pmol or with 80 pmol of Tsg101 siRNA or 40 pmol scr siRNA. Lower 
panel: Anti-CA antibody showing that depletion of Tsg101 inhibits virus release. Cells transfected with siRNA 
were also cotransfected with WT virus or with p6 T8N virus. About 40 h after the initial transfection, 
supernatants and cell lysates were collected and virus particles were pelleted over a 20 % sucrose cushion. (B) 
Levels of virus CA released into the medium were determined by quantitative WB and are shown relative to the 
WT virus treated with scr siRNA. 
 
3.7.1 Morphology of p6 T8N mutant virion analyzed by electron 
microscopy 
 
In order to investigate a potential role of the p6 T8N mutant on virus assembly and 
budding, virion morphology was examined by thin-section electron microscopy. HeLa cells 
were transfected with WT and p6 T8N mutant proviral constructs and chemically fixed at 24 
h pi and subjected to electron microscopy. In addition, HeLa cells transfected with the 
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proviral constructs p6 T8I and PTAP- served as negative controls. To compare the effect of p6 
mutations on virion assembly to HIV-1 wildtype and HIV-1 lacking PTAP, virus-like structures 
at or near the plasma membrane were quantified and sorted into three classes (budding 
arrested, immature and mature) (Figure 3.23). 
 
Figure 3.23 Visualization of p6 T8N virions by thin-section electron microscopy. 
 HeLa cells were transfected with the proviral constructs WT, T8N, T8I, T8D, T8Q and PTAP- and chemically 
fixed 48 h pt and processed for thin-section electron microscopy. (A) and (B) Low-magnification images 
showing  the morphological features of immature, budding arrested virions (A) at the plasma membrane and 
(B) mature wildtype virions at the periphery of the cell. The lower panels contain high-magnification images of 
the 3 main assembly phenotypes used to categorize virus particles generated from the different proviral 
constructs. The percentage of virus-like structures under each category was quantified by systematic uniform 
random sampling (50 virions were quantified per category) and are indicated in the graph. 
 
The assembly of the p6 T8N mutant was closest to that of wildtype HIV. More than 50 
% of virus-like structures consisted of mature virions with conical-shaped cores compared to 
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75 % in the case of wildtype HIV-1. In contrast, the p6 T8I mutant was strongly inhibited in 
release and maturation of these virions was similar to that typically seen during the 
assembly of virions lacking a PTAP motif. 80 % of virions were budding arrested compared to 
65 % for PTAP- viruses. No mature virion was observed in the case of the T8I mutant. The p6 
mutants T8Q and T8D showed a lower number of mature particles (10-20 %) in contrast to 
wild-type HIV-1 Gag. 
Taken together, these results confirm our data obtained with the virus release assay, 
indicating that the p6 T8N mutant is capable of achieving levels of wildtype release; 
moreover, it shows that the majority of viruses that are released are mature and appear 
morphologically identical to the wildtype virus. 
3.8 Characterization of the interaction properties between the p6 
T8N mutant and the Tsg101 UEV domain 
 
Because the T8N mutation in the PT8AP motif results in wildtype levels of virus 
release and gag processing and seems to be as infectious as the wildtype, we wanted to 
further characterize this mutant to reveal the biological and molecular basis of HIV-1 PNAP 
late domain function. To study the molecular basis of PNAP late domain function, we sought 
to study the structural properties between the Tsg101 UEV domain and a PNAP peptide in 
principal two ways: by crystallization of the complex and Isothermal Titration Calorimetry 
(ITC). Through the latter one can compare the binding affinity of a wildtype PTAP p6 peptide 
for its interacting cellular partner Tsg101 UEV domain to that of a PNAP p6 peptide and 
those of other p6 T8 mutants. 
3.8.1 Analysis of the crystal structure of the Tsg101 UEV domain in 
complex with a PNAP p6 peptide 
 
Obtaining the crystal structure of the complex formed between a PN8AP peptide and 
the Tsg101 UEV domain, may reveal the molecular basis of HIV PNAP late domain function. 
Moreover, it will help examine in detail the contacts made between the complex and how 
these compare to the well-characterized PTAP-Tsg101 UEV interaction (71, 117). For this 
purpose, a histidine (his)-tagged version of the Tsg101 UEV domain was cloned into a 
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bacterial expression vector and transformed into Escherichia coli (E. coli) BL21 cells. Protein 
expression was induced with IPTG (Isopropyl -D-1-thiogalactopyranoside); the cleared 
supernatant was loaded onto a Ni-NTA resin, eluted and dialyzed. Subsequently, the His tag 
was cleaved off and the untagged protein was purified by gel filtration. The Tsg101 UEV 
protein yield was concentrated to 43 mg/ml (Figure 3.24). 
 
Figure 3.24 Gel filtration purified Tsg101 UEV. 
 A his-tagged version of the 145 amino acid residue Tsg101 
UEV domain was synthetically produced, cloned into a 
bacterial expression vector and transformed into E. coli 
BL21 cells. Protein expression was induced with 100M 
IPTG. Cells were harvested and the cleared supernatant 
was loaded onto a Ni-NTA resin, eluted and dialyzed 
against 50 mM Tris pH 8.0/150 mM NaCl. Subsequently, 
the his-tag was removed by treatment with TEV protease 
and the untagged protein was purified by gel filtration and 
concentrated to 43 mg/ml. The resulting purified Tsg101 
UEV protein is indicated by an arrow. Positions of 
molecular mass markers in kDa are shown at the left. 
 
In addition, a nine amino acid residue PEPNAPPEE p6 peptide was synthetically 
produced. The p6 peptide and the Tsg101 UEV protein sample were sent for crystallization 
trials to the group of Dr. Winfried Weissenhorn in Grénoble. Overall, eight different crystals 
were obtained under two sets of conditions: 28 % PEG 8000, 0.1 M sodium cacodylate, 0.2 M 
ammonium sulfate, and 26 % PEG 4000, 100 mM Tris pH 8.5, 220 mM lithium sulfate. 
Diffraction of the crystals identified the Tsg101 UEV domain occurring in two different 
arrangements: either as a dimer or a dodecamer (Figure 3.25).  
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Figure 3.25 Tsg101 UEV crystal structure. 
 Tsg101 UEV microcrystals were obtained under two different conditions: (A) 28 % PEG 8000, 0.1 M sodium 
cacodylate, 0.2 M ammonium sulfate yielded three 2 Å resolution crystals in which Tsg101 UEV was found as a 
dimer; (B) 26 % PEG 4000, 100 mM Tris pH 8.5, 220 mM lithium sulfate yielded 2.8 Å resolution crystals in 
which Tsg101 UEV occurred as a dodecamer. 
 
However, as shown in Figure 3.25 no peptide was found in complex with it. The PTAP binding 
pocket in Tsg101 UEV is highlighted in Figure 3.26 A superimposing the known NMR 
structure (117) of the Tsg101 UEV-PTAP complex onto the crystal structure of the Tsg101 
UEV domain obtained in this study. An electron density map of the peptide binding site 
region indicates that no peptide is present in this area (Figure 3.26 B). One reasonable 
explanation of why no peptide was found complexed to Tsg101 UEV could be that 
suboptimal concentrations of peptide were used. Therefore, two approaches were used to 
introduce the peptide into the structure: 1) soaking of the crystals in the peptide solution; or 
2) recrystallization with a higher peptide to protein ratio. However, no crystal structure of 
the complex has been obtained so far. 
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Figure 3.26 Crystal structure of the Tsg101 UEV-PTAP complex. 
 (A) The image of the known NMR structure of the Tsg101 UEV (blue) and the wildtype PTAP p6 peptide (red) 
(117) was superimposed onto the crystal structure of the crystallized Tsg101 UEV during this study (green). The 
location of the PTAP peptide binding site in Tsg101 UEV is indicated by an arrow. (B) Electron density map of 
the top portion of the crystal structure of Tsg101 UEV shows that no peptide is present. 
 
3.9 Binding affinity between a PNAP p6 peptide and Tsg101 UEV 
 
Isothermal titration calorimetry (ITC) is a highly sensitive tool to measure the 
thermodynamic properties of protein-protein and protein-ligand interactions. ITC measures 
directly the binding equilibrium by determining the heat evolved upon association of a ligand 
with its binding partner (112). A typical power compensation calorimeter is depicted in 
Figure 3.27. In such an instrument, the reference cell is kept at a constant temperature, 
hence the term isothermal. In modern ITC instruments, a titrant is delivered at defined time 
intervals into the sample cell that contains the binding partner. Then as ligand and protein 
interact in the sample cell, any heat evolved or consumed from the reaction is sensed and a 
proportional amount of power is applied to keep the temperature between the sample and 
reference cells constant. The raw calorimetric signal is equal to the power (µcal/sec or 
µJ/sec) that must be applied to keep the sample cell from changing temperature as a 
function of time. The heat change or ΔH is equivalent to the time required for the 
temperature of the sample cell to return to a baseline value and is in proportion to the 
amount of binding that takes place. Thus, as the reaction reaches saturation the heat change 
is diminished until only the background heat of dilution is detected. 
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Figure 3.27 Schematic representation of a power compensation calorimeter. 
 In a typical experiment, a solution of a ligand is titrated into a solution of its binding partner. The heat released 
upon their interaction is measured over time. The output signal is in the form of  peaks that represent a heat 
change proportional to the amount of binding and power required to keep the sample cell temperature equal 
to that of the reference cell, which is kept constant. As consecutive injections are delivered and the system 
reaches saturation, the heat change becomes smaller, hence the smaller peaks, until only the heats of dilution 
are observed. A binding curve is then obtained from the heats of each injection against the ratio of ligand and 
macromolecule in the sample cell. Adapted from (44). 
 
We employed this method to measure and compare the binding affinities between 
Tsg101 UEV and three p6 peptides: the wildtype PTAP peptide, the PNAP peptide and a 
PAAP peptide. For this purpose, nine amino acid residue peptides containing the basic 
sequence PEPXAPPEE were synthetically produced and Tsg101 UEV protein was purified. The 
concentration of Tsg101 UEV was measured by two independent methods: by the Bradford 
Assay and by extinction coefficient. The peptide concentration was measured by infrared 
spectroscopy. In ITC, it is of utmost importance that both the ligand and protein are in the 
same buffer. Thus, both Tsg101 UEV and peptides were resuspended in a buffer containing 
150 mM NaCl and 1X PBS at pH 8.0, they were aliquoted and kept at -80°C. The protein and 
peptides were quick-thawed at 37°C, protein concentration was measured and appropriate 
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dilutions of both protein and ligand were made before each experiment. Samples were 
degassed by applying vacuum before being loaded into the ITC machine. The ITC machine 
was thoroughly washed before and in between experiments to reduce the occurrence of 
anomalous signals generated during the experiment. Starting concentrations of 25 mM 
Tsg101 UEV and 500 M peptide were used. About 250 l of Tsg101 UEV were injected into 
the sample cell and around 50 l of peptide were loaded into the syringe, which resulted in 
about 18 injections of titrant. Peptides were tested at a concentration range between 500 
M and 2 mM while the concentration of Tsg101 UEV remained constant throughout the 
experiments performed. A representative experiment for each peptide is shown in Figure 
3.28. The Kd values result from the average of at least 3 independent experiments per 
peptide. The average Kd obtained for the wildtype PTAP p6 peptide was 57.2 M which is in 
good agreement with that recently reported by Im et al (71). The other naturally occurring 
residue in the PT8AP position is Ser and although the binding affinity between a PSAP p6 
peptide and Tsg101 UEV has reportedly been measured, the actual Kd value has not been 
published before. Thus, we were interested in comparing the binding affinity between the 
PSAP and PTAP p6 peptides for Tsg101 UEV. As shown in Figure 3.28 C, the average Kd for 
the PSAP-Tsg101UEV interaction was 46.9 M and is thus as strong as the one exhibited by 
the PTAP peptide. On the other hand, the binding affinity between a PNAP p6 peptide and 
Tsg101 UEV (Figure 3.28 B) was 5 times lower than the wildtype interaction. Titration of the 
PAAP p6 peptide (Figure 3.28 C) gave rise to small peaks of equal and negligible size and had 
a correspondingly negligible binding affinity. Overall, the naturally occurring PTAP and PSAP 
p6Gag motifs bind Tsg101 with similar affinity and these motifs seem to be equally efficient in 
recruiting Tsg101 (54, 132). Although the binding affinity between a PNAP peptide and 
Tsg101 UEV was 5 times lower than the wildtype PT/SAP interaction, this binding affinity is 
clearly and significantly stronger than that displayed by the PAAP peptide. Moreover, the 
fact that the p6 T8N mutant can support HIV-1 release suggests that the binding affinity 
between Tsg101 UEV and p6Gag need not to be so tight to be able to recruit Tsg101 to sites of 
virus budding. In support of this observation, it has been shown that the interaction 
between Ub and Tsg101 UEV is rather weak, around 500 M (see section 1.4) while the 
interaction between Tsg101 and the ESCRT-0 component, Hrs is around 290 M. Moreover, 
the fact that simultaneous binding of Ub and a p6 peptide increases the binding affinity 
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between the Tsg101 UEV and p6 about 10-fold, suggests that if the affinity between a PNAP 
peptide and Tsg101 UEV is not tight enough to recruit Tsg101 to sites of virus budding, 
binding of a Ub moiety could solve this problem.  
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Figure 3.28 Isothermal titration calorimetry of the Tsg101 UEV-p6 peptide interaction. 
 The upper panels represent the ITC thermograms and the lower panels represent the fitted binding isotherms. 
The isotherm curves were fit to a 1:1 binding model. Values from at least 3 independent titration experiments 
were averaged to yield the indicated Kd values. p6 peptides (A) PTAP, (B) PNAP, (C) PAAP, (D) PSAP were 
titrated at a concentration range between 500 M to 2 mM into the cell containing Tsg101 UEV at 25 M at 
25°C in 150 mM NaCl, 1X PBS (pH 8.0). Shown are thermograms for peptides titrated at 1 mM. 
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4 Discussion 
Protein phosphorylation is a widely used posttranslational modification by the cell to 
convey specific messages in response to particular stimuli. It allows the coordination of a 
myriad of cellular processes in a timely and specific manner. It is no wonder that viruses 
have adapted the use of such a modification to their own advantage. This is evidenced by 
the fact that several families of DNA viruses encode their own kinases (74). In other 
instances, cellular kinases have been detected within purified virus particles. These virion-
associated protein kinases (VAPKs) usually phosphorylate viral proteins and contribute to the 
infectivity of the virus (65). Alternatively, viruses can engage the signaling activity of cellular 
kinases within their hosts such as that directed by mitogen-activated protein kinases 
(MAPKs) through a viral effector protein. This is particulary evident in the RNA viruses of the 
orthomyxoviridae, retroviridae, filoviridae, and flaviviridae (113). Viruses can recruit kinase 
activity by carrying consensus phosphorylation sequences in their genomes (140). There is 
evidence that structural proteins of HIV-1 such as CA, MA as well as the accessory proteins 
vif, vpu, rev, nef, tat and vpr are phosphorylated (19, 24, 26, 75, 101, 102). It is now 
becoming apparent how this viral peculiarity represents motif mimicry used as a tactic to 
reprogram the host cell. Viruses are able to recruit protein kinases, ligases or eukaryotic 
adaptor proteins by mimicking eukaryotic short linear motifs or SLiMs within disordered 
regions of their genetic sequence. Some of the most obvious examples are the eukaryotic 
motifs mimicked by viruses known as late domains (33). The PT/SAP and LYPXnL late 
domains of p6 HIV-1 redirect components of the ESCRT machinery to sites of virus assembly 
and budding, facilitating the catalysis of the last scission step that releases the nascent virion 
from its host cell. The HIV-1 p6 protein is an ideal example of a docking protein: it is highly 
flexible and unstructured—although it exhibits some regions of secondary structure under 
hydrophobic conditions (40)—and not only does it recruit diverse cellular and viral proteins 
but is also subject to several posttranslational modifications. For instance, p6 has been 
reported to be ubiquitinated at conserved Lys residues in positions 27 and 33 (107) and 
sumoylated at position 27 (57). An interesting observation is that p6 has 13 potential 
phosphorylation sites and in fact, p6 was previously identified by our group to exist as the 
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major phosphoprotein in HIV-1 particles (101). However, an in-depth study of the functional 
role of p6 phosphorylation has not been conducted to this date. Therefore, these 
observations prompted us to conduct a comprehensive analysis of the consequences of 
potential p6 phosphorylation in the HIV-1 replication cycle.  
 
4.1 Comprehensive analysis of HIV-1 p6Gag phosphorylation 
 
HIV-1 p6Gag contains 13 potentially phosphorylated residues: eight Ser, four Thr, and one 
Tyr. We made use of 3 phosphorylation prediction programs available on the web 
(NetPhos/NetPhosK, GPS, and DISPHOS) to select residues within p6 that were highly 
predicted to be phosphorylated. In addition, Ser, Thr and Tyr p6 residues that are highly 
conserved among HIV-1 subtypes were selected (Table 3.1 and Table 3.2). Information 
derived from these analyses was combined to choose the following p6 residues for 
mutational analysis: S14 and S25, as well as T8 and T23. We found that mutation of the p6 
S14 and S25 residues had no effect on virus maturation or production as assayed in 293T 
cells (Figure 3.1). Moreover, the replication capacity observed for these p6 mutants was 
comparable to that of the wildtype virus in both C8166 cells and primary lymphocytes 
(Figure 3.4 and Figure 3.5). Thus, although these Ser residues are rather highly conserved 
and have high scores for phosphorylation, they do not seem to play a role in the replication 
cycle of the virus. The p6 T23 residue had been previously analyzed by our group and was 
included in this study to further characterize it and to confirm previous observations 
obtained with this mutant. Like the S14 and S25 p6 residues, we can conclude that the T23 
residue plays no role in virus maturation, production or replication capacity of the virus. This 
contradicts results published by Hemonnot et al (60), who provided data that implicated the 
p6 T23 in HIV-1 release, maturation and infectivity. Reportedly, the p6 T23 residue was 
observed to be phosphorylated in vitro by the HIV-1 VAPK, ERK-2. Mutation of this residue to 
Ala resulted in multiple aberrant viruses, the majority of which were released but displayed 
an immature morphology. Although the same cell system and HIV-1 strain have been used in 
both studies, we failed to observe any effect of the p6 T23 mutant on any aspect of the viral 
replication cycle. Although we did not examine the morphology of the released virions, our 
release and infectivity data for this mutant suggests that they are not morphologically 
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aberrant since we did not observe accumulation of processing intermediates in these virions 
nor was their replicative capacity compromised. Moreover, although creating a Thr to Ala 
point mutation in p6 at this position results in an amino acid change within the pol frame, 
the inhibitory effect of the T23 mutation observed by Hemonnot et al cannot be attributed 
to this fact, since 1) our mutant also results in a change in pol and 2) most importantly, it has 
been published that deletion of residues T21-T23 in p6Gag or equivalent mutations in pol are 
dispensable for the virus, at least in cell culture systems (13, 111). So far, the reason for 
these discrepancies is not evident.  
The p6 T8 residue has a high phosphorylation prediction score and is strongly 
conserved among HIV-1 subtypes. Moreover, given that this residue is part of the critical p6 
PTAP late domain and that p6 is subject to various posttranslational modifications, there 
seemed to be a high likelihood that phosphorylation of this residue could be involved in the 
late domain activity of p6. It has also been shown before by biochemical methods that the 
late domain proteins of other viruses such as MLV, MPMV, and VSV are phosphorylated (29, 
133, 154, 155). Thus, to approach the potential role of p6 T8 phosphorylation we attempted 
to emulate a phosphorylated state of this residue by creating a point mutant containing an 
Asp instead of the Thr. We observed that the p6 T8D mutant virus was released to a slightly 
greater extent than the T8I, T8A, and PTAP- mutants in 293T cells. Moreover, we examined 
its ability to establish a productive spreading infection in C8166 cells. In these cells, the T8D 
mutant achieved virus titers that were at least 2- to 4-fold higher than the T8I and T8A 
mutants (Figure 3.4). When analyzed in a more relevant cell system such as primary 
lymphocytes, the T8D mutant exhibited delayed kinetics and reached virus titers comparable 
to the wildtype virus (Figure 3.5). However, it cannot be excluded that the delayed kinetics 
of virus production displayed by the T8D mutant could be due to the emergence of viral 
revertants. In fact, closer examination by thin-section EM revealed a significant proportion of 
immature and budding-arrested viruses (Figure 3.23) suggesting that the high virus titers 
exhibited by this mutant are likely due to reversion.  
As expected, the PTAP- mutant was strongly impaired in replication, while the T8I 
mutant exhibited an initial delay that did not reach wildtype virus titers at later timepoints.  
 To investigate whether the improved ability of the p6 T8D virus to exit the cell could 
be due to the mimicked phosphorylation state of the mutation, we replaced the T8 residue 
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by a Glu residue. Since this residue is bulkier than Asp and might better emulate a 
phosphorylated state of the residue, we reasoned that release might become even more 
efficient. However, the T8E mutant was not more efficiently released relative to the T8D 
mutant (Figure 3.7); on the contrary, the T8E mutant seemed to be even more impaired in 
release. Phosphorylation is a highly dynamic process, and it seems plausible that if 
phosphorylation would function as an ‘on’ signal in this scenario, a T8D or T8E mutant could 
presumably be in a constitutively active ‘on’ state without the possibility of ‘switching-off’ 
the signal. This could interfere with putative signaling events potentially required to facilitate 
virus release. This possibility, however, seems inconsistent with other observations as along 
with the T8E mutant we tested a p6 T8N mutant that was included as a negative control in 
our experiments. Unexpectedly, this mutant behaved similarly to the wildtype virus both in 
release and in single-round infection. This finding strongly argues against a role for p6 T8 
phosphorylation in virus release. Further supporting this conclusion is the p6 mass 
spectrometry data obtained from 3 independent 293T cell-derived virus preparations and 2 
independent MT-4 cell-derived virus preparations that indicate that this residue does not 
undergo phosphorylation. Thus, the improved ability of the T8D mutant to exit the host cell 
could be due to an overall slightly greater affinity for the cellular interaction partner, Tsg101 
relative to the T8I and T8A mutants. Importantly, this putative affinity of interaction 
between a T8D virion and Tsg101 is likely to be much lower than the wildtype interaction 
and could result in an overall less efficient recruitment of Tsg101 to sites of virus assembly 
and budding. This could result in Tsg101 and the ESCRT machinery reaching those sites when 
the Gag shell is almost complete. This could give rise to mainly immature, dead-end viruses 
as postulated by Carlson et al (see section 1.3.2.1.3) and as indicated by our EM data (Figure 
3.23).  
4.2 Uncoupling of the gag and pol overlapping reading frames to 
perform extensive mutations in p6Gag 
 
The HIV-1 genome has three main coding regions: gag which directs the synthesis of 
the internal structural proteins, pol which encodes the viral enzymes and env which gives 
rise to the envelope proteins. In HIV-1 the pol gene lacks an initiation codon and partially 
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overlaps with the gag reading frame. To support translation of the pol products, a small 
number of ribosomes undergo a -1 ribosomal frameshift event once every 20 gag translation 
events. The frameshift required for the translation of HIV-1 Gag-Pol is promoted by two cis-
active signals on the genomic RNA: a UUUUUUA heptamer termed the ‘slippery’ sequence 
and a stem-loop. These elements are located in the overlapping region of the gag and pol 
genes directly following the coding region for NC (62). C-terminal residues within p6Gag have 
been shown to be required for proper separation of the PR from the p6* (transframe) (111). 
Moreover, C-terminal residues within p6Gag also overlap with the PR sequence. Thus, 
extensive mutational analysis of p6Gag is hindered by this viral property. To overcome this 
limitation we applied a strategy recently described by Leiherer et al (89) in which the gag 
and pol overlapping reading frames are separated or ‘uncoupled.’ This is achieved by 
abrogating the frameshift signal at the N-terminus of the p6* and reintroducing it at the end 
of the gag codon (Figure 3.9). This results in an extended Gag by 5 amino acid residues, 
while the p6* is extended by 70 amino acid residues. A synthetic fragment containing the 
changes in the frameshift signal was introduced into the backbone of the HIV-1 NL4-3 
infectious clone. In agreement with the published study, we observed that such uncoupled 
viruses retain wildtype levels of virus production, protein processing and maturation as well 
as being infectious (Figure 3.10 and Figure 3.11). Since our main goal was to use this 
uncoupled construct to analyse the effect of extensive mutations in potentially 
phosphorylated residues in p6Gag, we further mutated extensive segments within the 
uncoupled construct’s p6Gag sequence, generating three main proviruses in which either all 
Ser, Thr and Tyr residues were mutated with the exception of Thr8 (FL) or in which only the 
N-terminal (Nter) or C-terminal (Cter) Ser, Thr, and Tyr residues were mutated (Figure 3.12). 
Initial analysis of these mutants revealed that both the FL and Cter p6 mutations were 
detrimental to virus release. However, further analysis of these mutants proved difficult to 
reach a conclusion since it appeared that cumulative Ser, Thr, and Tyr mutations within the 
p6 sequence had no significant effect on virus production. Thus, careful interpretation of 
these observations is warranted until further analysis clearly distinguishes whether virus 
release is affected or not. Nevertheless, some assumptions can be made in each possible 
scenario: first of all, if potential p6 phosphorylation proves not to be required for virus 
release, then the infectivity and replicative fitness of these virions must be examined, since it 
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is plausible that p6 phosphorylation is not required for virus release but for the association 
of cellular factors or viral proteins that are important during viral entry and replication. For 
instance, the HIV-1 accessory protein Vpr protein is incorporated into virions by recognition 
of two motifs within p6Gag, one of which is localized at the C-terminus of p6 and involves the 
41LRSLF sequence. Vpr is a highly basic protein which is itself phosphorylated (102) and has 
been implicated in nuclear import of the viral PIC (pre-integration complex) as well as in 
activation of transcription, cell-cycle arrest and in the induction of apoptosis (45). p6Gag 
phosporylation (for instance by inducing a negatively charged environment) might 
specifically serve as an activation signal to recruit Vpr to sites of virus assembly and budding. 
To test this, one could determine the degree of Vpr incorporation into p6 mutants and the 
effect this might have on viral replication. Importantly, the p6 mass spectrometry analysis 
identified S43 as a phosphoresidue which is part of the 41LRSLF motif. Furthermore, the MS 
analysis suggests that this modification is only present in p6Gag and is lost once p6 is cleaved 
off from the precursor protein (Table 3.3). This would imply that transient modification of p6 
could result in the recruitment of Vpr shortly before or concomitant with initiation of 
proteolytic cleavage of the Gag polyprotein precursor. Loss of the phosphorylation signal 
would induce the disassociation of Vpr from p6Gag which could be important for Vpr 
association with the PIC during viral entry.  
Alternatively, p6 phosphorylation could occur ‘accidentally’ due to sequence 
similarities with preferred substrate-binding sites. Yet another possibility is that 
phosphorylation could occur within the virus particle and have its effect during the early 
stages of virus entry. It has been reported that the ERK-2 kinase is incorporated into HIV-1 
particles (24). This suggests that kinases incorporated within HIV-1 particles can control the 
phosphorylation status of the substrate protein and catalyze its modification at a later stage 
during the infectious cycle of the virus. For instance, phosphorylation of the HIV-1 MA 
protein by virion-associated ERK/MAPK has been reported to be involved in the uncoating 
process during virus entry (75). 
Considering the second scenario where the FL and Cter mutants reflect a true 
phenotype suggesting that p6 phosphorylation would indeed play a role in virus release, this 
would suggest that the potential phosphorylation of Ser, Thr, and Tyr residues within the C-
terminus of p6 might be relevant for virus release. Impact on other viral processes such as 
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maturation, infectivity and replication capacity would require further examination. Although 
a defect in virus maturation was not readily detected by Western blot analysis in any of the 
experiments performed, a closer and more detailed look at these mutants should be 
conducted by EM. In addition, one could further discriminate between these residues to 
identify the particular residue(s) involved in the phenotype by narrowing down the extent of 
residues mutated within the C-terminus of p6. Moreover, the mass spectrometry analysis 
performed for wildtype NL4-3 viruses derived from two different cell lines suggests that p6 
C-terminal Ser residues 40, 43, and 51 could potentially be involved in the putative 
phenotype. Phosphorylation prediction programs such as NetPhosK can be used to identify 
kinases that might be involved in phosphorylating specific residues. According to this 
program, the S40 residue is putatively phosphorylated by the PKC kinase, S43 by CKI while 
three different kinases could in theory phosphorylate S51: CKII, DNAPK and ATM. The 
involvement of these kinases in viral processes is not without precedent. For instance, PKC 
has been reported to phosphorylate the viral P proteins of human parainfluenza virus type 3 
(HPIV3) and Sendai virus (34, 67). This modification is important for virus replication. In 
addition, PKCs have also been reported to phosphorylate the HIV-1 accessory protein Nef, 
resulting in increased viral replication (152). Both CKI and CKII are involved in regulating the 
gene repressive activity of the immediate early protein 63 (IE63) of varicella-zoster virus 
(VZV) (14) while the ATM kinase has been reported to enhance HIV-1 replication through 
enhanced Rev function (3). The DNAPK has been implicated in retroviral DNA integration 
(32). There is evidence that the late domains of other retroviruses are phosphorylated: The 
p24 protein of MPMV, the M protein of VSV and the p12 protein of MLV (101). In the case of 
MLV, it has been shown that phosphorylation of serines within this domain are required 
during early events of viral infection (156); alternatively, it has been suggested that 
phosphorylation of p12 might serve to bind to WW domain-containing proteins, such as E3 
Ub ligases (155). A direct role for phosphorylation in the late-domain activity of retroviral 
proteins has only been demonstrated for HTLV-1 and reportedly for HIV-1. HTLV-1 MA 
protein contains PTAP and PPPY L-domain motifs. A Ser residue in the vicinity to the L-
domain was observed to be phosphorylated by virion-associated ERK-2. This modification 
was found to decrease virus release and impair viral infectivity (61). The same group showed 
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that p6Gag Thr23 residue is phosphorylated by the ERK-2 kinase and that phosphorylation of 
this residue is important for virus release and infectivity (60).  
Phosphorylation and ubiquitination are posttranslational modifications that exhibit 
considerable crosstalk. For instance, phosphorylation may serve as a signal for the addition 
or removal of a second posttranslational modification or for recognition by a binding protein 
that carries out a second modification. In addition to phosphorylation, HIV-1 Gag is 
monoubiquitinated at Lys residues present in all of its domains (55). Moreover, Gag 
modification with Ub and an intact proteasome have been shown to be important for late 
domain activity (93). In this context, p6 phosphorylation might serve to recruit Ub ligase 
activity that in turn serves to recruit ESCRT components to sites of virus assembly and 
budding. The ESCRT-I component and cellular interaction partner of p6Gag, Tsg101 contains 
an UEV domain that serves to recognize and bind Ub during the sorting process of cargo 
proteins. Interestingly, it has been shown that the affinity between the p6 PTAP L-domain 
and Tsg101 is increased about 10-fold when a Ub-moiety is attached to the C-terminus of p6 
(49). Hence, p6Gag phosphorylation-directed Gag ubiquitination might serve to recruit more 
efficiently or bind Tsg101 more tightly. However, it has been shown that p6 ubiquitination is 
not required for the p6-Tsg101 association (35, 118). Another possibility is that 
ubiquitination of a nearby, yet unidentified protein would serve as a substrate and this 
would lead to the recruitment of ESCRT components, as suggested by Zhadina et al (157). 
Another scenario is set forth by the fact that Ub ligase activity can be regulated by 
phosphorylation as that reported for Nedd4-2 (135). In this context, p6 would be subject to 
adventitious phosphorylation by being in close proximity to kinases that control the activity 
of Ub ligases or due to ESCRT-III component phosphorylation. Indeed, the ESCRT-III 
components Vps4b and CHMP3 have been shown to be phosphorylated (105).  
4.3 p6 phosphopeptide analysis by mass spectrometry 
 
To unequivocally determine sites in p6 that are actual substrates to kinase-mediated 
phosphorylation we conducted a mass spectrometry analysis of HIV-1NL4-3 virus-derived 
protein bands. This study allowed us to identify phosphoresidues within p6 as well as in 
other viral structural proteins, such as MA and CA. The relevance and possible significance of 
the MA and CA modifications is beyond the scope of this study and will thus not be 
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addressed in more detail. The analysis permitted us to compare the p6 phosphorylation 
pattern obtained from viruses-derived either from 293T or MT-4 cells. It also allowed us to 
follow the phosphorylation pattern of p6 throughout its processing stages: from its existence 
as part of the Gag polyprotein precursor to its cleaved, processed form as p6. The analysis of 
virions derived from 293T cells indicates that p6 is phosphorylated as part of the Gag 
precursor in residues (residue positions are given in relation to p6) T22/23, S40, S43, and S51 
while the NCSP1p6 processing intermediate is phosphorylated at T21, T22/23. Finally, the 
free form of p6 is phosphorylated at T22/23, S40, and S51. The fact that both p6Gag and free 
p6 repeatedly showed phosphoresidues at S40 and S51 suggests that these phosphorylations 
are maintained during the processing step that yields the free form of p6. Nevertheless, it is 
possible that these modifications were not detected in the analysis of the NCSP1p6 
processing intermediate due to the low stoichiometry of the modification. Alternatively, it 
may actually reflect a regulatory activity by cellular kinases associated with the virion. As 
mentioned in section 4.2, S40 is putatively phosphorylated by the PKC kinase and S51 by one 
of these kinases: DNAPK, ATM or CKII. It would be of interest to know whether these kinases 
are packaged into the virion. This might hint at the timepoint at which phosphorylation takes 
place. For instance, if the kinases are not packaged within the virion, it could indicate that 
association of Gag with these kinases must occur at an early timepoint, prior to completion 
of the nascent virion scission reaction. Alternatively, if the kinases are packaged into the 
virion, it could suggest that phosphorylation during Gag processing could be regulated within 
it. ATP molecules could inadvertently become incorporated into viral particles during the 
AAA+ ATPase Vps4-catalyzed disassembly of ESCRT-III components. In the case of T22/23 it 
was not possible to pinpoint the phosphorylated residue due to the close proximity of their 
signals. The T23 is within a consensus sequence for phosphorylation by the ERK-2 kinase. 
There is biochemical evidence that ERK-2 is incorporated into HIV-1 particles and that the 
phosphorylation of T23 plays an important role in HIV-1 release and infectivity (24, 60). 
However, our own studies indicated that although T23 seems to be phosphorylated, this 
modification does not seem to play a role in the release or replication capacity of HIV-1. The 
T21 residue was consistently identified as a phosphoresidue exclusively in the context of the 
NCSP1p6 processing intermediate in 2 out of 3 virus preparations; this could suggest that 
this modification might positively regulate further processing of Gag intermediates by the 
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viral protease. The p6 phosphorylation pattern obtained from MT-4-derived virions was in 
principle similar to that obtained from 293T-derived virions with respect to the 
phosphoresidues identified. Although fewer residues were observed to be phosphorylated in 
MT-4-derived virions, no new phosphoresidues were identified in comparison to 293T-
derived virions. Hence, in MT-4-derived viruses, p6Gag was phosphorylated at T22/23 and 
S40; NCSP1p6 contained the phosphoresidues T22/23 and S51, while cleaved p6 was 
phosphorylated at S40 and S50/51. This could suggest that all p6 phosphorylations observed 
take place in p6 as part of the Gag precursor; alternatively, the phosphorylation at S51 might 
be acquired to signal activation of further processing. To better distinguish between the 
modifications taking place at the level of p6Gag, p6 as a cleavage intermediate or in its free 
form, an additional analysis from another independent virus preparation should aid in the 
interpretation of these results. Overall, the differences in phosphorylation patterns observed 
between 293T-derived and MT-4-derived viruses could either indicate that there is a true 
difference in p6 phosphorylation or that simply the analysis missed the identification of 
additional residues and it must be repeated in a different virus preparation. In addition, 
mass spectrometry analysis of p6 phosphosite mutants can help corroborate the identified 
phosphorylated residues. In summary, in agreement with the study published by Müller et al 
(101) we could detect p6 as a phosphoprotein that can exist in a multiply phosphorylated 
form, given the number of phosphoresidues we identified in the cleaved form of p6. 
Although phosphoamino acid analysis identified Tyr as a phosphoresidue in their study, our 
mass spec analysis did not detect such a modification in the single Tyr residue present within 
p6. In contrast to Müller et al, we could clearly identify Gag as a phosphoprotein, suggesting 
phosphorylation could take place during the assembly/budding reaction. Overall, mass 
spectrometry proved to be a powerful tool to identify phosphoresidues in p6.  
4.4 Interaction properties between a p6 T8N mutant and the 
Tsg101 UEV domain 
During our study of potential p6 phosphorylation mutants observed that a p6 T8N 
mutant that was constructed as a negative control for our release assay, surprisingly showed 
wildtype behavior both in release and in single-round infectivity. Moreover, the ability of this 
mutant virus to support virus release was confirmed by electron microscopy and we could 
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ascertain that a considerable amount of particles displayed mature capsid morphology. It is 
known that among different HIV-1 subtypes, the C-terminal p6Gag domain is the most 
variable in length and sequence. A PXXP amino acid sequence motif, occurring as PTAP or 
PSAP is highly conserved and has even been observed to be duplicated within HIV-1 subtype 
C strains (145). The integrity of this motif is critical for proper nascent virus detachment from 
the host cell membrane (53, 64). Hence, our results with the p6 T8N mutant were 
unexpected and we therefore sought to characterize this mutant in further detail to 
understand the basis for its activity. Biochemically, we could confirm that it can support virus 
release similar to the wildtype virus. Moreover, this mutant proved to be infectious by 
single-round infectivity. To determine whether more subtle differences in replication might 
explain the reason why this mutant does not occur in nature, we analyzed its ability in 
establishing a spreading infection, however, results await analysis. It was also possible that 
changing the T8 residue to an Asn would change the specificity for an interaction partner. 
Normally, the PT/SAP L-domain recruits the ESCRT-I component, Tsg101 to sites of virus 
budding facilitating virus release. We could prove, albeit indirectly, that the mutant PNAP L-
domain retains its Tsg101 recruiting activity. This was further supported by our binding 
affinity studies that showed that the Tsg101 UEV domain and a PNAP-containing p6 peptide 
interact with an average Kd of 295.1 M. Although this affinity is 5-fold lower than what we 
observed between the PT/SAP peptide and Tsg101 UEV, it is significantly higher than that 
measured between a PAAP peptide and UEV, which was negligible (Figure 26). Moreover, 
the ITC measurements are in agreement with the biochemical data obtained with the p6 T8A 
and T8N mutants. The fact that Tsg101 UEV and PNAP can interact with 5-fold less affinity 
and still support HIV-1 release indicates that the interaction need not be so tight and that 
this affinity is sufficient to mediate recruitment of Tsg101 and catalyze release. In fact, the 
affinity of the interaction that occurs between Tsg101 UEV and a PSAP peptide derived from 
the ESCRT-0 component Hrs is 6-fold lower than the p6 PT/SAP-Tsg101 UEV interaction (71). 
It is also possible that ubiquitination of p6Gag or other domains in Gag may increase the 
affinity of the interaction. It has been shown that fusion of a Ub moiety to the C-terminus of 
p6 increases the affinity of the interaction 10-fold (49). The present study, however, did not 
address the role of Gag ubiquitination in the recruiting activity of Tsg101 by the PNAP L-
domain. This could be tested by using a Tsg101 mutant for Ub binding. Although Tsg101 
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binds to both Ub and PT/SAP through its UEV domain, different interfaces are used to 
recognize the respective ligands. Moreover, it has been shown that mutation of the Tsg101 
UEV Ub-binding site does not interfere with p6 binding (49). To obtain more structural 
information regarding the mode of interaction between PNAP and Tsg101 UEV we 
attempted to crystallize the complex. However, so far we have only obtained crystals of the 
uncomplexed protein. It is possible that due to the lower affinity of the interaction, it is 
harder to obtain a crystal of the complex. We recently obtained new crystals of the protein 
which will be incubated with high concentrations of the PNAP peptide in an effort to force 
the peptide into the structure.  
The question that still remains elusive is why the PNAP L-domain does not occur in 
natural HIV-1 isolates? It could be that a PNAP in place of a PT/SAP has a replicative 
disadvantage. This could be resolved by comparing the replicative fitness of such viruses. 
Another simple explanation could be that it is just a matter of structural conservation. In the 
wildtype interaction, the main-chain amide of the critical PTAP T8 residue forms a hydrogen 
bond with the main-chain carbonyl of Asn69 in UEV. In addition, the side-chain hydroxyl 
group of T8 forms a hydrogen bond with the main-chain amide of Asn69, while the methyl of 
T8 makes no direct contacts to the UEV domain (71). In principle, an Asn residue conserves 
structural properties of a Thr residue (9). Importantly, Asn has a high propensity to hydrogen 
bond since the amide group can accept two and donate two hydrogen bonds. Thus, in 
principle, the N8 residue could still maintain the hydrogen bonding interactions of the T8 
residue necessary to interact with the UEV domain. Importantly, the lower affinity resulting 
from the PNAP-UEV interaction suggests that the structural properties of the complex are 
nevertheless altered. The only other existing evidence that interaction between a PNAP 
residue and Tsg101 UEV can take place comes from a p6 peptide substitution study where 
the affinity of p6 mutants for GST-UEV is tested on a SPOT membrane. It is observed that 
binding still exists, albeit to a lesser extent when the T8 residue is replaced by an Asn residue 
(130). Another, perhaps more interesting, possibility is that PNAP functionality in the context 
of HIV-1 release, has been preferentially replaced by residues of higher affinity throughout 
evolution. In support of this assumption it the fact that, at least in the context of main-chain 
to side-chain hydrogen bonding patterns in proteins, asparagine and aspartate residues 
frequently interconvert, as do the serine and threonine residues. It is also clear that the two 
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pairs of residues often interconvert from S/T to D/N, more often than with any of the other 
amino acid residues. The rate is lower than S to T or D to N, but is nevertheless highly 
significant. In contrast, asparagine residues rarely interchange to glutamine (147). This 
correlates well with the effect we observed with the p6 T8Q mutant, which was not able to 
rescue virus release as the p6 T8N mutant did. To explore the likelihood that the PNAP motif 
has been evolutionarily replaced by a motif of higher affinity, such as PT/SAP we conducted 
a search for viral and eukaryotic proteins containing the P-N-A-P motif. The most relevant 
eukaryotic proteins identified were the voltage-dependent calcium channel and the 
melanoma antigen recognized by T cells 1 (MART-1). The MART-1 protein, for example, 
contains tandem PNAPPAY motifs predicted to interact with WW domain-containing ligases. 
In fact, both of these proteins interact and are regulated by Nedd4 ligases (92, 123). The 
adaptor-related protein complex 4, beta 1 subunit (AP4B1) was also identified to contain a 
PNAP motif. The AP4B1 is a subunit of the AP-4 protein. The AP proteins in general recruit 
cytosolic components of the transport machinery to assemble into protein coats and form 
the budding vesicle on the membrane of a donor organelle (6). The PNAP motif was 
prominently found in two unrelated viruses: EIAV and human hepatitis B virus (HBV). In EIAV, 
the PNAP motif is within an accessible loop in the CA protein. EIAV contains a YPDL L-domain 
within the C-terminal p9 domain that is known to be required to mediate virus release. 
However, it has also been reported that EIAV Gag is able to use not only Alix, but also Tsg101 
or Vps28 for efficient budding. (138). As a lentivirus, it is intriguing why this virus does not 
possess a PT/SAP L-domain as in HIV-1. The finding that the PNAP motif can provide L-
domain function could suggest that preference towards domains of higher affinity or that 
provide an evolutionary advantage could substitute for its function. Interestingly, although 
EIAV seems to bypass the need for ubiquitin in YPDL-mediated virus release (93), fusion of a 
Ub moiety to the C-terminus of an EIAV L-domain mutant is capable of rescuing virus 
production. Moreover, fusion of Ub rendered EIAV release sensitive to Tsg101 depletion 
(78). Thus, it is tempting to speculate that the PNAP motif present in the EIAV CA could be 
responsible for this phenotype, acting as a remnant ancestral L-domain. As mentioned 
above, concomitant binding of Ub and a PTAP peptide increases the Tsg101 UEV-PTAP 
interaction by 10-fold. Thus, it is plausible that Ub fusion to EIAV functions in the same way, 
strengthening the interaction between its PNAP motif and Tsg101. The HBV core contains 
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two candidate late domain-like motifs, PPAY132 and PN136AP (82). Interestingly, a study 
conducted by Ponsel et al (114) showed that mutation of the N136 residue allowed virus 
nucelocapsid formation but inhibited particle envelopment and virion release. Nevertheless, 
this motif has not been recognized as a true L-domain since it was found that a P135A 
mutant did not prevent HBV virion release (114) presumably questioning the relevance of 
the whole motif in virus release. However, as reported by Im et al (71), at least in the context 
of the PTAP motif, the P7 is not so critical for binding and thus, a P7A mutant leads to a less 
than 3-fold reduction in affinity for Tsg101 UEV. Thus, it is not surprising that HBV 
production can still take place in this context. Moreover, there is evidence that inhibition of 
the ESCRT-associated factor Vps4 inhibits HBV replication and secretion (82), hinting at the 
possibility that ESCRT components might be engaged through the HBV core.  
In summary, the finding that a PNAP p6 peptide is able to support wildtype levels of 
HIV-1 release invokes further exploration into the interaction properties that mediate this 
interaction. This is especially relevant in the design of p6-UEV peptide inhibitors. Perhaps, a 
high affinity PNAP-containing peptide could be designed in the future that would act as a 
competitive inhibitor of the PTAP-UEV interaction. Importantly, this inhibition is unlikely to 
disturb other endocytic process involving Tsg101 as shown by Im et al (71). Hence, the 
unprecedented functionality of the PNAP-UEV interaction should be an important addition 
to the future design of small molecule inhibitors. 
4.5 Future directions 
 
HIV-1 is a virus that greatly benefits from usurping cellular factors at different stages 
of its replication cycle. It can achieve this by effectively mimicking cellular protein motifs. In 
this way, it has become a substrate to varied posttranslational modifications, including 
phosphorylation, thus engaging key machinery that helps orchestrate a myriad of cellular 
processes. Elucidation of the detailed role of HIV-1 p6 phosphorylation in the viral 
replication cycle must be pursued further. It will be necessary to unequivocally determine 
the effect potential p6 phosphorylation site mutants have in virus release, maturation and 
replication. This will eventually help pinpoint the relevant residue(s) involved in the 
phenotype, if any. The uncoupled constructs were designed in a way to contain additional 
restriction sites, facilitating the exchange of fragments with a selected amount of mutations 
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and enabling further site-directed mutagenesis. Furthermore, the results obtained by the 
mass spectrometry analysis will help corroborate the observations and will provide 
additional information regarding the putative kinases that could phosphorylate them. In this 
regard, an additional preparation from MT-4 cell-derived HIV-1 virions should be analyzed. 
Detected phosphoresidues should be compared to the other two virus preparations to help 
define whether there is an actual difference in the phosphorylation pattern between HIV-1 
virions derived from 293T cells as compared to those derived from MT-4 cells. It is also 
possible to ascertain the apparent absence of a morphological defect of the p6 mutants by 
visualizing them through electron microscopy. The uncoupled gag-pol construct proved to 
be an excellent tool to generate extensive mutations in p6 without affecting the partially 
overlapping pol frame and it allows further exploration of Gag domains that could not be 
studied in detail before, such as SP1.  
Regarding the p6 PNAP mutant, it will be important to analyze its ability to support a 
spreading infection in primary lymphocytes. The experiments have been conducted and only 
the analysis is pending. It will be interesting to see if such mutants revert to the wildtype 
motif. This might shed light on the reason why this motif does not occur in natural HIV-1 
isolates. On the other hand, the crystal structure of the Tsg101-UEV complex will provide 
critical information regarding the interaction properties between the two which will provide 
us with a better understanding of the flexibility of residues that can exist within this position. 
At the same time, this information might help in the future design of peptides that can 
effectively interfere with the HIV-1 budding reaction. New crystals of Tsg101 UEV have been 
obtained and the peptide will be forced into the structure by using high concentrations of it. 
Analysis of the crystals will be carried out in Grénoble. 
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Appendix A: Analysis of the role of E3 ubiquitin ligase 
recruitment in retrovirus formation 
 
Special domains within the major structural retroviral protein Gag play a central role 
in the fission process that separates a budding retrovirus from the host cell membrane. 
These highly conserved peptide motifs are termed late domains and recruit cellular factors, 
such as components of the ESCRT (endosomal sorting complex required for transport) 
pathway. This pathway consists of a complex of proteins that participates in the sorting of 
ubiquitinated cargo proteins into multivesicular bodies (MVBs). In analogy to its role in MVB 
formation, the ESCRT system is required to separate the nascent virion from the infected 
cell. How enveloped viruses access the ESCRT system depends on the type of late domain 
present. There are 3 types of late domains, PT/SAP, YPDL and PPXY that recruit the ESCRT 
component Tsg101, the ESCRT-associated protein AIP1/Alix or interact with HECT E3 
Ubiquitin ligases of the Nedd4 family, respectively. While the connection between Tsg101 
and AIP1/Alix to the ESCRT system is well studied, the mechanism by which HECT Ubiquitin 
ligases mediate viral budding is not clearly understood. Although HIV-1 does not possess an 
L-domain of the PPXY type, it has been shown that overexpression of a specific isoform of 
the Nedd4 HECT E3 ubiquitin-ligase can enhance release of an HIV-1 clone lacking both of its 
known L-domains (22). 
This study was aimed at providing evidence that interaction of Gag with ubiquitin and 
HECT E3 ligases facilitate virus release. By making use of a heterodimerizer sytem (ARIAD 
Pharmaceuticals) Figure A 1, which allows induction of interaction between proteins through 
a small molecule we sought to assay the contribution of different HECT Ub ligases and their 
subdomains to virus release and analyze the different requirements for E3 ligases among 
different retroviruses. A scheme of the dimerizer-inducible system for Gag budding is shown 
in Figure A 2. 
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Figure A 1 The heterodimerizer system: 
 The FKBP (12 kDa) and FRB (11 kDa) 
domains can be each fused to a protein 
of interest A and B. Addition of the 
bivalent small chemical compound 
AP21967, the heterodimerizer, links the 
FKBP and FRB domains thereby bringing 
protein A and B into close proximity. 
 
 
 
 
Figure A 2 Schematic of the dimerizer-inducible system for Gag budding. 
The naturally occurring HIV-1 Gag-ESCRT interaction mediated by the Gag late domain and a Gag-binding 
domain of the relevant cellular factor is replaced by the heterodimerizer-inducible interaction of the FKBP and 
FRB domains, respectively. The p6 domain of HIV-1 Gag, containing the late domain motif was replaced by the 
FKBP domain while the FRB domain was fused to cellular factors that play a role in HIV-1 release such as 
Tsg101. In the presence of the dimerizer molecule, budding of the HIV-1 Gagp6-FKBP should be reconstituted 
when a promoting factor such as Tsg101-FRB is coexpressed.  
 
The ability of the Nedd4 family of E3 Ub ligases: WWP1, WWP2, Nedd4L and Itch 
were tested as FRB fusion proteins for their ability to rescue HIV-1 Gag-FKBP release. 293T 
cells were cotransfected with each of the ligases at various concentrations and with the HIV-
1 Gag-FKBP. Cell lysates and virus supernatants were harvested and virus-like particles 
were pelleted over a 20 % sucrose cushion 24 h after transfection. The levels of released 
VLPs were determined by quantitative western blotting of the viral Gag protein. Initial 
experiments showed that the WWP2 and Itch ligases partially enhance VLP production 
(Figure A 3). 
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Figure A 3 Effect of HECT Ub ligases in HIV-1 Gagp6 release. 
293T cells were cotransfected with HIV-1 Gagp6-FKBP and various amounts of plasmid DNA (100 ng-20 ng-5 
ng) of the WWP1-, WWP2-, Nedd4L- and Itch-FRB tagged ligases. 50 nM AP21967 dimerizer were added 6 h 
after transfection. Gag release was determined 24 h after transfection by quantitative Western blotting of 
pelleted supernatants and expressed as arbitrary units (AU). As a positive control, FRB-tagged Tsg101 was 
tested in the presence (+) or absence (-) of dimerizer. Cell lysates were probed for HA to check for the 
expression of the ligase-FRB-HA fusion protein.  
 
The FRB-tagged Itch and WWP2 constructs were selected for further analysis and 
tested at an additional range of concentrations. While the WWP2 construct failed to achieve 
higher levels of virus production (data not shown), the Itch construct efficiently rescued HIV-
1 Gagp6 release up to 50 % of wildtype levels (Figure A 4). 
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Figure A 4 Effect of the FRB-tagged Itch ligase in rescuing HIV-1 Gag p6-FKBP release. 
293T cells were cotransfected with HIV-1 Gagp6-FKBP and various amounts of FRB-Itch plasmid DNA (12.5 ng-
10 ng-7.5 ng-5 ng) Cells were incubated either in the presence or absence of heterodimerizer as indicated. 50 
nM AP21967 dimerizer was added 6 h after transfection. Gag release was determined 24 h after transfection by 
quantitative Western blotting of cell lysates and pelleted supernatants and expressed as the relative Gag 
release. The release efficiency of HIV-1 Gagp6-FKBP in presence of Tsg101-FRB and dimerizer was set to 1.0. 
 
The role of the HECT ubiquitin ligases was also tested in the context of a L-domain 
mutant rous sarcoma virus (RSV). Hence, the FRB-tagged WWP1, WWP2, Nedd4L and Itch 
were cotransfected with a L-domain mutant FKBP-tagged RSV GagPPPYLYPSL and their 
ability to rescue RSV release was tested. None of the ligases was able to promote release of 
the mutant RSV Gag (data not shown).  
Although ubiquitination of retroviral Gag proteins has been extensively researched, 
the precise role of Gag ubiquitination is still unclear. Given the similarities between MVB 
sorting and viral budding, and the fact that fusion of Ub to the C-terminus of HIV-1 Gag 
enhanced its interaction with Tsg101 in vitro (49), a direct relevance of Gag ubiquitination 
appears plausible. We sought to address the role of ubiquitin overexpression and delivery to 
sites of HIV-1 Gagp6-FKBP assembly and budding through the dimerizer system. The ability 
of the FRB-Ub fusion protein in rescuing release of HIV-1 Gagp6-FKBP is shown in Figure A5. 
Experiments conducted using Tsg101-FRB as a positive control showed that overexpression 
of a Ub moiety can rescue release up to 50 % of the wildtype levels. The Alix protein can 
mediate release of L-domain mutant HIV-1 when overexpressed, thus we also included this 
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construct in some of the analyses as an additional positive control (data not shown). While 
the FRB-tagged Tsg101 control provided the most consistent results and was able to rescue 
release of L-domain deficient HIV-1 Gag, Alix-FRB did not. I repeatedly observed 
inconsistencies in the behavior of this construct in the absence of heterodimerizer.  
 
 
Figure A 5 Effect of FRB-Ub overexpression in the rescue of HIV-1 Gagp6-FKBP particles. 
293T cells were cotransfected with HIV-1 Gagp6-FKBP and various amounts of FRB-Ub plasmid DNA (100 ng-
20 ng-5 ng) Cells were incubated either in the presence or absence of heterodimerizer as indicated. 50 nM 
AP21967 dimerizer was added 6 h after transfection. Gag release was determined 24 h after transfection by 
quantitative Western blotting of cell lysates and pelleted supernatants and expressed as the relative Gag 
release. The release efficiency of HIV-1 Gagp6-FKBP in presence of Tsg101-FRB and dimerizer was set to 1.0. 
 
Taken together, out of the HECT E3 ligases tested the Itch ligase most efficiently 
rescued L-domain deficient HIV-1 Gag but not RSV in this system. In addition, Ub 
overexpression seemed to help HIV-1 Gagp6 overcome part of its late domain deficiency; 
however we obtained conflicting results with the Alix control (see above). These 
inconsistencies must be considered in the final interpretation of the data and the behavior 
of the Alix construct must be evaluated carefully.  
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6 List of abbreviations 
 
aa amino acid 
AA acrylamide 
AAA+ ATPase ATPase associated with a variety of cellular activities 
AIDS acquired immunodeficiency virus 
ALG-2 apoptosis-linked gene 2 
ALIX ALG-2 interacting protein X 
AMSH associated molecule with the SH3 domain of STAM  
app. approximately 
APS ammonium peroxodisulfate 
BIS N,N’-methylene bisacrylamide 
CA capsid 
CHMP charged multivesicular body protein  
CIAP calf intestine alkaline phosphatase 
CTD C-terminal domain 
DMEM dulbecco's Modified Eagle Medium 
DNA desoxyribonucleic acid 
dNTPs deoxy-nucleoside-triphosphates 
DUB deubiquitinase 
EAP ELL-associated protein 
ECL enhanced chemiluminescence  
EDTA ethylene-diamine-tetra-acetic acid 
EGFR epidermal growth factor receptor 
EIAV equine infectious anemia virus 
ELISA enzyme-linked immunosorbent assay 
EM electron microscopy 
Env envelope 
ESCRT endosomal trafficking complex required for transport 
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FCS fetal calf serum 
Fig. figure 
FKBP FK506 binding protein 
FRB FKBP12 rapamycin-binding domain 
Gag group specific antigen 
GLUE GRAM-like ubiquitin binding in EAP45 
h hour 
HA hemagglutinin 
HECT homologous to E6-AP C-terminus 
HIV-1 human immunodeficiency virus-1 
HRS hepatocyte growth factor-regulated tyrosine kinase 
substrate 
Hsp heat shock protein 
HTLV human T cell leukemia virus 
ILV intralumenal vesicle 
IPTG isopropyl-β-D-thiogalactopyranosid 
kDa kilo Dalton 
LB lysogeny broth 
LC-MS/MS liquid chromatography-tandem mass spectrometry 
LTR  long terminal repeat 
LTR long terminal repeat 
MA matrix 
MLV murine leukemia virus 
MPMV mason pfizer monkey virus 
mRNA messenger RNA 
MVB multivesicular body 
NC nucleocapsid 
Nedd4L neural precursor cell expressed, developmentally 
down-regulated 4 
NEM N-ethylmaleimide 
NMR nuclear magnetic resonance 
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nt  nucleotide 
NTD N-terminal domain 
p protein 
p24 alternative designation of the HIV-1 CA protein 
PAGE polyacrylamide gel electrophoresis 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PIC preintegration complex 
pol polymerase 
PR protease 
RNA ribonucleic acid 
rpm rotations per minute 
RRE Rev responsive element 
RSV rous sarcoma virus 
RT room temperature 
RT room temperature 
RTC reverse transcription complex 
SDS sodium dodecyl sulfate 
siRNA small interfering RNA 
SP1 spacer 1 
SP2 spacer 2 
TBS tris buffered saline 
TMB 3,3’,5,5’ tetramethylbenzidine 
Tris tris(hydroxymethyl)aminomethane 
TSG101 tumor suppressor gene 101 
U unit 
Ub ubiquitin 
UBD ubiquitin binding domain 
UEV ubiquitin E2 varient 
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UIM ubiquitin interacting motif 
UTR untranslated terminal region  
Vps vacuolar protein sorting 
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